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General anaesthesia in horses carries a higher risk of mortality compared to other species. The 
increased incidence of intraoperative complications and death is partly related to the dose 
dependent cardiovascular depression induced by inhalation anaesthetics, commonly used for 
long procedures. In order to reduce the required amount of inhalants and associated side 
effects, combinations of different anaesthetic drugs are often incorporated in the so-called 
‘balanced anaesthetic protocols’. Nowadays, this term has reached new dimensions with the 
use of less soluble inhalant anaesthetics in combination with short-acting intravenous (IV) 
anaesthetic drugs. In equine anaesthesia, the aims of balanced anaesthesia are to preserve an 
optimal intraoperative cardiopulmonary function and to assure good recoveries without 
adverse events. 
 
Perioperative fatalities associated with equine general anaesthesia 
The overall incidence of anaesthetic and sedation-related death has been reported to be 0.17 in 
dogs and 0.24% in cats, increasing to 1.33 and 1.40% respectively in sick patients (Brodbelt et 
al. 2007, 2008). These values are substantially higher than those seen in human anaesthesia: a 
review study reported an overall mortality rate of 0.008% that may increase up to 0.05% in 
ASA IV (American Society of Anesthesiologists) patients (Lagasse 2002). Different studies 
have been carried out in an attempt to determine the mortality rate associated with general 
anaesthesia in equines, although it remains difficult to determine whether death is either 
related purely to anaesthesia, or rather to the result of underlying diseases and/or surgical 
complications. Tevik (1983) reported a perioperative mortality of 0.8% in horses undergoing 
different types of surgery. The surgical/anaesthetic death rate was 0.63% in horses undergoing 
elective procedures, although only 0.08% was directly attributable to anaesthesia (Mee et al. 
1998a). Young & Taylor (1993) described a 0.68% incidence of anaesthetic-related deaths in 
horses undergoing orthopaedic surgery, radiography or minor soft tissue surgery. Higher 
mortality rates (31.4%) were noticed for emergency procedures (Mee et al. 1998b). More 
recently, a study performed in a private referral practice reported the prevalence of equine 
fatalities directly related to anaesthesia to be 0.12%, increasing to 0.24% when horses 
euthanized or dying within seven days after general anaesthesia were included (Bidwell et al. 
2007). However, several factors contributed to this lower fatality rate. Most of the horses were 
healthy, the duration of anaesthesia was usually shorter than sixty minutes and the 
anaesthetists were familiar with the standard protocol used in their practice. 
 The CEPEF (Confidential Enquiry into Perioperative Equine Fatalities) is the largest 
observational study of equine fatalities. This study was performed over a period of six years 
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and included data collected from 41,824 horses undergoing general anaesthesia in 129 
different equine clinics (Johnston et al. 2002). During anaesthesia or within a period of seven 
days after anaesthesia, an overall death rate of 1.9% was found. This overall number was 
reduced to 0.9% when only non-colic horses were included, but increased to 11.7% in colic 
horses. This report was also useful to identify major important risk factors other than 
emergency abdominal surgery, such as age, type and time of surgery and drugs used for 
premedication, induction and maintenance of anaesthesia. Induction of anaesthesia with 
volatile agents, night-time and weekend surgical procedures and fracture repairs were 
associated with higher risks as well. Furthermore, the maintenance of anaesthesia with 
volatile agents carried a much higher risk of death (0.99%) compared to total intravenous 
anaesthetic (TIVA) protocols (0.31%). Intravenous agents were suggested to produce less 
cardiorespiratory depression compared to volatile agents, resulting in a better outcome 
(Taylor et al. 1998). These data suggest that volatile agent anaesthesia can significantly 
contribute to the high anaesthestic mortality in equines, mostly due to the occurring 
cardiovascular effects (Steffey & Howland 1978). However, TIVA is routinely only applied 
in horses anaesthetized for less than forty five minutes (Hubbell 2007), mainly because of the 
risk of drug accumulation and associated side effects. Although the numbers in the CEPEF 
study were insufficient for a proper statistical evaluation, two out of sixty two horses (3.2%) 
anaesthetized with a TIVA protocol for more than ninety minutes died (Johnston et al. 2002). 
Johnston et al. (2002) also demonstrated that 33% of the deaths were due to cardiac 
arrest (including cardiovascular collapse). Furthermore, 32% of the horses were euthanized 
due to occurring fractures or myopathies during the recovery period with the remaining 35% 
of deaths related to a wide range of etiologies. Cardiac arrest is often the end-result of pre-
existing, pronounced cardiovascular depression. Moreover, the association between myopathy 
and hypotension has been well established in horses. Myopathy develops as a result of 
inadequate muscle perfusion during anaesthesia, caused by decreases in blood pressure and 
cardiac output      , combined with increased intracompartmental pressures in dependent limb 
muscle (Grandy et al. 1987; Lindsay et al. 1989). It also seems likely that some of the 
fractures reported in the CEPEF study were related to muscle dysfunction and/or myopathy 
caused by an inadequate oxygen delivery during anaesthesia. Indeed, Edner et al. (2005) 
demonstrated with the microdialysis technique the occurrence of an anaerobic metabolic 
response, even in muscles of healthy horses undergoing long-term inhalation anaesthesia. 
Horses with myopathy are supposed to have difficulties or are even unable to stand, leading to 
excitation and prolonged recumbency, causing further muscle damage. Moreover, fractures 
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may occur during unsuccessful attempts to stand due to muscle weakness (Lindsay et al. 
1989). Although myopathies have different intensities and are not always fatal, the prognosis 
remains very poor when a generalized myopathy is present in equine patients. Myopathy was 
also the main reported cause of death in the other study including 1314 healthy horses (Young 
& Taylor 1993). 
The studies of Young & Taylor (1993) and Johnston et al. (2002) included a large 
number of horses and showed that perioperative death in horses was closely linked with 
inadequate tissue oxygen delivery. This confirms the importance of maintaining a good 
cardiovascular function during anaesthesia, not only in high risk patients such as the colic 
horse, but also in healthy horses. Consequently, an adequate monitoring of anaesthetized 
horses must allow the anaesthetist to detect cardiovascular depression on time. 
 
Cardiovascular depression due to inhalational agents 
At the present moment, volatile anaesthetics are widely used in horses because they are the 
most controllable method for producing general anaesthesia (Steffey 2009). However, these 
agents are not free of side effects since they induce a ‘dose dependent’ cardiovascular 
depression (Clarke 2008). Halothane has been widely used since its introduction into clinical 
practice in the late 1950s by Dr. Leslie Hall (Clarke 2008) and enabled many of the advances 
in veterinary surgery. This drug is no longer available in most countries. Halothane produces 
bradycardia by increasing vagal tone, depressing sino-atrial and atrioventricular activity. 
Moreover, it reduces myocardial contractility and     and sensitizes the heart to 
catecholamines, which may lead to arrhythmias. Arterial blood pressure (ABP) also decreases 
but there is some vasoconstriction and at one minimum alveolar concentration (MAC), 
hypotension is less pronounced than anticipated (Clarke 2008). Isoflurane, a greater 
respiratory depressant than halothane (Steffey & Howland 1980), is nowadays the most 
commonly used licensed inhalation anaesthetic agent in horses. This volatile agent reduces 
systemic vascular resistance (SVR), inducing a marked vasodilation and a decreased ABP. On 
the other hand, isoflurane maintains heart rate (HR) better and has less effect on myocardial 
contractility compared to halothane, preserving a better     and peripheral perfusion. 
Sevoflurane, a newer volatile agent, has also been commercialized for dogs and is on the ‘list 
of essential substances’ for food producing horses with a six-month withdrawal (Clarke 
2008). Its use has been reported in different experimental (Aida et al. 1994; Rezende et al. 
2011) and clinical studies (Matthews et al. 1999) and cardiopulmonary depressant side effects 
have been observed. Sevoflurane anaesthetized horses will breathe at lower frequencies and 
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can become hypercapnic (Steffey et al. 2005a), which is similar to findings in horses 
anaesthetized with isoflurane (Steffey & Howland 1980). Sevoflurane also induces a fall in 
the SVR and ABP, without changes in cardiac contractility or HR. Although desflurane is not 
licensed for use in animals, this volatile agent has been studied in experimental horses (Clarke 
et al. 1996; Tendillo et al. 1997; Bettschart-Wolfensberger et al. 2001; Steffey et al. 2005b). It 
produces profound hypoventilation in horses, but a less severe cardiovascular depression at 
doses of 1-1.5 MAC compared with other inhalation anaesthetics (Steffey et al. 2005b). The 
reported cardiovascular effects are similar to those of isoflurane, although at concentrations 
above one MAC it may produce cardiovascular stimulation (Peck et al. 2008).  
As previously stated, inhalant agents carried a higher risk of mortality compared with 
TIVA protocols (0.99 versus 0.31%) (Johnston et al. 2002). In that study most of the horses 
were anaesthetized with halothane. During the latter stages of data collection, isoflurane was 
licensed as an alternative inhalational anaesthetic agent. Experimental and clinical evidence 
suggests that isoflurane has a cardiovascular benefit over halothane (Grosenbaugh & Muir 
1998; Raisis et al. 2000a; Blissitt et al. 2008), i.e.     is more depressed during halothane 
compared with isoflurane anaesthesia (Raisis et al. 2005). Isoflurane was also found to be 
safer in young horses and high risk cases (Johnston et al. 2004). During sevoflurane 
anaesthesia, haemodynamic and pulmonary indices were similar to those of isoflurane, with 
less pronounced decreases in     and systemic arterial pressure compared to halothane 
anaesthesia (Grosenbaugh & Muir 1998). Less pharmacological support (dobutamine) was 
needed during sevoflurane anaesthesia than in isoflurane anaesthetized horses, mainly because 
of less suppression of vasomotor tone (Driessen et al. 2006). Nevertheless, independently of 
the agent used, cardiovascular depression, hypoxaemia and hypoventilation are common 
problems associated with the use of volatile anaesthetics in horses and    , stroke volume and 
left ventricular work will decrease during anaesthesia, especially in dorsal recumbent horses 
(Gasthuys et al. 1991a). 
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Principles of treatment of cardiovascular depression 
Cardiovascular depression and its consequences should be anticipated in order to reduce the 
complication rate in equine anaesthesia. Preventive measures include preoperative preparation 
of the horse, correcting abnormalities such as hypovolaemia, the use of an adequate padding 
and careful positioning once the horse is positioned on the surgical table, adequate 
monitoring, availability of equipment for artificial ventilation and last but not least, a firm 
reduction of anaesthetic time. Furthermore, cardiovascular function must be restored if 
required. Overall, three general principles are the fundaments of the prevention and treatment 
of cardiovascular depression: high-volume fluid therapy, the use of cardiovascular stimulant 
drugs and reduction of anaesthetic depth. 
 Fluids can be administered in order to increase circulating volume and cardiovascular 
performance. The use of crystalloids as routine fluid therapy, colloids (Jones et al. 1997; 
Hallowell & Corley 2006) and hypertonic solutions (Dyson & Pascoe 1990; Schmall et al. 
1990; Gasthuys et al. 1992) has been studied in anaesthetized horses. Cardiovascular 
stimulant drugs including adrenaline (Gaynor et al. 1992), dopamine (Gasthuys et al. 1991b; 
Lee et al. 1998), dopexamine (Muir 1992a, b; Lee et al. 1998), ephedrine (Hellyer et al. 1998) 
and dobutamine (Donaldson 1988; Gasthuys et al. 1991b; Lee et al. 1998; Raisis et al. 2000b) 
are also widely used during routine equine anaesthesia. The use of milrinone (Muir 1995), 
enoximone (Schauvliege et al. 2007, 2009), arginine vasopressin (Valverde et al. 2006), 
noradrenaline (Valverde et al. 2006), phenylephrine (Lee et al. 1998; Raisis et al. 2000c) or 
antimuscarinics (Teixeira Neto et al. 2004; Pimenta et al. 2011) has also been reported. 
However, these drugs are not always effective or free of side effects. 
Reduction of the anaesthetic depth is another important method to treat cardiovascular 
depression. Volatile anaesthetics have only poor (if any) analgesic properties (Tomi et al. 
1993; Petersen-Felix et al. 1995) and reducing anaesthetic depth is normally not possible 
when using only an inhalant agent for maintenance of anaesthesia, especially during painful 
surgical procedures. The use of locoregional techniques (Doherty et al. 1997; Haga et al. 
2006) and/or systemically administered anaesthetics/analgesics (Muir & Sams 1992; Doherty 
& Frazier 1998; Bettschart-Wolfensberger et al. 2001) can reduce the need for volatile 
anaesthetics. 
 
 
 
 
General introduction 
  
16 
 
Balanced anaesthetic techniques in order to reduce the amount of inhalant agents 
An ideal anaesthetic protocol includes a combination of different compounds, providing 
unconsciousness and analgesia, producing muscular relaxation and suppressing autonomic 
and somatic reflexes. This principle, the so-called ‘anociassociation’ was first described by 
George W. Crile (1910) who suggested the use of light general anaesthesia with local 
anaesthesia for blocking painful stimuli. The concept of ‘balanced anaesthesia’ was first 
introduced by John S. Lundy (1926) using different agents and techniques such as 
premedication, regional analgesia and general anaesthesia in order to achieve the different 
goals of an optimal anaesthetic procedure (analgesia, amnesia, muscle relaxation and 
reduction or elimination of autonomic reflexes while maintaining homeostasis). Currently, a 
single ideal anaesthetic drug is not available. Although some drugs have advantages in certain 
areas, they lack other important properties or may even produce side effects. More recently, 
the introduction of newer volatile agents and drugs with improved pharmacokinetics allowed 
this concept to reach new dimensions. Nowadays, the idea of balanced anaesthesia may differ 
in literature but it has been stated by Tonner (2005) that ‘a combination of anaesthetics will 
act synergistically with respect to the desired effects such as hypnosis or analgesia, but not 
with respect to side-effects’. 
 Balanced anaesthesia in horses is mainly applied for inhalation-based anaesthetic 
techniques, aiming to maintain a good intraoperative cardiopulmonary function followed by a 
calm, smooth and coordinated recovery (Bettschart-Wolfensberger & Larenza 2007). 
Although the ideal equine balanced anaesthetic technique is not available, different 
combinations have shown advantages and benefits. Local and regional anaesthetic techniques 
have been described (Doherty et al. 1997; Haga et al. 2006), while the concomitant use of 
inhalants and IV anaesthetics/analgesics has gained popularity (Muir & Sams 1992; Valverde 
et al. 2005; Ringer et al. 2007; Enderle et al. 2008).  
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Summary 
All volatile anaesthetics depress cardiovascular function dose dependently. Drugs that 
reduce the requirements for volatile anaesthetics might improve cardiovascular function 
during anaesthesia. Different drugs can be administered systemically for this purpose. 
Because of its analgesic properties, lidocaine, a classic local anaesthetic drug, can be 
used to reduce the requirements for volatiles. However, ataxia resulting in 
uncontrollable recoveries may occur so the infusion should be discontinued thirty 
minutes before the end of anaesthesia. Ketamine, a dissociative agent, can also be 
infused at a low dose to obtain additional analgesia, amnesia and immobility, with 
minimal depression of the cardiovascular function reducing the requirements of the 
inhalant agents. Unwanted emergence reactions have been reported during the recovery 
period. Although the systemic use of opioids is supposed to provide a high level of 
perioperative analgesia, the use of these narcotics remains controversial in horses, 
mainly because of adverse effects including behavioral changes and ileus, without clear 
reductions in the minimal alveolar concentration (MAC) of the inhalants. Finally, 2-
agonists provide sedation and analgesia in anaesthetized horses, considerably reducing 
the MAC, but may have a negative impact on cardiovascular function. 
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1.1. Lidocaine 
Lidocaine is an amino amide local anaesthetic that has traditionally been used to provide local 
anaesthesia in man and animals but also for the treatment of premature ventricular 
contractions when administered systemically (Peck et al. 2008). The local anaesthetic 
properties are mainly induced by the blockade of sodium channels (Peck et al. 2008) although 
other mechanism of actions have been reported, some of these effects occurring at lower 
concentrations (Hollmann & Durieux 2000). Other sites of action include calcium (Xiong & 
Strichartz 1998) and potassium channels (Bräu et al. 1998) and M1 muscarinic (Hollmann et 
al. 1999), glycine (Hara et al. 1995), gamma-aminobutyric acid (GABA)A (Sugimoto et al. 
2000), G protein-coupled (Hollmann et al. 2001) and N-methyl-D-aspartate (NMDA) 
receptors (Sugimoto et al. 2003). 
In human medicine, the use of intravenous (IV) lidocaine for anaesthetic and analgesic 
purposes was first reported over sixty years ago (Gilbert et al. 1951; De Clive-Lowe et al. 
1958) Its use decreased for over thirty years due to toxicity matters. Because local 
anaesthetics were shown to be efficient at blood concentrations lower than those considered to 
be toxic (Rimbäck et al. 1986, 1990), a renewed interest was formulated in the 1980s for new 
applications of IV lidocaine, such as the treatment of neuropathic pain (Kastrup et al. 1987; 
Ferrante et al. 1996) and the reduction of the duration of colonic stasis (Rimbäck et al. 1990). 
Additionally, IV lidocaine decreases postoperative pain (Koppert et al. 2004), has 
antihyperalgesic (Koppert et al. 1998) and anti-inflammatory properties (Hollmann & Durieux 
2000), improves gastrointestinal function postoperatively (Groudine et al. 1998), facilitates 
rehabilitation (Kaba et al. 2007) and reduces the minimal alveolar concentration (MAC) of 
volatile agents (Himes et al. 1977). 
 Systemically administered lidocaine has recently gained popularity in equine 
anaesthetized patients as it produces anaesthetic-sparing (Doherty & Frazier 1998; Dzikiti et 
al. 2003), analgesic (Murrell et al. 2005; Robertson 2005) and anti-inflammatory effects 
(Nellgård et al. 1996; Cook et al. 2009). The mechanism by which lidocaine reduces the MAC 
of volatile anaesthetics may involve different receptor types, such as NMDA, GABAA, 
acetylcholine and glycine (Zhang et al. 2007). Lidocaine dose dependently reduced the MAC 
of halothane in six experimental ponies (Doherty & Frazier 1998) receiving a loading dose 
(2.5 or 5 mg/kg) over five minutes followed by a CRI (50 or 100 µg/kg/min) for one hour. In 
a clinical study performed in twelve horses, Dzikiti et al. (2003) reported that IV 
administration of lidocaine at 2.5 mg/kg over ten minutes (fifteen minutes after induction) 
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followed by a CRI of 50 µg/kg/min during seventy five minutes resulted in a 25% reduction 
in isoflurane requirement, without negative effects on the cardiovascular system. 
Administration of IV lidocaine in colic horses (1.5 mg/kg bolus before surgery followed by a 
CRI 30 µg/kg/min) produced analgesia and dose dependent MAC sparing effects ranging 
from 20-25% with no significant cardiovascular or other side effects (Driessen 2005). More 
recently, the administration of a bolus of lidocaine (1.3 mg/kg) over fifteen minutes followed 
by 50 µg/kg/min CRI in eight experimental adult horses was shown to reduce the MAC of 
sevoflurane by 27% (Rezende et al. 2011). Nevertheless, under clinical circumstances, 
management of anaesthesia in horses receiving lidocaine (2 mg/kg over fifteen minutes plus 
CRI of 50 µg/kg/min) was more difficult and a higher expired fraction of isoflurane (FE´ISO) 
was required to maintain an appropriate, stable surgical plane of anaesthesia compared with 
those receiving medetomidine (Ringer et al. 2007). 
The new concept of partial intravenous anaesthesia (PIVA) has been recently 
introduced in equine anaesthesia (Bettschart-Wolfensberger & Larenza 2007; Nannarone & 
Spadavecchia 2012). This principle has been defined as a form of balanced anaesthesia and 
implies the use of low concentrations of inhalation anaesthetics in combination with more 
than one injectable agent to reduce the cardiorespiratory depressant effects and to improve 
anaesthesia and anaesthetic stability. The co-administration of IV lidocaine and ketamine in 
horses was reported to produce an additive effect on the inhalant anaesthestic-sparing effects. 
This was first suggested by Enderle et al. (2008) and confirmed by Villalba et al. (2011), with 
MAC reductions of 40% and 49% respectively at different doses and rates. In a recent blinded 
clinical trial, the mean FE´ISO in anaesthetized horses undergoing elective surgery when 
receiving lidocaine and ketamine infusions was 1% (0.62-1.2%) and was further reduced to 
0.65% (0.4-1.0%) when a medetomidine CRI was added (Kempchen et al. 2012). 
With regard to antinociception, the mechanism whereby systemic lidocaine exerts an 
analgesic action has not been completely elucidated. Tanelian & MacIver (1991) suggested 
that the analgesia produced by lidocaine is the result of the suppression of tonic neural 
discharges in injured peripheral A-delta and C fibre nociceptors, although a direct action on 
spinal transmission in the spinal cord has also been proposed (Woolf & Wiessenfeld-Hallin 
1985; Nagy & Woolf 1996; Koppert et al. 2000). It may also be possible that both peripheral 
and central actions contribute to the analgesic action of systemic lidocaine and that the 
predominant mechanism varies according to the nature of pain (Wallace et al. 1996). Low 
doses of systemic lidocaine have been used with good results for the treatment of severe cases 
of laminitis in equine patients (Malone & Graham 2002). Furthermore, 
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electroencephalographic findings have demonstrated that lidocaine provides antinociception 
contributing to additional analgesia during castration in ponies (Murrell et al. 2005). 
However, much less is understood about the action of lidocaine on the visceral pain. Indeed, 
lidocaine did not have a significant effect on the response to colorectal or duodenal distension 
in horses (Robertson et al. 2005), although it did inhibit, the cardiovascular responses to 
colorectal distension in rats, in a dose dependent manner (Ness 2000). Furthermore, lidocaine 
significantly increased the thermal threshold in horses (Robertson et al. 2005), which is in 
clear contrast with the findings in human volunteers, where systemic lidocaine had no effect 
on thermal thresholds (Wallace et al. 1997). 
The molecular mechanisms involved in the anti-inflammatory effects are not well 
described, although it has been suggested that lidocaine has effects on cyclic adenosine 
monophosphate, G protein-coupled receptors, nicotinamide adenine dinucleotide, sodium-
hydrogen antiporter and protein kinase C (Hollmann & Durieux 2000), reduces inducible 
nitric oxide synthase by suppression of nuclear factor B activation (Huang et al. 2006) and 
reduces the ex vivo production of interleukins IL-1 ra and IL-6 (Yardeni et al. 2009). 
Systemic lidocaine has also been shown to provide other potential benefits in the equine, such 
as reduction in the incidence of postoperative ileus (POI) (Cohen et al. 2004), with 
desiderable effects on intestinal motility (Brianceau et al. 2002) and resulting in a shorter 
hospitalization time in horses with POI (Malone et al. 2006). Furthermore, in horses with 
ischaemia-injured jejunum, lidocaine reduced the plasma prostaglandin E2 metabolite 
concentration and mucosal cyclooxygenase-2 expression and ameliorated the flunixin-induced 
increase in neutrophil counts (Cook et al. 2009) and has been investigated for its potential 
therapeutic effects in models of endotoxemia in laboratory animals (Taniguchi et al. 1996; 
Schmidt et al. 1997). 
 Recovery from general anaesthesia is the most critical phase when anaesthetizing 
horses. No negative effects were noted by Dzikiti et al. (2003) during the recovery period in 
horses receiving a CRI of lidocaine throughout anaesthesia compared with a saline group. 
When a bolus of 1.5 mg/kg of lidocaine was administered just before surgery and the infusion 
of 30 µg/kg/min stopped when the surgeon started to close the abdomen, horses with 
lidocaine did not show worse recoveries than those of the control group (Driessen 2005). In 
contrast, Valverde et al. (2005) described in a clinical study involving fifty four horses (2 
mg/kg over fifteen minutes followed by 50 µg/kg/min) higher degrees of ataxia and lower 
recovery qualities in horses receiving lidocaine until the end of the surgery. These authors 
recommended to discontinue the CRI thirty minutes before the end of the surgery. Ringer et 
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al. (2007) reported significantly better recoveries after the continuous infusion of 
medetomidine (3.5 µg/kg/hr) compared with lidocaine where both CRIs were stopped at the 
end of surgery and sedation was given prior to recovery. Furthermore, in a clinical study 
performed in twelve horses undergoing elective surgery, the addition of a medetomidine 
infusion (5 µg/kg/hr) to an infusion of lidocaine (2 mg/kg plus infusion at a rate of 50 
µg/kg/min) improved the quality of recovery compared with lidocaine alone (Valverde et al. 
2010a). In horses undergoing field castration, a bolus of lidocaine (3 mg/kg, IV) did not affect 
the recovery quality, although the overall recovery period was longer. Its use also did not 
reduce the needs for additional injectable anaesthesia during surgery (Sinclair & Valverde 
2009). 
In the equine, lidocaine is metabolized via the hepatic cytochrome P450 (CYP450) 
system into the active metabolites monoethylglycinexylidide and glycinexylidide, both 
lidocaine and the metabolites being excreted in the urine (Doherty & Frazier 1998). As it is 
highly metabolized by the liver and has a very short half-life (Engelking et al. 1987), it may 
be used intraoperatively as a bolus followed by a CRI. Lidocaine clearance is highly 
dependent on hepatic blood flow (Engelking et al. 1987) and general anaesthesia has a 
profound effect on serum lidocaine concentrations in horses, mainly due to a decrease in the 
volume of distribution and clearance of lidocaine (Feary et al. 2005). Moreover, other 
anaesthetic drugs metabolized via the CYP450 system may compete for binding sites and 
delay clearance (Doherty & Seddighi 2010). 
 Toxicosis should be considered when lidocaine is included in balanced anaesthetic 
protocols, especially because its neurological signs (weakness or ataxia) may be masked by 
anaesthesia. In the last decade, efforts have been made to determine the toxic blood levels for 
lidocaine in the horse. Meyer et al. (2001) demonstrated that lidocaine produced muscle 
fasciculations, tremors and ataxia in healthy awake horses at plasma levels between 1.85-4.53 
µg/mL, substantially different from humans (1.56 ± 0.61 µg/mL) (Wallace et al. 1997) and 
dogs (8.21 ± 1.69 µg/mL) (Wilcke et al. 1983). Serum lidocaine concentrations ranged from 
1-2 µg/mL in awake horses after abdominal surgery, receiving a loading dose of 1.3 mg/kg, 
followed by a CRI of 50 µg/kg/min. This resulted in a reduction in the volume of gastric 
reflux in horses with proximal enteritis and ileus postoperatively, while clinical signs of 
toxicosis were not observed (Malone et al. 1999). In patients undergoing elective procedures, 
Feary et al. (2005) showed that general anaesthesia with sevoflurane has a profound effect on 
lidocaine disposition in horses, and that lidocaine plasma levels were higher during 
anaesthesia than in awake horses (3.35 ± 0.60 and 1.85 ± 0.39 µg/mL respectively) after a 
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loading dose of 1.3 mg/kg followed by a CRI of 50 µg/kg/hr. Although no clinical signs of 
toxicosis were observed, the authors speculated that general anaesthesia may mask neurologic 
manifestations of toxicosis. Lower doses compared to previous studies were recommended by 
Brianceau et al. (2002), who used a loading dose of 0.65 mg/kg during the first thirty minutes 
of general anaesthesia followed by a maintenance rate of 25 µg/kg/min in colic horses. 
Lidocaine had also favourable effects on jejunal distension and peritoneal fluid accumulation 
after abdominal surgery. The mean intraoperative lidocaine concentration was 1.06 ± 0.6 
µg/mL, although in one horse intraoperative concentrations of 2.72 µg/mL were found. The 
authors attributed this variability mainly to individual differences in cardiac output (    . 
Horses experiencing pain may have a higher    , higher clearance of the drug and lower 
lidocaine serum concentrations. More compromised patients, with impaired cardiovascular 
function, will have a reduced liver blood flow and metabolism and higher lidocaine plasma 
levels. 
 In conclusion, lidocaine can be included in balanced anaesthetic protocols at different 
doses, providing intraoperative analgesia and reducing (dose dependently) the MAC of the 
volatile agent. However, potential side effects such as toxicosis should be taken into account, 
especially in cardiovascularly impaired patients. Furthermore, the infusion should be stopped 
at least thirty minutes before the end of anaesthesia to reduce the incidence of ataxia, 
improving the quality of the recoveries. An overview of the use of lidocaine in equine 
anaesthesia is provided in Table 1. 
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Table 1: Different loading doses and infusion rates reported for the use of IV lidocaine in equine balanced anaesthesia. 
     
     
Animals Loading dose mg/kg CRI µg/kg/min Main findings Reference 
6 experimental ponies 2.5-5 over 5 mins 50-100 ↓ MACHALO dose dependently Doherty & Frazier 1998 
28 colic horses 0.65 over 30 mins 25 Desiderable intestinal effects  Brianceau et al. 2002 
12 healthy clinical horses 2.5 over 10 mins 
(15 mins after induction) 
50 ↓ MACISO by 25% 
No bad recoveries 
Dzikiti et al. 2003 
50 colic horses 1.5 before start of surgery 30 ↓ MACISO & SEVO by 20-25% 
No worse recoveries 
Driessen 2005 
54 healthy clinical horses 2 over 15 mins 50 Affects degree of ataxia 
Stop CRI 30 mins before end of surgery 
Valverde et al. 2005 
16 experimental horses 1.3 over 15 mins 50 Anaesthesia influences lidocaine disposition Feary et al. 2005 
69 healthy clinical horses 2 over 15 mins 50 Maintenance easier and lower FE´ISO with 
medetomidine 
Ringer et al. 2007 
8 experimental horses 1.3 over 15 mins 50 ↓ MACSEVO by 27% Rezende et al. 2011 
CRI = constant rate infusion, MAC = minimum alveolar concentration, HALO = halothane, ISO = isoflurane, SEVO = sevoflurane, FE´ = expired fraction.
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1.2. Ketamine 
Ketamine is a drug discovered in 1962 and was introduced into human clinical anaesthesia in 
1964 (Reich & Silvay 1989; Jansen 2000). It causes an anaesthetic trance-like state referred to 
as ‘dissociative anaesthesia’ (Domino et al. 1965), producing an electrophysiological 
dissociation between the thalamo-neocortical and limbic systems (Kohrs & Durieux 1998). 
This term has been used in humans who reported a feeling of being dissociated from their 
body and environment after administration of ketamine (Muir 2009). Although its role in 
human medicine has diminished with the introduction of newer IV anaesthetics, ketamine is 
still widely used outside the hospital for emergencies, disaster situations, and in third world 
countries as it is reliable for induction and maintenance of general anaesthesia, providing 
good surgical conditions with few side effects (Paix et al. 2005; Visser & Shug 2006). 
Moreover, its use at subanaesthetic doses is accepted in order to provide multimodal analgesia 
in patients with pain related to opioid tolerance but also for the treatment of acute severe, 
neuropathic, ischaemic, peripheral somatic, visceral, cancer or chronic post surgical pain 
(Menigaux et al. 2001; Petrenko et al. 2003; Correll et al. 2004; Visser & Schug 2006). 
Nonmedical use of ketamine has been unfortunately linked to the ‘dance culture’ (Jansen 
2000). 
Ketamine is a non-competitive antagonist of the NMDA receptor, which is a ligand 
gated calcium channel with glutamate as its major endogenous agonist (Kohrs & Durieux 
1998). The NMDA receptors are of major importance for normal brain function and have a 
central role in learning, memory and the development of central nervous system (CNS) 
hyperactive states (Petrenko et al. 2003). Blockade of NMDA receptors enhances analgesia, 
but when exaggerated may result in memory impairment, excitation, dementia, ataxia and 
motor incoordination (Muir 2010). Interaction with NMDA receptors is responsible for 
general anaesthetic effects and analgesia (Visser & Schug 2006). However, although most of 
its effects (analgesic, amnesic and neuroprotective) are mediated via NMDA receptors (Kohrs 
& Durieux 1998; Chang et al. 2002), ketamine also interacts with non-NMDA glutamate, 
opioid, nicotinic, muscarinic and GABAA receptors (Kohrs & Durieux 1998; Knobloch et al. 
2006). The clinical use of NMDA antagonists at routine doses can be restricted mainly 
because of the psychomimetic side effects, ataxia and uncoordinated motor activity (Petrenko 
et al. 2003). These side effects are dose dependent and less common when using small, 
subanaesthetic doses (Himmelseher & Durieux 2005). 
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In contrast to the other drugs used for induction of anaesthesia, ketamine produces 
indirect cardiovascular stimulation with significant increases in blood pressure and heart rate 
(HR) (Zielmann et al. 1997). Additionally, it induces only a minimal respiratory depression 
with mild hypercapnia (Werner et al. 1997) and has been shown to antagonize the 
hypoventilation induced by alfentanil in man (Persson et al. 1999). In horses, IV doses of 2.2 
mg/kg combined with xylazine provided excellent short term anaesthesia with stable 
cardiorespiratory function (Muir et al. 1977). Heart rate and mean arterial blood pressure 
(MAP) did not change when plasma ketamine concentration increased but     did significantly 
increase during ketamine infusion (Muir & Sams 1992). In contrast with these findings, 
Lankveld et al. (2006) reported significant increases in respiratory rate (RR), HR and arterial 
blood pressure during infusion of ketamine at different rates.  
In equine practice, ketamine has been used for induction and maintenance of general 
anaesthesia for many years and has become a popular drug, especially when combined with 
an 2-agonist or centrally acting muscle relaxants (Muir et al. 1977; Butera et al. 1978; Luna 
et al. 1997; Hubbell et al. 2000). Nowadays, ketamine is also administered in horses in 
combination with other drugs to achieve multimodal analgesia for acute and chronic pain 
(Muir 2010). Moreover, it produces effective epidural analgesia (Gómez de Segura et al. 
1998) and local anaesthetic effects (López-Sanromán et al. 2003a, b). 
When administered IV in the equine, ketamine produces antinociceptive (Johnson et 
al. 1999; Knobloch et al. 2006; Peterbauer et al. 2008; Levionnois et al. 2010a) and 
anaesthetic effects (Bettschart-Wolfensberger et al. 1996; Mama et al. 2005). Up to now, the 
possible role in the treatment of equine endotoxaemia, remains controversial (Lankveld et al. 
2005; Alcott et al. 2011). A 1.5 mg/kg/hr CRI of ketamine in healthy conscious horses 
showed that an infusion of ketamine can be safely administered for at least six hours 
(Lankveld et al. 2006). In contrast, Fielding et al. (2006) studied the effects of three different 
infusion rates (0.4, 0.8 and 1.6 mg/kg/hr) in adult conscious horses and clear signs of 
excitation after two hours of infusion of the the highest dose were observed. Ketamine also 
reduced the inhalant anaesthetic requirements up to 37% (related to its plasma concentration) 
in halothane anaesthetized horses (Muir & Sams 1992). Rates reported during equine 
balanced anaesthesia range between 0.5 and 3 mg/kg/hr (Muir 2010). 
Ketamine is frequently included not only in total intravenous anaesthetic protocols 
(TIVA) with other drugs for the maintenance of general anaesthesia (Greene et al. 1986; 
Watkins et al. 1987; Flaherty et al. 1997; Umar et al. 2006; Hubbell et al. 2012) but also in 
multiple PIVA protocols (Spadavecchia et al. 2002; Yamashita et al. 2002; Kushiro et al. 
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2005; Enderle et al. 2008; Villalba et al. 2011; Kempchen et al. 2012; Nannarone & 
Spadavecchia 2012). Moreover, experimental studies have been performed in ponies in order 
to achieve predictable and stable blood drug concentrations, avoiding problems such as under- 
or overdosage by means of target-controlled infusions (TCIs) of ketamine (Knobloch et al. 
2006; Levionnois et al. 2010b). Specific software allows to set a target drug concentration and 
adjusts the administration rate according to predicted drug concentrations in plasma, offering 
better control than CRIs (Hu et al. 2005; Levionnois et al. 2010b). 
Ketamine is a racemic mixture of R- and S-enantiomers, the latter having 
approximately four times greater affinity for the active site of the NMDA receptor, resulting 
in an increase of the hypnotic properties (White et al. 1985; Oye et al. 1992). Currently, S-
ketamine is only available in some European countries for veterinary use. Biotransformation 
of ketamine in the equine occurs by the hepatic and lung microsomes (Knobloch et al. 2006; 
Schmitz et al. 2008). Ketamine is extensively metabolized by the hepatic CYP450 to the 
active metabolite norketamine (S- or R-norketamine) via N-demethylation, which possesses a 
potency of one-third to one-fifth compared to the parent compound, but may be involved in 
the prolonged analgesic actions of ketamine (Kohrs & Durieux 1998). Norketamine forms 
hydroxynorketamine via hydroxylation (White et al. 1982), is later metabolized to 
dehydronorketamine (Lankveld et al. 2006) and is also eliminated by renal excretion (Sams & 
Pizzo 1987). Older studies reported that the elimination half-life of racemic mixture was 
approximately one hour (Kaka et al. 1979; Waterman et al. 1987). In contrast, S-ketamine was 
proven to have a higher clearance compared to the R-enantiomer not only during the 
administration of the racemic mixture but also when the two enantiomers were administered 
separately (Geisslinger et al. 1993; Ihmsen et al. 2001). In humans and horses, more recent 
studies suggest that ketamine pharmacokinetics are ʻcontext sensitiveʼ and differ depending 
on the dose, mode of administration (bolus or infusion) and mainly the duration of 
administration (White et al. 2006; Larenza et al. 2009a). In vitro studies described a slower 
elimination of S-ketamine in the presence of the R-enantiomer in human (Kharasch & Labroo 
1992) and equine models (Schmitz et al. 2008). Clinical studies supported this assumption as 
elimination of S-ketamine was faster when given alone than when administered as part of a 
racemic mixture in standing ponies sedated with xylazine (Larenza et al. 2008) and in 
unsedated ponies (Larenza et al. 2009a). In contrast, the pharmacokinetics of racemic or S-
ketamine in isoflurane anaesthetized ponies did not differ significantly (Larenza et al. 2007), 
mainly due to changes in hepatic and renal enzyme activities mediated by the different co-
administered drugs. 
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 As a consequence of its faster elimination, S-ketamine offers shorter recovery times 
than the racemate in humans (Engelhardt et al. 1998; Ihmsen et al. 2001). In ponies, S-
ketamine (1.1 mg/kg, IV) produced a similar degree of immobility after a single injection and 
faster recoveries compared with the racemate (2.2 mg/kg, IV) (Larenza et al. 2008). When 
administered as a CRI in standing ponies at subanaesthetic doses, S-ketamine was considered 
to be a better option because of the suggested faster elimination (Larenza et al. 2009a). In an 
experimental trial involving ten horses undergoing elective arthroscopy, the recovery from 
anaesthesia was better in horses that were premedicated with xylazine and where anaesthesia 
was induced with S-ketamine (1.1 mg/kg, IV) and maintained with isoflurane and a CRI of S-
ketamine (0.5 mg/kg/hr) compared to horses where the racemic mixture was used instead 
(Larenza et al. 2009b). Additionally, two clinical studies including horses for castration using 
TIVA, showed that horses receiving S-ketamine had quieter and more controlled recoveries 
compared to those where the classic ketamine was administered (Filzek et al. 2003; Rossetti 
et al. 2008). Moreover, Rossetti et al. (2008) reported minor excitatory effects during 
induction, with lower doses of other anaesthetic drugs for maintenance of anaesthesia when S-
ketamine was administered. Unfortunately, it has been stated that S-ketamine may lack an 
antinociceptive effect as a result of rapid metabolism and lower plasma concentrations in the 
equine (Peterbauer et al. 2008). 
 Ketamine and its metabolites may produce excitatory side effects that can turn into 
fatal events in the recovery period in horses (Schatzmann & Girard 1984; Bettschart-
Wolfensberger & Larenza 2007), mainly associated with the R-enantiomer (White et al. 1985; 
Filzek et al. 2003). When given at low doses in standing ponies, S-ketamine produced more 
ataxia and disorientation compared to the racemate, but these effects were of short duration 
(Peterbauer et al. 2008). Side effects in the recovery such as excitement or ataxia may occur 
when using ketamine as the sole agent for induction and maintenance of general anaesthesia 
(Bettschart-Wolfensberger et al. 1996). Furthermore, when infused in combination with other 
anaesthetics/analgesics, its adverse effects during the recovery phase may be prevented by 
reducing ketamine administration early enough before recovery (Knobloch et al. 2006). 
Prolonged infusions may lead to excessive norketamine formation and accumulation in fat 
and muscle (Knobloch et al. 2006), causing undesiderable side effects. Consequently, IV 
boluses higher than 2 mg/kg or CRIs exceeding 1 mg/kg/hr should not be used in anaesthetics 
longer than 90-120 minutes while ketamine CRIs should be reduced in long procedures and/or 
stopped fifteen to twenty minutes before the recovery (Bettschart-Wolfensberger & Larenza 
2007). Alternatively, an 2-agonist can be administered to reduce the incidence of 
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complications during the recovery phase (Santos et al. 2003). Furthermore, ketamine 
infusions may produce increases in gastrointestinal transit time and decreases in fecal output 
(Elfenbein et al. 2011). 
In summary, low doses of IV racemic or S-ketamine may be useful in equine balanced 
anaesthetic protocols because of the demonstrated analgesic effects, the reduction of the 
anaesthetic requirements and the improvements of the cardiovascular haemodynamics. 
However, caution should be taken to prevent its undesiderable excitatory side effects that may 
worsen the quality of the recoveries, mainly by avoiding high doses/rates and prolonged 
infusion times. 
 
1.3. Opioids 
Opium, extracted from the poppy seeds (Papaver somniferum) for thousand years, has been 
used in the treatment of cough and diarrhea and to relieve pain, while it may also produce 
euphoria (Kieffer 1999). The active ingredients of opium are alkaloid compounds, the so-
called opioids, which possess analgesic (Dickenson 1991) and addictive (Koob 1992) 
properties. Morphine was the first opioid isolated from the poppy seeds in 1803 by Seturner, 
although its structure was not elucidated until 120 years later by Gulland & Robinson (1923) 
(Janecka et al. 2004). Today, in human medicine, morphine remains the reference opioid and 
is clinically used as an analgesic, despite a considerable number of side-effects including 
respiratory depression, nausea and vomiting, sedation and drowsiness, constipation, urinary 
retention or multifocal myoclonus (Schug et al. 1992; Inturrisi 2002). Morphine has been used 
in veterinary medicine since many years in order to produce analgesia, different degrees of 
sedation and reduction of the MAC of inhalant anaesthetics in dogs, rats, pigs, monkeys and 
cats (Murphy & Hug 1982; Lake et al. 1985; Steffey et al. 1994; Ilkiw et al. 2002; Muir et al. 
2003). Apart from morphine, other synthetic opioids such as pethidine (Steffey et al. 1977), 
butorphanol (Murphy & Hug 1982; Ko et al. 2000), methadone (Credie et al. 2010; Ferreira et 
al. 2011), fentanyl (Moon et al. 1995; Hellyer et al. 2001; Reilly et al. 2013), alfentanil (Lake 
et al. 1985; Hall et al. 1987a; Ilkiw et al. 1997), remifentanil (Allweiler et al. 2007; Ferreira et 
al. 2009) or sufentanil (Hall et al. 1987b; Polis et al. 2004) have been widely employed 
systemically in veterinary medicine for the same reasons. 
Three different types of opioid receptors have been identified and cloned, the µ, δ and 
 receptors (Kieffer 1999; Janecka et al. 2004). The diversity of opioid receptors is further 
extended by the existence of several subtypes of opioid receptors (Smith & Lee 2003). It has 
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been described that µ-receptors mediate the most potent antinociceptive effects, but are also 
responsible for the development of dependence and adverse effects (Kieffer 1999; Janecka et 
al. 2004). Lower efficacy in mediating pain relief with a reduced addictive potential has been 
linked to δ-receptors (Janecka et al. 2004). The use of -receptor agonists may be restricted to 
peripheral tissues, mainly due to their potential dysphoric effects (Kieffer 1999). Moreover, 
interactions between receptors play a major role in opioid actions. Local, involving receptors 
of the same tissue, and nonlocal interactions, between receptors located in different tissues, 
have been described (Smith & Lee 2003). An ‘orphan’ (ORL) receptor has also been 
identified, which mainly mediates anti-opioid, rather than typical opioid effects (Fukuda et al. 
1994; Mollereau et al. 1994). Opioid receptors are part of a large superfamily of membrane-
bound receptors that are coupled to G-proteins (Smith & Lee 2003). Opioid receptor binding, 
via activation of different types of G-proteins, may inhibit adenylyl cyclase activity, activates 
receptor-operated potassium ion currents and suppresses voltage-gated calcium ion currents 
(Inturrisi 2002; Lamont & Mathews 2007). 
The analgesic effects of the opioids are due to the direct inhibition of the ascending 
transmission of nociceptive information from the spinal cord dorsal horn, and due to 
activation of pain-control circuits that descend from the midbrain via the rostral ventromedial 
medulla to the spinal cord (Lamont & Mathews 2007). Opioids have also been reported to 
produce peripheral analgesia and anti-inflammatory effects (Stein et al. 2001). Opioid 
receptors are located in the joints of dogs (Keates et al. 1999), horses (Sheehy et al. 2001), 
rats (Nagasaka et al. 1996) and humans (Lawrence et al. 1992) as well. Different opioids have 
been used in humans and animal species in different ways to provide analgesia, i.e. also as 
anaesthetic adjuvants for inhalation anaesthetics, with the aim to reduce their MAC values. 
The use of opioids in horses can be justified by their analgesic and sedative properties, 
but remains controversial due to their undesirable effects (Bennett & Steffey 2002; Clutton 
2010). The use of morphine for pain relief in horses was first reported in 1898 (Guinard 1898) 
and its excitatory effects were described one year later (Guinard 1899). In 1917, the sedative 
effects of a low dose of morphine in horses were described (Milks 1917). Twenty years later, 
Amadon & Craigie (1937) described a ‘minimal analgesic dose’ at 0.2 mg/kg and a ‘minimal 
excitant dose’ at 0.5 mg/kg. Opioids have been associated with ‘excitement and 
unpredictable’ reactions in horses (Tobin 1981) and it has been suggested by Kamerling et al. 
(1989) that the behavioural and cardiovascular effects of morphine are stronger than its 
analgesic effects. When morphine was administered in ‘pain-free horses’ at a dose of 0.12 
mg/kg, Muir et al. (1979) did not detect behavioural effects, although higher doses (0.66 
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mg/kg) stimulated locomotor activity for four to five hours (Kalpravidh et al. 1984). When 
fentanyl was administered by rapid IV injection, a sharp increase in locomotor activity was 
observed (Tobin et al. 1979). The different behavioural reactions to opioids compared with 
other species such as dogs may be related to the binding and distribution of opioid receptors 
in the brain, as the equine cerebral cortex is rich in µ-opioid receptors (Hellyer et al. 2003). 
More recent studies showed that the horse´s cerebral cortex possesses a high concentratrion of 
high-affinity µ-receptors and lower concentration of δ- and - receptors, which resembles that 
of other species where opioid-induced CNS stimulation occurs (Thomasy et al. 2007), and 
differs markedly from the dog (Sharif et al. 1990) and human cerebral cortex (Pfeiffer et al. 
1982). In horses, k-receptor opioids seem to promote less locomotor and sympathetic 
stimulation than µ-opioids (Bennett & Steffey 2002). 
With respect to their volatile anaesthetic sparing effects, opioids did not consistently 
alter the MAC in the equine. When morphine was administered as boluses at two different 
doses (low dose at 0.25 mg/kg and high dose 2.0 mg/kg), the change in MAC of isoflurane 
ranged from -20.2 to +28.3% and -18.9 to +56.2% after low and high doses respectively 
(Steffey et al. 2003). In contrast, when morphine was administered as an IV bolus (0.15 
mg/kg) followed by a CRI (0.1 mg/kg/hr) in halothane anaesthetized horses undergoing 
elective surgical procedures, horses tended to receive fewer and lower doses of additional 
anaesthetic drugs, although this was not of statistical significance (Clark et al. 2005). In a 
study performed in ponies, Matthews & Lindsay (1990) did not find a statistically significant 
reduction of the MAC of halothane when administering two different IV doses of 
butorphanol, and the MAC was even increased in two ponies. Moreover, Doherty et al. (1997) 
reported in seven ponies that butorphanol did not significantly change the MAC of halothane, 
with an increase in three ponies, decrease in one and no effects in the other three ponies. 
When assessing the effects of three plasma concentrations of alfentanil, no significant 
changes in the MAC of halothane were observed in five horses (Pascoe et al. 1993). When 
fentanyl was administered IV to eight isoflurane anaesthetized horses at different doses and 
rates, the results suggested that this drug might consistently decrease anaesthetic requirements 
(Thomasy et al. 2006). However, in a more recent study, Knych et al. (2009) found no 
consistent changes in the MAC of isoflurane in eight horses. When combined with other 
drugs such as xylazine, morphine did not further reduce the MAC of halothane in six healthy 
horses (Bennett et al. 2004) and the addition of a CRI of morphine to a combination of two 
CRIs of ketamine and lidocaine did not further decrease the MAC of isoflurane (Villalba et al. 
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2011). However, the MAC sparing effects of a CRI of morphine alone have been not 
determined in the equine. 
Behavioural effects associated with the use of opioids in horses may affect recovery. 
Steffey et al. (2003) noticed individuals recovering violently with signs of CNS excitement 
when high doses (2.0 mg/kg) were administered IV in a MAC study in six adult horses, 
whereas horses that received the low dose (0.25 mg/kg) recovered well, with little evidence of 
ataxia. After receiving IV fentanyl, one horse showed a violent recovery where the horse 
‘frenetically attempted to circle in both directions and fell down several times’ (Thomasy et 
al. 2006). Moreover, in the study reported by Knych et al. (2009), undesiderable and 
excitatory behaviours were observed after fentanyl administration. The authors concluded that 
the routine use of fentanyl is not supported. On the other hand, in a retrospective study 
involving eighty four healthy horses, Mircica et al. (2003) found that the recovery quality was 
better in horses receiving IV boluses of morphine (0.1 and 0.17 mg/kg) five to ten minutes 
after induction. The same findings were reported by Love et al. (2006) in horses undergoing 
anaesthesia for upper respiratory tract surgery with significantly better recoveries in horses 
receiving morphine at two different doses (0.1 and 0.2 mg/kg, IV). In another study, 
recoveries from general anaesthesia receiving morphine IV (0.15 mg/kg followed by a CRI of 
0.1 mg/kg/hr) were better, with fewer attempts to attain sternal recumbency and standing and 
shorter times from the first recovery movement to the time at standing, compared to horses 
where morphine was not administered (Clark et al. 2008). 
Other side effects should be taken into consideration when using opioids in the equine, 
such as risks of reduction of gastrointestinal motility and postoperative colic (Roger et al. 
1985; Sellon et al. 2004; Boscan et al. 2006) or respiratory depression that could lead to a 
rapid increase in arterial partial pressure of carbon dioxide during general anaesthesia (Steffey 
et al. 2003). Although Steffey et al. (2003) showed undesiderable residual CNS stimulating 
locomotor effects after administration of morphine, box-walking behaviour after general 
anaesthesia was either not observed (Love et al. 2006; Clark et al. 2008) or only present in 
one horse out of fifty one receiving morphine (Mircica et al. 2003). In an experimental study 
involving eight isoflurane anaesthetized horses testing different concentrations of fentanyl, 
two horses required active cooling by applying ethanol to the skin when their temperatures 
reached 38.2°C (Thomasy et al. 2006). Although unclear, morphine may have been involved 
in the development of postoperative pulmonary oedema in two horses (Kaartinen et al. 2010). 
The authors hypothesized that a relative fluid overloading during the prolonged anaesthetic 
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period was worsened by ‘morphine-induced reduction in urine production, further aggravated 
by potential morphine-induced changes in pulmonary permeability’. 
Clinical evidence seems to suggest that opioids enhance the sedative and analgesic 
effects of 2-agonists. Morphine, methadone and butorphanol improved the sedative effects of 
2-agonists, decreasing the responses to external stimuli, with butorphanol producing the 
most reliable response (Clarke & Paton 1988). Butorphanol (0.05 mg/kg, IV) reduced the 
response to imposed stimuli in horses sedated with romifidine, with no further cardiovascular 
changes than those induced by romifidine but an increased degree of respiratory depression 
(Clarke et al. 1991). The combination of butorphanol or levomethadone with detomidine 
increased the nociceptive threshold to somatic pain in horses, thereby prolonging the 
analgesic effect of detomidine (Schatzman et al. 2001). Butorphanol (0.05 mg/kg) and 
romifidine (0.1 mg/kg) IV provided better sedation than romifidine alone and, although the 
quality of sedation was significantly better than when romifidine was combined with 
morphine (0.1 mg/kg), the latter was concluded to be a suitable alternative (Corletto et al. 
2005). In horses undergoing exploratory laparascopy, the IV combination of medetomidine 
and morphine resulted in reliable sedation and stable cardiorespiratory function (Solano et al. 
2009). Romifidine (0.1 mg/kg) and butorphanol (0.05 mg/kg) IV resulted in a longer duration 
of sedation and analgesia than romifidine or butorphanol alone (DeRossi et al. 2009). The 
addition of both types of drugs when performing equine balanced anaesthesia may enhance 
sedation and provide multimodal analgesia while avoiding the potential excitatory side effects 
linked to the use of opioids in horses. 
In conclusion, opioids may be added when using IV balanced anaesthetic techniques 
in horses providing additional analgesia and sedation. However, their inconsistent MAC 
reduction, CNS stimulation, reduced gastrointestinal motility and other side effects may limit 
its use. Combination with other drugs such as 2-agonists may enhance their sedative and 
analgesic properties, providing a multimodal analgesic approach while reducing their 
potential excitatory effects. 
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Table 2: Effects reported after IV administration of different opioids in horses undergoing general anaesthesia. 
Drug Animals Bolus Infusion rate Effects Reference 
Mor 6 experimental horses 0.25 mg/kg - Good recoveries, MAC (-20.2 to +28.3%) Steffey et al. 2003 
Mor " 2.0 mg/kg - Bad recoveries, MAC (-18.9 to +56.2) " 
Mor 84 healthy clinical horses 0.1-0.17 mg/kg - Better recoveries with Mor Mircica et al. 2003 
Mor 6 experimental horses 0.1-0.2 mg/kg - Mor does not alter Xyl sparing effect  Bennett et al. 2004 
Mor 38 clinical horses 0.1-0.2 mg/kg - Better recoveries Love et al. 2006 
Mor 38 healthy clinical horses 0.15 mg/kg 0.1 mg/kg/hr Fewer & lower extra anaesthetics Clark et al. 2005 
Mor 22 healthy clinical horses 0.15 mg/kg 0.1 mg/kg/hr Less attempts & short times to recover Clark et al. 2008 
Butor 9 experimental ponies 0.022-0.044 mg/kg - No changes MACHALO Matthews & Lindsay 1990 
Butor 7 experimental ponies 0.05 mg/kg - No changes MACHALO Doherty et al. 1997 
Alfent 5 experimental horses 3 different targeted plasma concentrations No changes MACHALO Pascoe et al. 1993 
Fent 8 experimental horses  0.3-3.0-4.7 µg/kg 0.4-3.5-6.8 µg/kg/hr ↓ MACISO, 1 violent recovery  Thomasy et al. 2006 
Fent 8 experimental horses 4.2-6.2-8.3 µg/kg 6-9-12 µg/kg/hr No changes MACISO, bad recoveries Knych et al. 2009 
Mor = morphine, Butor = butorphanol, Alfent = alfentanil, Fent = fentanyl, MAC = minimum alveolar concentration, Xyl = xylazine, HALO = halothane, ISO = isoflurane.
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1.4. Alpha2-adrenoceptor agonists 
Clonidine, the first 2-agonist, was synthesized at the beginning of the 1960s. This drug was 
used as a nasal decongestant, further developed as an antihypertensive agent and finally used 
for alleviation of the symptoms of opiate withdrawal (Stähle 2000). Xylazine was initially 
also commercialized in 1962 as an antihypertensive. Despite, or in fact because of its potent 
sedative side effects in humans (Kästner 2006), its use in veterinary medicine became popular 
(Rosenberger et al. 1968; Clarke & Hall 1969; Müller et al. 1969; Kerr et al. 1972). In the 
1980s, different 2-agonists were developed such as detomidine (Virtanen et al. 1985; Lowe 
& Hilfiger 1986; Jöchle & Hamm 1986), medetomidine (Savola et al. 1986; Stenberg et al. 
1987; Virtanen 1988), dexmedetomidine (Kallio et al. 1989) and romifidine (Gasthuys et al. 
1990; England et al. 1992). Currently, xylazine, detomidine and romifidine are approved for 
use in horses in Europe. Medetomidine and dexmedetomidine are licensed for small animals 
only, although both drugs have been studied in horses (Bryant et al. 1991; Bettschart-
Wolfensberger et al. 1999, 2005). 
Adrenoceptors are situated on the cell membrane sites where noradrenaline and 
adrenaline act as important neurotransmitters in the peripheral and CNS. It was first observed 
by Dale (1905) that the pressor effect of adrenaline was reversed by ergotoxine, but it was not 
until 1948 that Ahlquist proposed the classification of adrenoceptors into  and  (Ahlquist 
1948). Differentiation between 1 receptors, which mediate the responses in the effector 
organs (i.e. heart, lung, liver, arteries) and 2, located presynaptically to regulate the release 
of the neurotransmitter, but also present postsynaptically, was suggested by Langer (1974) 
and later accepted by Berthelsen & Pettinger (1977). Molecular cloning technology and the 
development of more selective drugs revealed three 2-adrenoceptor subtypes (2a/d, 2b, 2c) 
(Bylund 1994; Guimarães & Moura 2001). The division between 1 and 2-adrenoceptors is 
made depending on their selectivity to specific agonist and antagonist agents (England & 
Clarke 1996). Clonidine, xylazine, romifidine, detomidine, medetomidine and 
dexmedetomidine are agonists whilst atipamezole and yohimbine are the classic antagonists 
(Scheinin & Macdonald 1989). 
The 2-adrenoceptors are transmembrane receptors coupled to the inhibitory 
heterotrimetric GTP-binding protein inhibiting the activity of adenylyl cyclase (Cotecchia et 
al. 1990; Wise et al. 1997; Khan et al. 1999) and the opening of voltage-gated calcium 
channels (Cotecchia et al. 1990) while activating potassium channels (Surprenant et al. 1992). 
Presynaptic 2-adrenoceptors in sympathetic nerve endings and noradrenergic neurons in the 
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CNS inhibit the release of noradrenaline (Langer 1980). Postsynaptic 2-adrenoceptors are 
present in the liver, pancreas, platelets, kidney, adipose tissue and the eye (Khan et al. 1999). 
The locus coeruleus of the brain contains a high density of 2-adrenoceptors (Unnerstall et al. 
1984) mediating the sedative action by 2a-adrenoceptors (Scheinin & Schwinn 1992). High 
densities of 2a-adrenoceptors are also present in the descending pathways within the spinal 
column, modulating nociceptive stimuli and interactions with opioids (Fairbanks et al. 2009). 
Furthermore, the 2-adrenoceptors are densely distributed in the dorsal motor nucleus of the 
vagus and nucleus tractus solitarius (Robertson & Leslie 1985), activating the cardiac vagal 
nerve through the action on those brainstem areas (Kawada et al. 2012), and in the superficial 
laminae and substantia gelatinosa of the dorsal horn (Nicholas et al. 1993). The dorsal horn of 
the spinal cord contains 2a-adrenoceptors, while the primary sensory neurons contain both 
2a and 2c (Murrell & Hellebrekers 2005). Centrally, the subtype 2b has been found scarcely 
in the thalamic region in rats (Scheinin et al. 1994), although these receptors have been 
involved in modulating nitrous oxide mediated nociception in mice together with the 2a-
adrenoceptors (Guo et al. 1999; Sawamura et al. 2000). In vascular smooth muscle the 2b-
subtypes mediate peripheral hypertension after 2-agonist administration (Link et al. 1996). 
The 2c-receptors influence several complex memory and behavioural functions (Björklund et 
al. 1999; Scheinin et al. 2001). 
Alpha2-agonists are potent sedatives with good analgesic properties which are used 
frequently in combination with other drugs during anaesthesia in horses. Side effects include 
bradycardia, arrhythmias, decreases in     and increases in systemic vascular resistance, 
respiratory depression, transient decreases in arterial partial pressure of oxygen and ataxia 
(England & Clarke 1996; Yamashita et al. 2000), especially after bolus administration. 
Reported sedative effects of 2-agonists in horses include decreased awareness, ptosis of the 
head, lower lip and eyelids, ataxia and a wide stance (England & Clarke 1996; Valverde 
2010b), all of which are mediated through 2a-receptors (Knaus et al. 2007). These sedative 
effects are related to their spinal and supraspinal actions, demonstrated in visceral pain 
models (Pipi & Lumb 1979; Muir & Robertson 1985; Kohn & Muir 1988; Elfenbein et al. 
2009). Intestinal motility has been shown to decrease in horses after IV administration of 
different 2-agonists (Adams et al. 1984; Freeman & England 2001). On the other hand, as 
suggested by Valverde (2010b), 2-agonists could produce beneficial effects on the stomach 
as shown in rats, mediated by 2b-receptors, inducing a gastroprotective effect by regulating 
gastric acid secretion and inhibiting chemically (non-steroidal anti-inflammatory drugs) and 
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physically (stress) induced gastric mucosal lesions (Gyires et al. 2000, 2009; Fülöp et al. 
2005). Furthermore, these drugs are known to increase urine output in awake (Thurmon et al. 
1984) and anaesthetized healthy equids (Tranquilli et al. 1984; Steffey & Pascoe 2002), 
mainly due to hyperglycaemia from hypoinsulinaemia (Gasthuys et al. 1986, 1987) mediated 
through 2a and 2c-receptors (Peterhoff et al. 2003) and additionally due to a reduced 
arginine vasopressin secretion (Alexander & Irvine 2000). In patients receiving 2-agonists 
during general anaesthesia, the placement of a urinary catheter is justified to avoid excessive 
bladder distension but also to monitor urinary output (Bettschart-Wolfensberger & Larenza 
2007; Valverde 2010b). 
The use of IV 2-agonists in balanced anaesthetic techniques has become more and 
more popular over the last years, mainly to reduce the MAC of inhalation anaesthetic agents 
and to provide sedation and analgesia perioperatively. Furthermore, their use is extended as 
their administration after inhalation anaesthesia improved the quality of recovery without 
producing significant cardiorespiratory effects (Santos et al. 2003). 
Xylazine, the least selective 2-agonist [selectivity ratio (α2/α1) 160:1], has been used 
widely and successfully as a premedicant in the horse (England & Clarke 1996). Under 
experimental conditions, isoflurane MAC was reduced by 25 and 34% after administration of 
IV xylazine at 0.5 and 1.0 mg/kg respectively (Steffey et al. 2000) and halothane MAC by 
20% after a bolus of 0.5 mg/kg (Bennett et al. 2004). Up to date, only one abstract has been 
reported using xylazine as a CRI (1 mg/kg/hr after 0.7-0.8 mg/kg) in isoflurane anaesthetized 
horses, resulting in pronounced reduction of blood pressure support and anaesthetic 
requirements compared to isoflurane alone (0.95 ± 0.07 versus 1.16 ± 0.13) (Pöppel et al. 
2012). 
A CRI of detomidine (260:1), administered with a TCI device to achieve a plasma 
level of 25 ng/mL (10.8 µg/kg/hr), reduced the MAC of halothane by 33% in horses (Dunlop 
et al. 1991). Based on these results, the effects of a CRI of detomidine were investigated in 
nine halothane anaesthetized horses undergoing neurectomy (Wagner et al. 1992). One group 
consisted of five horses receiving a detomidine CRI to accomplish a plasma concentration of 
25 ng/mL during halothane anaesthesia at an FE´ISO of 1.1%. In the remaining four horses, 
anaesthesia was maintained using 1.5 % FE´HALO. Both protocols should result in an 
equivalent depth of anaesthesia according to the previous preliminary trials by Dunlop et al. 
(1991). Apart from a significantly lower HR in the detomidine group, no other changes were 
reported in cardiovascular function and recovery parameters. A recent blinded clinical study 
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using a detomidine bolus (10 µg/kg) followed by a CRI (5 µg/kg/hr) was performed by our 
research group in twenty adult healthy horses undergoing elective surgery (Schauvliege et al. 
2011). Typical cardiovascular effects of 2-agonists were observed, with no effect on the 
isoflurane requirements, recovery duration or recovery quality. 
 Recently, the pharmacokinetic profile and pharmacodynamic effects of romifidine 
(340:1) in the horse have been described (Wojtasiak-Wypart et al. 2012). Its use as a CRI for 
balanced anaesthesia was first reported by Kuhn et al. (2004) in a double-blinded clinical 
study of twenty isoflurane-anaesthetized horses undergoing elective surgery. After IV 
premedication with 80 µg/kg of romifidine, a CRI of 18 µg/kg/hr was continued. Isoflurane 
requirements were reduced significantly, with beneficial effects on the cardiovascular and 
pulmonary parameters. Unfortunately, the effect of mechanical ventilation was not taken into 
account, two different anaesthetists were involved and a description of the recoveries was 
lacking. In contrast, Devisscher et al. (2010) failed to detect inhalation sparing effects in a 
blinded clinical study involving thirty isoflurane anaesthetized horses undergoing routine 
arthroscopy when using the same loading dose followed by a CRI at 40 µg/kg/hr. This 
protocol did not affect cardiovascular function or recovery quality. 
  Although not licensed for horses, medetomidine (1620:1) has been widely studied in 
the equine. It has been used as a sedative/analgesic for restraining horses and as 
premedication prior to general anaesthesia (Bryant et al. 1991; England & Clarke 1996), with 
cardiovascular effects of short duration (Bryant et al. 1996; Yamashita et al. 2000). The 
pharmacokinetic and pharmacodynamic properties of medetomidine have been studied in 
ponies when administering an IV bolus of 7 µg/kg followed by a CRI of 3.5 µg/kg/hr 
(Bettschart-Wolfensberger et al. 1999) and in horses after an IV bolus of 10 µg/kg (Grimsrud 
et al. 2012). Properties such as high clearance and short half-life make the drug suitable for 
continuous infusion in the horses (Bettschart-Wolfensberger et al. 1999). Identical dosages as 
described by Bettschart-Wolfensberger et al. (1999) reduced the MAC of desflurane in an 
experimental trial involving seven healthy ponies by 28% compared to previously reported 
MAC values in literature (Bettschart-Wolfensberger et al. 2001). Clinical studies performed 
by the same group of researchers using the same protocol, found a reduction in the MAC of 
isoflurane of approximately 20% (Neges et al. 2003). In a retrospective study of Kalchofner et 
al. (2006) this protocol appeared to be suitable in horses undergoing routine surgery, with 
well maintained cardiopulmonary function and an incidence of hypotension and hypoxaemia 
comparable to other anaesthetic regimes. The latter study also described the ‘lighter’ 
appearance of horses under anaesthesia when medetomidine is infused compared with 
General introduction 
  
44 
 
traditional inhalant protocols and reported good and calm recoveries. When comparing this 
protocol with a lidocaine infusion, MAP tended to be higher and the surgical plane of 
anaesthesia was better maintained in horses receiving medetomidine, with less need of 
additional ketamine and thiopental (Ringer et al. 2007). Even more, the combination of an 
intraoperative CRI of medetomidine and lidocaine did not affect the cardiovascular function 
of isoflurane anaesthetized horses but improved the quality of the recovery when compared 
with lidocaine alone (Valverde et al. 2010a). In a recent study, the addition of a CRI of 
medetomidine to horses also receiving CRIs of lidocaine and ketamine reduced the FE´ISO 
from 1 to 0.65% (Kempchen et al. 2012).  
 To summarize, the 2-agonists used in combination with volatile agents reduced the 
MAC of these agents and provided extra sedation and analgesia, with ease of maintenance of 
anaesthesia and better recovery qualities. However, their impact on cardiovascular function 
should be considered. It is worth mentioning that all the studies reporting the use of 2-
agonists were performed in healthy horses. The use of these drugs in compromised (colic) 
horses remains controversial. A list with the different studies using 2-agonists in equine 
balanced anaesthesia is provided in Table 3. 
 The cardiopulmonary effects and pharmacokinetics of the newest 2-agonist 
dexmedetomidine have been studied in ponies after IV administration (Bettschart-
Wolfensberger et al. 2005). With similar cardiopulmonary effects to those reported by other 
2-agonists, this drug was defined as a rapidly redistributed and short-acting sedative drug in 
horses, useful for CRIs protocols. Moreover, the administration of the active enantiomer of 
the racemic mixture alone may have some cardiovascular and analgesic benefits, being 
slightly more potent and predictable than medetomidine (Kuusela et al. 2001; Granholm et al. 
2007).  
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Table 3: Different loading doses and infusion rates reported for the use of IV 2-agonists in equine balanced anaesthesia. 
Drug Animals Loading doses Infusion rates Main findings Reference 
Xyl 51 healthy clinical horses 0.7-0.8 mg/kg 1.1 mg/kg/hr Pronounced ISO reduction  Pöppel et al. 2012 
Det  Plasma concentration 25 ng/mL ↓MACHALO by 33% Dunlop et al. 1991 
Det 9 healthy horses 10.8 µg/kg/hr to achieve 25 ng/mL ↓ MACHALO Wagner et al. 1992 
Det 20 healthy clinical horses 10 µg/kg 5 µg/kg/hr No sparing ISO effects Schauvliege et al. 2011 
Rom 20 healthy clinical horses 80 µg/kg 18 µg/kg/hr Significant reduction ISO Kuhn et al. 2004 
Rom 30 healthy clinical horses 80 µg/kg 40 µg/kg/hr No sparing ISO effects Devisscher et al. 2010 
Med 5 experimental ponies 7 µg/kg 3.5 µg/kg/hr Suitable for infusion Bettschart-Wolfensberger et al. 1999 
Med 7 experimental ponies 7 µg/kg 3.5 µg/kg/hr ↓ MACDESF by 28% Bettschart-Wolfensberger et al. 2001 
Med 40 healthy clinical horses 7 µg/kg 3.5 µg/kg/hr ↓ MACISO by 20% Neges et al. 2003 
Med 69 clinical horses 7 µg/kg 3.5 µg/kg/hr Maintenance easier and ↓ 
FE´ISO than lidocaine 
Ringer et al. 2007 
Xyl = xylazine, Det = detomidine, Rom = romifidine, Med = medetomidine, MAC = minimum alveolar concentration, HALO = halothane, ISO = isoflurane, DESF = 
desflurane, FE´ = expired fraction.
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Conclusions 
Several drugs and their combinations can be administered systemically in order to improve 
cardiovascular function and recovery qualities and to provide a multimodal analgesic 
approach, although their advantages and disadvantages should be evaluated. The use of the 
different protocols reviewed here requires some clinical experience in order to avoid 
intraoperative and postoperative complications, such as inadequate depth of anaesthesia and 
analgesia, toxicity, poor recovery qualities or postoperative complications. In the search for 
the ideal agent, previous results in ponies and other species pointed out dexmedetomidine as 
an attractive alternative for equine balanced anaesthetic protocols. An overview of data and 
dosages of different combination of drugs used for CRIs is provided in Table 4.
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Table 4: Different loading doses and infusion rates reported for use of IVcombinations of drugs in equine balanced anaesthesia. 
Drugs Animals Loading doses Infusion rates Main findings Reference 
Lid/Ket 40 healthy clinical horses Lid: 1.5 mg/kg (10 mins) 
Ket: 3 mg/kg  
Lid: 40 µg/kg/min 
Ket: 3.6 mg/kg/hr 
↓ MACISO by 40% Enderle et al. 2008 
Lid/Ket 6 experimental horses Lid: 2 mg/kg (10 mins) 
Ket: 3 mg/kg  
Lid: 50 µg/kg/min 
Ket: 3 mg/kg/hr 
↓ MACISO by 49% Villalba et al. 2011 
Lid/Ket/Mor " Lid/Ket as above 
Mor: 0.15 mg/kg 
Lid/Ket as above 
Mor: 0.1 mg/kg/hr 
↓ MACISO by 53% " 
Lid/Ket 40 healthy clinical horses Lid: 1.5 mg/kg (10 mins) 
Ket: 3 mg/kg  
Lid: 33 µg/kg/min 
Ket: 2 mg/kg/hr 
FE´ISO 1%  
(0.62-1.2%) 
Kempchen et al. 2012 
Lid/Ket/Med " Lid/Ket as above 
 
Lid/Ket as above 
Med: 3.6 µg/kg/hr 
FE´ISO 0.65% 
(0.4-1.0%) 
" 
Lid/Med 12 healthy clinical horses Lid: 2 mg/kg (10 mins) Lid: 50 µg/kg/min 
Med: 5 µg/kg/hr 
Better recoveries than 
lidocaine alone 
Valverde et al. 2010a 
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Drugs Animals Loading doses Infusion rates Main findings Reference 
Gu/Ket 28 healthy clinical horses Gu: 60 mg/kg 
Ket: 2.2 mg/kg 
Gu: 0.3-1 mg/kg/min 
Ket: 0.9-2.4 mg/kg/hr 
↓ FE´HALO from 1.24% to 
0.61% 
Spadavecchia et al. 2002 
 
Gu/Ket/Med 
 
40 healthy horses 
 
Ket: 2.2 mg/kg 
Gu: 0.4 mg/kg/min 
Ket: 1 mg/kg/hr 
Med: 1.2 µg/kg/hr 
↓ MACSEVO 
by  
38% 
Yamashita et al. 2002 
Gu/Ket 45 healthy clinical horses Gu: 50 mg/kg 
Ket: 2.2 mg/kg 
Gu: 1 mg/kg/min 
Ket: 2.4 mg/kg/hr 
Adequate anaesthesia at 
0.75 MACISO 
Nannarone & 
Spadavechia 2012 
Rom/Ket 45 healthy clinical horses Rom: 50 µg/kg 
Ket: 2.2 mg/kg 
Rom: 24 µg/kg/hr 
Ket: 2.4 mg/kg/hr 
Adequate anaesthesia at 
0.75 MACISO 
Nannarone & 
Spadavechia 2012 
 
Mdz/Ket/Med 
 
6 experimental horses 
 Mdz: 0.04 mg/kg 
Ket: 2.5 mg/kg 
Med: 5 µg/kg 
Mdz: 0.02 mg/kg/hr 
Ket: 1 mg/kg/hr 
Med: 1.25 µg/kg/hr 
Adeaquate anaesthesia at  
0.74 MACSEVO 
 
Kushiro et al. 2005 
Lid = lidocaine, Ket = ketamine, Mor = morphine, Med = medetomidine, Gu = guaifenesin, Rom = romifidine, Mdz = midazolam, HALO = halothane, ISO = isoflurane, 
SEVO = sevoflurane, MAC = minimum alveolar concentration, FE´ = expired fraction. 
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Summary 
Dexmedetomidine, the most selective 2-agonist, is a drug with a beneficial 
pharmacological profile (short half-life and rapid redistribution) that produces 
sedation, anxiolysis and analgesia. This 2-agonist has been used in human and 
veterinary medicine for years, more specifically in ‘balanced anaesthesia’ reducing 
the use of volatile anaesthetics. In the equine, only the pharmacokinetics and 
cardiopulmonary effects after administration of an intravenous bolus in ponies 
have been described. Dexmedetomidine was proven to be safe for sedation. 
Although the kinetics suggest its use as a continuous infusion, this had not been 
investigated in depth in anaesthetized equines at the beginning of this PhD.  
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2.1. History of dexmedetomidine 
Medetomidine, a racemic mixture of two individual isomers (Vickery et al. 1988; 
Savola & Virtanen 1991) has been marketed as Domitor (Orion Corporation, Espoo, 
Finland) for use in dogs and cats since 1987. Dexmedetomidine is the 
pharmacologically active optical enantiomer (Savola & Virtanen 1991), being entirely 
responsible for the sedative, analgesic and dose dependent anaesthetic sparing effects 
(Segal et al. 1988; Ansah et al. 1998; Kuusela et al. 2000). Reports have suggested that 
at equivalent concentrations, dexmedetomidine may be less likely to cause drug 
interactions compared to the racemate (Kharasch et al. 1992). Moreover, its use may 
offer advantages over medetomidine (Ansah et al. 1998; Kuusela et al. 2000), being 
slightly more potent (Savola & Virtanen 1991; Kuusela et al. 2000). The European 
Commision granted a marketing authorization for Dexdomitor (Orion Corporation, 
Espoo, Finland) in 2002, which was renewed in 2007. It is indicated for use as a 
sedative and analgesic in dogs and cats to facilitate clinical examinations, clinical 
procedures, minor surgical procedures and as a pre-anaesthetic to general anaesthesia. 
Dexmedetomidine (Precedex

, Hospira, Inc., Lake Forest, IL) was also 
approved for use in humans in the US specifically as a continuous infusion up to one 
day for sedation and analgesia in the intensive care unit (ICU). Afterwards, Dexdor

 
(Orion Corporation, Espoo, Finland) was licensed in 2011 in all European Union 
member states for use as a constant rate infusion (CRI) for sedation of adult ICU 
patients. Recent reports showed safety outcomes in patients receiving this 2-agonist 
over a long period of time (> twenty four hours) (Abuhasna et al. 2012).  
 
2.2. Mechanism of action of dexmedetomidine 
Dexmedetomidine is a potent 2-agonist with a high 2:1 selectivity (approximately 
1600:1) (Kamibayashi & Maze 2000). By virtue of this potency, it is considered to be a 
full 2-agonist, allowing the use of relatively high doses without the unwanted vascular 
effects resulting from stimulation of 1-adrenoceptors (Ebert et al. 2000). Even more, 
activation of these receptors may induce arousal, restlessness, increased locomotor 
activity and vigilance, antagonizing hypnosis (Monti 1982; Guo et al. 1991; Puumala et 
al. 1997). The 2-agonists produce their effects after binding to the 2-adrenoceptors 
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(Figure 1). As described in Section 1, 2a-adrenoceptors in the brain are responsible for 
the antinociceptive, sedative, sympatholytic, hypothermic and behavioural responses 
(Paris & Tonner 2005). The 2b-subtype mediates vasoconstriction and the short-term 
hypertensive response (Link et al. 1996; Kamibayashi & Maze 2000), while 2c-
adrenoceptors affect memory and behaviour and induce hypothermia (Scheinin et al. 
2001). Its effects are effectively reversed by atipamezole, a selective 2-antagonist 
(Scheinin et al. 1998). 
Dexmedetomidine also combines with the imidazoline receptors I1 (brain) and 
I2 (brain, kidney and pancreas), by recognizing its imidazoline-ring structure (Hieble & 
Ruffolo 1995; Khan et al. 1999). Central hypotensive effects are suggested to be 
attributed to the I1 receptors in the ventrolateral medulla (Bousquet et al. 1984; 
Ernsberger et al. 1990; Kamisaki et al. 1990). Moreover, I1 receptors produce central 
inhibition of catecholamine-induced dysrhythmias (Kamibayashi et al. 1995; Mammoto 
et al. 1996), with a low influence on sedation (Prichard & Graham 2000). Although not 
completely understood, I1 receptors are thought to be G-protein linked (Khan et al. 
1999). The role of peripheral imidazoline receptors remains controversial. Imidazoline 1 
receptors in the carotid bodies may act with opposite effects to those of peripheral 2-
adrenoceptors (Ernsberger et al. 1998). Peripheral I2 receptors are found in 
mitochondrial membranes and their mechanism of action is not related to G-proteins 
(Regunathan et al. 1991a, b, 1993). 
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Figure 1: Possible responses mediated by 2-adrenoceptors. Adapted from 
Kamibayashi & Maze 2000. 
 
2.3. Pharmacokinetics of dexmedetomidine 
The metabolisation of medetomidine has been studied in rats. It consists of 
hydroxylation with further glucuronidation or oxidation to carboxylic acid and 
production of eight metabolites (Salonen & Eloranta 1990). Metabolism via the lungs 
and the kidneys has also been described (Salonen 1991). Dexmedetomidine may reduce 
its own clearance and elimination rate dose dependently via its haemodynamic effects 
(Salonen et al. 1995; Kuusela et al. 2000; Escobar et al. 2012; Pypendop et al. 2013), 
most likely because liver blood flow decreases after administration of this drug 
(Lawrence et al. 1996a). In humans, the effect of dexmedetomidine on cardiac output 
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(   ) influenced the pharmacokinetics of dexmedetomidine (Dutta et al. 2000). In 
contrast, studies in dogs suggested hepatic biotransformation to be the rate-limiting 
factor in the metabolic clearance rather than the degree of liver perfusion. Low rates of 
biotransformation in canine hepatocites have been described for dexmedetomidine and 
its racemate (Kaivosaari et al. 2002; Duhamel et al. 2010). 
 Kuusela et al. (2000) studied the pharmacokinetics of dexmedetomidine, 
levomedetomidine and the racemate in dogs. Equipotent doses of medetomidine and 
dexmedetomidine showed similar clearance, and a trend for the steady state volume of 
distribution (Vss) and terminal half-life (t1/2) to be lower after dexmedetomidine 
administration. Clearance and Vss were significantly higher after levomedetomidine 
administration, with tendency of the t1/2 to be lower. The authors concluded that 
dexmedetomidine may offer benefits over the racemic mixture, as the effects of the 
active enantiomer are easier to predict. While some discrepancies in the 
pharmacokinetics between both enantiomers could be explained by different rates of 
their hepatic biotransformation, equipotent doses of dexmedetomidine and its racemate 
still produced comparable plasma concentrations in dogs (Kuusela et al. 2000). 
 
2.4. Clinical effects of dexmedetomidine 
2.4.1. Sedation and analgesia 
The sedative properties of 2-agonists are mediated via the 2a-adrenoceptors, with the 
locus coeruleus (LC) as the main site of action (Correa-Sales et al. 1992; Mizobe et al. 
1996). Dexmedetomidine has been successfully used in humans for sedation in the ICU 
(Venn et al. 1999; Panzer et al. 2009). Its analgesic effects are produced at the level of 
the spinal cord and supraspinal sites. Its main central antinociceptive action is mediated 
via spinal 2-adrenoceptors in the substantia gelatinosa within the dorsal horn (Howe et 
al. 1983; Kuraishi et al. 1985; Sullivan et al. 1992). A supraspinal component via the 
LC has also been suggested (Pertovaara et al. 1991; Guo et al. 1996), but this remains 
controversial (Hämäläinen & Pertovaara 1995). Studies with medetomidine in humans 
suggested that analgesia might also be mediated by attenuation of the affective-
motivational component of pain (Kauppila et al. 1991). Intra-articular dexmedetomidine 
also provides analgesia via 2a-adrenoceptors (Al-Metwalli et al. 2008), enhancing the 
local anaesthetics´ effects (Yoshitomi et al. 2008). 
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The sedative and analgesic effects of dexmedetomidine have been studied in 
depth in rats (Bol et al. 1999; Xu et al. 2000; Franken et al. 2008), cats (Ansah et al. 
1998, 2000; Selmi et al. 2003; Granholm et al. 2006; Slingsby & Taylor 2008; Slingsby 
et al. 2009), dogs (Kuusela et al. 2000, 2001; Granholm et al. 2007; van Oostrom 2011; 
Lervik et al. 2012) and pigs (Sano et al. 2010). Its sedative effects were elicited at lower 
doses than those required for analgesia (Bol et al. 1999; Slingsby & Taylor 2008; van 
Oostrom 2011). Nevertheless, analgesia cannot be produced without sedation and 
sedation is not necessarily linked to comparative degrees of analgesia (Franken et al. 
2008). 
In dogs, the level of sedation did not differ between two different intravenous 
(IV) doses, (10-20 µg/kg) suggesting a ceiling effect, but the larger dose did have a 
longer duration of action (Kuusela et al. 2000). The sedative effects observed in cats 
were reported to be dose dependent after intramuscular (IM) administration (Ansah et 
al. 1998). However, when given IV, the dose dependent sedative effects were limited, 
and increases in serum concentrations beyond certain levels induced a reversal of 
sedation (Ansah et al. 2000). In pigs, dexmedetomidine enhanced the sedative effects of 
propofol (Sano et al. 2010). 
 Human reports conclude that the obtained degree of analgesia is not clearly dose 
dependent (Jaakola et al. 1991). The depth of sedation increases with higher doses with 
no clear advantages for analgesia (Hall et al. 2000). In dogs, a ceiling effect for both 
sedative and analgesic effects was seen when the drug was infused at two different rates 
(3-5 µg/kg/hr, IV) (van Oostrom et al. 2011). In cats, the degree of analgesia increased 
with higher drug concentrations, although the differences between analgesic scores at 
higher dose levels were narrow (Ansah et al. 2000). The analgesic effects of 
dexmedetomidine (20 µg/kg, IV) were longer than those of medetomidine in dogs 
(Kuusela et al. 2000), most likely because the levo-enantiomer competes 
with/antagonizes the dextro-form, or even acts on 1-adrenoceptors, reducing the 
sedative and analgesic effects (Kuusela et al. 2001). This suggests greater analgesic 
potency and predictability of dexmedetomidine, in agreement with the study of 
Granholm et al. (2007), where the analgesic scores were higher after IM 
dexmedetomidine, although the differences were not clinically appreciable. The use of 
low IV infusion rates was suggested to reduce the risk of post-operative chronic pain 
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development (Lervik et al. 2012). In cats, IM dexmedetomidine produced dose 
dependent analgesia (Ansah et al. 1998) comparable to that of medetomidine (Granholm 
et al. 2006). However, sedation may have influenced the reactions to stimuli (Ansah et 
al. 1998). Intramuscular dexmedetomidine at 40 µg/kg produced analgesia, whereas 
lower doses only produced dose dependent sedation (Slingsby & Taylor 2008). The oral 
transmucosal route may produce similar effects (Slingsby et al. 2009). 
 In order to provide good sedation and analgesia lasting beyond the procedure 
itself, lower doses are frequently used in combination with opioids (Selmi et al. 2003; 
Slingsby et al. 2010), mainly due to additive or synergistic effects (Ossipov et al. 1989). 
 
2.4.2. Anaesthetic sparing effects 
Sedation and analgesia probably account for the sparing effects on the minimum 
alveolar concentration (MAC) of volatile anaesthetic agents (Hall et al. 2000). In 
humans, IV dexmedetomidine decreased the MAC of isoflurane dose dependently (Aho 
et al. 1991; Aantaa et al. 1997). In dogs, IV boluses (1, 3 and 10 µg/kg) reduced clearly 
the MAC of halothane by 30, 60 and more than 90% respectively (Vickery et al. 1988). 
Furthermore, a 20 µg/kg IV bolus reduced the MAC of isoflurane in dogs by 86% 
(Weitz et al. 1991) and 89% (Bloor et al. 1992). When infused as a CRI, 
dexmedetomidine was shown to be a reliable and valuable adjunct to isoflurane 
(Uilenreef et al. 2008), while a CRI of 0.5 and 3 µg/kg/hr dexmedetomidine reduced 
isoflurane´s MAC by 18 and 59% respectively in the canine species (Pascoe et al. 
2006). Oral dexmedetomidine (15 µg/kg) reduced the MAC of halothane by 27% in cats 
(Schmeling et al. 1999) and, when given IV, the MAC of isoflurane decreased in a 
plasma concentration dependent manner (Escobar et al. 2012). The MAC of inhalants 
was also reduced when dexmedetomidine was given intraperitoneally in rats (Segal et 
al. 1988; Savola et al. 1991) or as an IV CRI (Rioja et al. 2006) and as an IV bolus in 
small ruminants (Kästner et al. 2007a). 
 Dexmedetomidine also reduced the requirements of injectable agents in humans 
(Venn et al. 1999; Scheinin et al. 1992) and animals (Salmenperä et al. 1994; Mendes et 
al. 2003). In human medicine, it improved patient comfort and postoperative analgesia 
when administered concurrently with opioids, resulting in a decreased need for 
additional pain medication (Arain et al. 2004; Unlugenc et al. 2005). 
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 Also, when administered epidurally, dexmedetomidine produces MAC 
reductions of isoflurane in dogs (Campagnol et al. 2007) and cats (combined with 
lidocaine) (Souza et al. 2010). This route of administration increases the intensity and 
duration of analgesia, with reduced haemodynamic adverse effects (Campagnol et al. 
2007). 
 
2.4.3. Cardiorespiratory effects  
The cardiovascular effects of dexmedetomidine result from both central and peripheral 
2-adrenoceptor activity. In humans, dose dependent decreases in heart rate (HR) and 
    and a biphasic effect on mean arterial pressure, pulmonary arterial pressure and 
vascular resistance have been reported. Such a biphasic response is most clearly seen 
with high dose boluses and consists of bradycardia and hypertension due to initial 
stimulation of peripheral 2b-vascular receptors, followed by central sympatholysis and 
a decline in blood pressure (Ebert et al. 2000). This has been considered to improve the 
haemodynamics of tachycardic, hypertensive patients. In contrast, these effects may be 
unwanted in compromised patients, whose     is rate dependent or with conduction 
system disease (Panzer et al. 2009). 
 In dogs, marked vasoconstriction and hypertension can be seen initially, with an 
increase in systemic vascular resistance and central venous pressure, followed by 
baroreflex-mediated bradycardia (Bloor et al. 1992) and a decrease in the cardiac index 
and oxygen delivery (Flacke et al. 1993). The following central sympatholysis and 
increase in parasympathetic tone leads to a reduction in systemic blood pressure, 
sustained bradycardia and decreases in cardiac index (Xu et al. 1998). These results can 
be explained by activation of central 2-adrenoreceptors, causing a reduction in 
sympathetic drive, with a presynaptically induced decrease of norepinephrine release at 
the sympathetic neuron terminals and activation of postsynaptic 2-receptors on 
vascular smooth muscle cells (Roekaerts et al. 1997). Dexmedetomidine does not seem 
to have a direct myocardial depressant effect (Flacke et al. 1992), although indirect 
suppression by catecholamine reduction has been suggested (Weitz et al. 1991; Flacke 
et al. 1993; Roekaerts et al. 1997). Cardiovascular changes in denervated dogs were 
reversed by atipamezole (Flacke et al. 1990). In cats, dose dependent decreases in HR 
and    , increases in total vascular resistance and transient mild changes in blood 
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pressure, are expected side effects of dexmedetomidine (Ansah et al. 1998, 2000; Selmi 
et al. 2003; Granholm et al. 2006).  
In human medicine, dexmedetomidine produces limited respiratory effects, 
leading to a wide safety margin (Ebert et al. 2000; Venn et al. 2000). Due to its 
beneficial properties, dexmedetomidine was approved in the USA for procedural 
sedation in non-intubated patients in 2008 (Panzer et al. 2009). Decreases in respiratory 
rate (RR) with mild reductions in arterial oxygen tensions were reported after IV 
administration in dogs (Kuusela et al. 2000, 2001; Granholm et al. 2007). However, 
periods of short apnoea with slight cyanosis have been reported in dogs (Kuusela et al. 
2000, 2001; Granholm et al. 2007). In cats, transient (Ansah et al. 1998; Granholm et al. 
2006) or even non-significant (Selmi et al. 2003) decreases in RR were seen after IM 
administration. On the other hand, RR was not significantly affected by the dose in cats 
receiving different CRIs (Ansah et al. 2000). In small ruminants, dexmedetomidine (2 
mg/kg, IV) produced decreases in arterial oxygenation, with goats being more sensitive 
than sheep due to the centrally mediated cardiovascular effects (Kutter et al. 2006). This 
was prevented by the use of a CRI in goats, but not in sheep, most likely due to 
individuals with high sensitivity (Kästner et al. 2007b). 
 
2.4.4. Organ protective effects  
Recently, there is increasing evidence that dexmedetomidine has organ protective 
effects against ischaemic and hypoxic injuries (Panzer et al. 2009). In human medicine, 
dexmedetomidine’s neuroprotective properties, mediated by the 2a-subtype, made its 
use popular in neuroanaesthesia (Ma et al. 2004; Bekker & Sturaitis 2005). Moreover, it 
produces vasoconstriction in cerebral vessels, decreasing cerebral blood flow (Zornow 
et al. 1993; Bekker & Sturaitis 2005) with no detrimental effects on local brain tissue 
oxygenation (Drummond & Sturaitis 2010). It also reduces the cerebrovascular dilation 
induced by isoflurane or sevoflurane in experimental dogs (Ohata et al. 1999) while 
intracranial pressure did not change in anaesthetized rabbits (Zornow et al. 1992) and 
dogs (Keegan et al. 1995) after administration of dexmedetomidine and medetomidine 
respectively. These properties make this drug a useful adjunct in inhalant anaesthesia in 
situations where increases in cerebral blood flow should be avoided (i.e. traumatic brain 
injury, large brain tumors). 
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In humans, 2-agonists decrease HR and arterial blood pressure during 
tachycardia and hypertension, suggesting their potential role in cardioprotection (Panzer 
et al. 2009). Dexmedetomidine reduced the mortality rate and the incidence of 
myocardial infarction after vascular surgery by reducing the degree of ischaemia 
(Wijeysundera et al. 2003), produced haemodynamic benefits (Talke et al. 1995) and 
decreased the incidence of ventricular arrhythmias compared to propofol (Herr et al. 
2003). Moreover, its use was associated with a trend towards improved cardiac 
outcomes in non-cardiac surgery (Biccard et al. 2008) and with better outcomes in 
cardiac surgery (Ji et al. 2013). In experimental anaesthetized dogs, dexmedetomidine 
showed beneficial effects on ischaemic myocardium, preserving coronary blood flow, 
reducing oxygen demand and deficiency (Roekaerts et al. 1996a, b), while minimizing 
emergence-related myocardial ischaemia (Willigers et al. 2003). Moreover, it prevented 
halothane/epinephrine induced dysrhythmias in dogs (Hayashi et al. 1991), via the 
imidazoline receptors (Kamibayashi et al. 1995), while medetomidine failed to produce 
a similar response (Pettifer et al. 1996). After dexmedetomidine IV, experimental goats 
showed a better balance between myocardial oxygen supply and demand than other 
species (Lawrence et al. 1997). However, rising IV doses from 1 to 10 µg/kg increased 
myocardial oxygen extraction, mediated by coronary vasoconstriction (Lawrence et al. 
1996b). Moreover, first and second degree atrioventricular blocks were reported after 
IV dexmedetomidine in dogs (Kuusela 2000, 2001; Lervik et al. 2012) although 
ventricular arrhythmias were not detected more frequently (Kuusela et al. 2002).  
With respect to other tissues, dexmedetomidine preserved flow to the most vital 
organs (brain, liver, kidneys) at the expense of less vital organs (Lawrence et al. 1996a). 
This is in agreement with reports on medetomidine which, when given IM, reduced 
intestinal and skeletal muscle blood flows, whereas renal cortical microvascular blood 
flow remained unaffected in isoflurane anaesthetized dogs (Pypendop & Verstegen 
2000). In dogs, IM medetomidine increased the central nervous system (CNS) uptake of 
a lipophilic tracer during brain perfusion imaging (Waelbers et al. 2011). The authors 
postulated that the central distribution of the tracer might have been enhanced due to a 
lower proportionate decrease in CNS perfusion compared to peripheral tissues. 
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2.4.5. Other effects  
Dexmedetomidine also induces adverse effects in animal species, such as vomiting in 
dogs and cats (Kuusela et al. 2000, 2001; Granholm et al. 2006; Slingsby & Taylor 
2008) and uncontrolled elimination of urine and faeces in cats (Slingsby & Taylor 
2008). Myoclonic twitching was seen in cats after administration of dexmedetomidine 
in combination with butorphanol, but not when given alone (Selmi et al. 2003). 
Furthermore, dexmedetomidine inhibited the transit in the small intestine in rats and 
guinea pigs (Asai et al. 1997; Herbert et al. 2002), increasing the gastrointestinal transit 
time. 
 Decreases in body temperature have been reported in dogs and cats (Ansah et al. 
1998; Selmi 2003; Granholm et al. 2006, 2007) and may be of importance during long 
lasting anaesthetic procedures. These decreases are expected consequences of decreased 
heat production and muscular activity during sedation and direct effects on 
thermoregulation (Paris & Tonner 2005).  
Diuresis is another relevant effect caused by inhibition of the antidiuretic 
hormone (Saleh et al. 2005; Villela et al. 2005). Moreover, medetomidine and 
dexmedetomidine altered blood glucose homeostasis via insulin inhibition by 2a-
adrenoceptors (Burton et al. 1997; Fagerholm et al. 2004) and modulated physiological 
stress responses (Benson et al. 2000; Kuusela et al. 2003). In humans, dexmedetomidine 
is also used to treat shivering in patients after regional and general anaesthesia (Talke et 
al. 1997; Bajwa et al. 2012). 
 
2.5. Dexmedetomidine in horses 
At the beginning of the present PhD, only the cardiopulmonary effects and 
pharmacokinetics of dexmedetomidine had been reported in ponies (Bettschart-
Wolfensberger et al. 2005). A bolus of dexmedetomidine (3.5 µg/kg, IV) induced 
similar cardiopulmonary changes as the other 2-agonists but of very short duration. 
Heart rate and central venous pressure did not differ from baseline values for sixty 
minutes and the stroke volume was significantly reduced five minutes and cardiac index 
five to ten minutes after bolus administration. Arterial blood pressures were 
significantly increased for five minutes, reduced after twenty, thirty and forty five 
minutes and became normal at sixty minutes. Mean pulmonary arterial blood pressure 
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and systemic vascular resistance index were also increased five minutes after 
administration. Respiratory rate was reduced significantly but arterial blood gas tensions 
were not different compared to presedation values. Dexmedetomidine plasma 
concentrations declined rapidly, falling beyond levels of sedation within sixty to ninety 
minutes. No more information was available about the use of dexmedetomidine in the 
equine at that time. 
The idea of using dexmedetomidine as a CRI in horses seemed attractive as it 
has been described as a short-acting sedative with rapid redistribution (Bettschart-
Wolfensberger et al. 2005). The use of medetomidine had been widely reported in 
horses with positive results (see Section 1 of the general introduction) while reports in 
dogs suggested benefits of dexmedetomidine over its racemate. In theory, the use of 
dexmedetomidine in equine balanced anaesthesia may provide sedation and analgesia, 
reducing the MAC of volatile agents and their potential side effects while improving the 
quality of recovery from general anaesthesia. However, potential side effects such as 
typical cardiopulmonary effects of 2-agonists, reduction of intestinal motility or 
increased diuresis inducing an overfilled bladder during general anaesthesia should be 
taken into consideration. 
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In order to reduce the dose dependent cardiovascular depression induced by volatile 
anaesthetics, combinations of different drugs can be used in equine anaesthetized 
patients. The objective of such combinations is to maintain a good intraoperative 
cardiopulmonary function followed by calm, smooth and coordinated recoveries. 
Dexmedetomidine is the most potent and selective 2-agonist marketed for small 
animals, and has been used intraoperatively in these species to provide sedation and 
analgesia and to reduce the amount of inhalant agents. At the beginning of the present 
PhD, only one study described the pharmacokinetics and cardiopulmonary effects after 
an intravenous bolus in ponies, favouring its use as constant rate infusion (CRI). 
 The overall aim of the present PhD was to investigate the inclusion of a CRI of 
dexmedetomidine in anaesthetized horses.  
The first objective was to study the safety of two rates of dexmedetomidine 
CRIs in experimental ponies by detailed evaluation of the cardiopulmonary parameters. 
Using the results of this study in healthy ponies, the higher rate CRI protocol was 
studied in isoflurane anaesthetized equine patients, with the focus on the 
cardiopulmonary function and recovery quality. 
The second objective was to assess to what extent the expired sevoflurane 
fraction could be reduced in the presence of a dexmedetomidine CRI. Additionally, the 
sevoflurane requirements were investigated when combined with either a morphine CRI 
or a combination of dexmedetomidine/morphine CRI. 
The third objective was to compare the effects of a dexmedetomidine CRI with 
those of a morphine infusion in a clinical study, in order to determine potential benefits 
or disadvantages. 
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Abstract 
Objective To evaluate the cardiopulmonary effects of two different constant rate 
infusions (CRI) of dexmedetomidine (1 and 1.75 µg/kg/hr) in experimental ponies. 
Study design Prospective, randomized, experimental study. 
Animals Six healthy ponies (mean 306 ± SD 71 kg, 7.0 ± 1.6 years). 
Methods After premedication with intravenous (IV) dexmedetomidine (3.5 µg/kg), 
anaesthesia was induced (T0) with ketamine (2.2 mg/kg, IV) and midazolam (0.06 
mg/kg, IV) and maintained with isoflurane (expiratory fraction of isoflurane 1.50 %) in 
55 % oxygen for 150 minutes. Normocapnia was maintained using artificial ventilation. 
Three ponies received dexmedetomidine CRIs of 1 and 1.75 µg/kg/hr from T30 to T60 
and T90 to T120 respectively. In the other three ponies, the order of the doses was 
reversed. Continuous monitoring included pulse oximetry, electrocardiography, 
anaesthetic gas monitoring, arterial and central venous pressures. Cardiac output 
(LiDCO technique) was measured and arterial and venous bloods taken every fifteen 
minutes. Cardiac index (CI), systemic vascular resistance (SVR), arterial and venous 
oxygen content (CaO2, CvO2) and oxygen delivery (DO2) were calculated. Analysis of 
variance with separate models for each CRI rate was used to detect differences between 
values obtained at the end of the CRI and their respective baseline values. A mixed 
model with these differences as response variable, pony as random effect and treatment 
and period as fixed effects was applied to find differences between the two CRIs (α = 
0.05 for all analyses). 
Results Heart rate (HR), CI, CaO2, CvO2 and DO2 decreased significantly, while 
significant increases were found in SVR, systolic arterial pressure and right atrial 
pressure with both infusion rates. No differences were found between the two 
dexmedetomidine CRI rates. 
Conclusions and clinical relevance Although significant, cardiopulmonary effects of 
the dexmedetomidine CRIs in isoflurane anaesthetized ponies were minimal, without 
differences between the two dose rates. 
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Introduction 
General anaesthesia carries a higher risk of mortality in horses compared to small 
animals and humans (Johnston et al. 2002). Inhalation anaesthesia is used commonly for 
long procedures. The incidence of deaths resulting directly or indirectly from 
anaesthesia may be related at least partly to the dose dependent cardiovascular 
depression induced by inhalation anaesthetics (Steffey & Howland 1980). Constant rate 
infusions (CRIs) of different drugs can provide analgesia and increase anaesthetic depth 
during surgical interventions, reducing the requirement for inhalant anaesthetics. 
Lidocaine (Doherty & Frazier 1998), ketamine (Muir & Sams 1992) and different α2-
agonists (Wagner et al. 1992; Kuhn et al. 2004; Ringer et al. 2007) have been used as 
CRIs in anaesthetized horses for this purpose. Alpha2-agonists are potent sedatives with 
good analgesic properties and reduce the minimum alveolar concentration (MAC) of 
inhalation anaesthetic agents (England & Clarke 1996; Steffey et al. 2000; Bettschart-
Wolfensberger et al. 2001, 2005). Classic side effects of α2-agonists in horses, include 
bradycardia, arrhythmias, a decrease in cardiac output and an increase in vascular 
resistance (England & Clarke 1996; Yamashita et al. 2000), but despite these effects, the 
agents have been accepted for use in balanced anaesthetic protocols. The most 
prominent side effects of the most commonly used α2-agonists occur following an 
intravenous (IV) bolus. However, under steady state conditions of medetomidine 
infusions in ponies, cardiac index (CI) and systemic vascular resistance index (SVRI) 
were reported not to be different from presedation values (Bettschart-Wolfensberger et 
al. 1999a). 
Xylazine, detomidine and romifidine have a marketing authorisation for use in 
horses in countries of the European Union. Medetomidine is a potent and selective 2-
agonist (Pertovaara 1993; Bryant & Clarke 1996; Virtanen et al. 1998) but is licensed 
specifically for small animals. However, its use as a CRI during inhalation anaesthesia 
in horses has been investigated, not only under experimental conditions (Bettschart-
Wolfensberger et al. 2001), but also in clinical circumstances (Kalchofner et al. 2006). 
A medetomidine CRI provides good intra-operative analgesia, stable cardiopulmonary 
function and a rapid, good quality recovery (Bettschart-Wolfensberger et al. 1999a, b) 
and its pharmacokinetics make it suitable for prolonged use by infusion (Bettschart-
Wolfensberger et al. 1999b). 
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Dexmedetomidine, the dextro-rotary, active enantiomer of medetomidine, 
provides more analgesia compared to an equivalent dose of the racemic mixture in dogs 
(Kuusela et al. 2000). The plasma half-life of dexmedetomidine is shorter than that of 
medetomidine, not only in dogs (Kuusela et al. 2000) but also in ponies (Bettschart-
Wolfensberger et al. 2005). In ponies, dexmedetomidine was more rapidly redistributed 
compared to humans, the cause being attributed to a larger volume of distribution 
(Bettschart-Wolfensberger et al. 2005). Additionally, studies in humans and dogs 
demonstrated that dexmedetomidine results in a significant reduction of the MAC of 
isoflurane (Aantaa et al. 1997; Pascoe et al. 2006). To the authors’ knowledge, the 
effects of a dexmedetomidine CRI under clinical circumstances have only been studied 
in dogs (Uilenreef et al. 2008) and small ruminants (Kästner et al. 2007). 
The cardiopulmonary effects and pharmacokinetics of an IV bolus of 
dexmedetomidine have been reported in experimental ponies, whereby a dose of 3.5 
µg/kg dexmedetomidine was considered to be equivalent to 7 µg/kg medetomidine. The 
observed cardiopulmonary effects were similar to those induced by other α2-agonists, 
but of shorter duration (Bettschart-Wolfensberger et al. 2005). 
The effects of dexmedetomidine as a CRI have not been documented in horses 
or ponies in conjunction with inhalation anaesthesia. The objective of the present study 
was to determine the cardiopulmonary effects of a thirty minute infusion of 
dexmedetomidine, administered at two different dose rates, in isoflurane anaesthetized 
ponies. 
 
Materials and methods 
The experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of the University of Ghent (2008/005). 
 
Animals and instrumentation 
Six healthy ponies (five geldings and one mare), aged 7.0 ± 1.6 years and weighing 306 
± 71 kg, were included in this study. The left carotid artery had been transposed to a 
subcutaneous position at least two years before the experiments. Food, but not water, 
was withheld for twelve hours before general anaesthesia. 
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 Following subcutaneous administration of a local anaesthetic (2 mL 
mepivacaine, Scandicaine 2%, Astrazeneca, Belgium), a 5 Fr Swan-Ganz catheter was 
inserted into the right jugular vein, with the distal port of the catheter in the right atrium. 
Correct positioning of the catheter was confirmed using the characteristic pressure 
waveforms, visualised on a cardiovascular monitor. A venous blood sample was taken 
for determination of plasma sodium concentration. 
 The ponies were then sedated with dexmedetomidine (3.5 µg/kg, IV). A 14-
gauge catheter was placed in the left jugular vein. Fifteen minutes later, anaesthesia was 
induced with IV midazolam 0.06 mg/kg (Dormicum, Roche, Belgium) and ketamine 2.2 
mg/kg (Anesketin, Eurovet, Belgium) mixed in the same syringe. After endotracheal 
intubation (24 or 26 mm tube), the ponies were positioned in right lateral recumbency 
on a surgical table and were supported by soft foam rubber pillows (twenty cms). The 
endotracheal tube was connected to a large animal anaesthetic unit (Matrx Medical Inc., 
NY, USA mounted on a Sulla 909V, Dräger, Germany) with an out-of-circuit vaporizer 
(Drägerwerk AG) and a large animal ventilator (Smith respirator LA 2100, model 2002, 
Veterinary Technics/BDO-Medipass, The Netherlands). Anaesthesia was maintained 
with isoflurane (Isoflo, Abbott Laboratories Ltd., UK) in a mixture of oxygen (O2) and 
air [inspired oxygen fraction (FiO2) 55 %]. Isoflurane vaporizer setting was adjusted to 
maintain an expiratory fraction of isoflurane (FE´ISO) of 1.50%. Respiration mode was 
‘assisted-controlled’, with a tidal volume of 10 mL/kg, respiratory rate (RR) of 10 
breaths/min, peak inspiratory pressure of 1.96 kPa (20 cmH2O) and inspiration time of 
1.8 seconds. The settings were then adjusted to maintain arterial partial pressure of 
carbon dioxide (PaCO2) between 4.66 and 6.00 kPa (35 and 45 mmHg). 
Lactated Ringer’s solution (Ringer Lactate, Vetoflex, France) was infused 
during the anaesthetic period at a rate of 5 mL/kg/hr using two volumetric pumps 
(Colleague, Baxter Healthcare Corporation, IL, USA). A urinary catheter was placed in 
all ponies. 
The skin over the transposed left carotid artery was surgically prepared and a 22-
gauge catheter (Vasocan Braunüle Luer Lock, B. Braun Melsungen AG, Germany) was 
placed in the artery and connected to a pressure transducer (placed at the level of the 
right atrium). The distal port of the Swan Ganz catheter was connected to a second 
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pressure transducer. The pressure monitoring system was calibrated against a mercury 
manometer before each experiment and zeroed at the level of the right atrium. 
Inspiratory and expiratory CO2, O2 and isoflurane concentrations were measured 
from gas withdrawn continuously from the Y-piece of the anaesthetic circuit, using a 
calibrated, methane-insensitive, multi-gas analyzer (HP M1025B, Hewlett Packard 
Company, TX, USA). A CMS-Patient monitor (Hewlett-Packard, GmBh, Germany) 
was used to record the ECG (base-apex lead), to monitor systolic (SAP), diastolic 
(DAP), mean arterial (MAP) and right atrial pressure (RAP), to perform pulse oximetry 
(probe placed on the tongue) and to measure body temperature using an oesophageal 
probe. Cardiac output was obtained with the lithium dilution technique (LiDCOplus 
Haemodynamic Monitor, LiDCO Ltd.). A one mL bolus of lithium chloride (1.5 
mmol/mL) was injected in the central venous circulation through the proximal port of 
the thermodilution catheter for each measurement. Haemoglobin concentration was 
calculated from the packed cell volume (PCV) measured fifteen minutes after induction 
(T15) using the following formula (Linton et al. 2000): Hb (g/dL) = 34 × PCV (L/L). 
 
Experimental design 
The ponies were divided randomly into two treatment groups. Each pony was 
anaesthetized once only, for a period of 150 minutes. T0 was the time when the ponies 
were connected to the anaesthetic circuit. Ponies from treatment 1 (ponies 1, 3 and 5) 
received a CRI of 1µg/kg/hr dexmedetomidine between T30 and T60 (period A) and 
1.75 µg/kg/hr between T90 and T120 (period B). In treatment 2 (ponies 2, 4, 6), the 
order of the doses was reversed. A syringe driver was used to administer the 
dexmedetomidine CRIs. Values recorded at T30 and T90 were regarded as baseline 
values for periods A and B respectively. 
Values for inspiratory and expiratory CO2 and O2, heart rate (HR), SAP, MAP, 
DAP, RAP and body temperature were recorded at five minute intervals throughout 
anaesthesia (until T150). Cardiac output was measured and arterial and central venous 
blood samples were collected for immediate analysis at fifteen minute intervals (ABL5, 
Radiometer, Denmark). Blood gas data were corrected for body temperature. 
Cardiac index, stroke volume (SV), stroke volume index (SVI), arterial oxygen 
content (CaO2), central venous oxygen content (CvO2), degree of venous admixture, 
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oxygen delivery (DO2) and oxygen consumption were calculated using standard 
formulas (Schauvliege et al. 2008). 
After T150, all catheters were removed and the ponies were placed in right 
lateral recumbency in a padded recovery box and allowed to recover without assistance 
or additional sedation. Oxygen was insufflated (flow rate of 8 L/min) through the 
endotracheal tube and nasally after extubation. The endotracheal tube was removed 
once the ponies were able to swallow. Extubation time, time to sternal recumbency and 
time to stand were recorded. A score, on a scale of 1-5 (Table 1) was awarded for the 
quality of recovery. 
 
Table 1: Scoring system used to grade recovery of experimental ponies. 
Score Description 
1 One attempt to stand, no ataxia. 
2 One to two attempts to stand, some ataxia. 
3 More than two attempts to stand but quiet recovery. 
4 More than two attempts to stand, excitation. 
5 Severe excitation. Pony injured. 
 
Statistical analysis 
An analysis of variance with separate models for each CRI rate was used to detect 
differences between values obtained at the end of the CRI and their respective baseline 
values. These differences were used as the response variable in an analysis of variance 
with period as fixed effect, and separate models were fitted for the 1 and 1.75 µg/kg/hr 
CRIs. The significance level was set at 5%. Additionally, a mixed model with the 
difference as response variable, pony as random effect and treatment and period as fixed 
effects was applied to evaluate the difference between the two treatments. A paired t-
test was performed to compare the two baseline periods (T30 versus T90). 
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Results 
Cardiovascular system (Table 2) 
The paired t-tests performed between the two baselines demonstrated that all the 
parameters were comparable except HR (decreasing 3 ± 2 beats/min from T30 to T90) 
and RAP (increasing 4 ± 3 mmHg from T30 to T90). 
At the end of the 1 µg/kg/hr CRI, HR and CI decreased significantly [mean 
decreases of 3 ± 1 beats/min (p = 0.02) and 4.9 ± 0.3 mL/kg/min (p = 0.0001) 
respectively], while SAP increased significantly [mean increase of 8 ± 3 mmHg (p = 
0.047)] compared to the respective baseline values. Similar decreases in HR and CI 
were found following the 1.75 µg/kg/hr CRI [mean decreases of 3 ± 0 beats/min (p = 
0.0001) and 7.7 ± 2.4 mL/kg/min (p = 0.02) respectively], while RAP increased 
significantly [mean increase of 2 ± 1 mmHg (p < 0.0446)]. No significant differences 
for any of the measured variables were found between the two different CRI rates. 
At T60, after period A (T30 to T60), HR and CI decreased significantly [mean 
decrease of 4 ± 0 beats/min (p = 0.001) and 6.7 ± 1.8 mL/kg/min (p = 0.02) 
respectively] compared with the respective baseline values (T30). At T120, after period 
B (T90 to T120), HR and CI were significantly lower [mean decrease of 2 ± 0 beats/min 
(p = 0.01) and 5.9 ± 1.8 mL/kg/min (p = 0.03) respectively] while SAP, MAP and DAP 
were significantly higher [mean increases of 11 ± 2 mmHg (p = 0.01), 10 ± 3 mm Hg (p 
= 0.02) and 9 ± 3 mmHg (p = 0.03) respectively]. Significant differences between 
periods A and B were found for HR (p = 0.02), SAP (p = 0.05) and RAP (p = 0.03). 
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Table 2: Cardiovascular parameters in six isoflurane anaesthetized ponies supplemented with constant rate infusions of 
dexmedetomidine.  
Values Differences Unit Group Period A Period B 
 
    
T30 T60 T90 T120 T150 
HR *, §, # beats/min 1 43 ± 3 39 ± 3 39 ± 1 37 ± 1 39 ± 3 
   
2 42 ± 1 39 ± 1 39 ± 1 38 ± 1 38 ± 0 
SAP * mmHg 1 80 ± 5 84 ± 5 80 ± 9 91 ± 10 82 ± 13 
   
2 76 ± 5 75 ± 9 71 ± 9 82 ± 6 83 ± 10 
MAP 
 
mmHg 1 63 ± 6 67 ± 5 64 ± 10 76 ± 14 66 ± 13 
   
2 56 ± 3 57 ± 6 57 ± 6 65 ± 6 67 ± 11 
DAP 
 
mmHg 1 52 ± 5 55 ± 4 54 ± 10 65 ± 15 56 ± 14 
   
2 47 ± 3 48 ± 6 49 ± 6 55 ± 6 58 ± 12 
RAP §, # mmHg 1 13 ± 2 17 ± 3 17 ± 2 18 ± 4 17 ± 3 
   
2 18 ± 5 20 ± 4 22 ± 7 21 ± 6 21 ± 7 
SVR 
 
dyne/sec/cm
5
 1 242 ± 40 268 ± 26 250 ± 73 393 ± 190 286 ± 100 
   
2 181 ± 53 201 ± 73 173 ± 29 244 ± 63 256 ± 94 
CI *, § mL/kg/min 1 59.8 ± 7.4 54.5 ± 7.8 56.5 ± 13.6 49.1 ± 19.6 51.8 ± 12.5 
   
2 56.2 ± 15.7 48.2 ± 10.3 51.7 ± 14.0 47.2 ± 13.4 47.3 ± 13.3 
SI 
 
mL/kg 1 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.4 1.3 ± 0.5 1.3 ± 0.4 
   
2 1.3 ± 0.4 1.2 ± 0.2 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 
Heart rate (HR), systolic (SAP), diastolic (DAP), mean arterial (MAP) and right atrial (RAP) pressures, systemic vascular resistance (SVR), cardiac index (CI) and 
stroke index (SI) in six isoflurane anaesthetized ponies supplemented with constant rate infusions (CRIs) of dexmedetomidine. Ponies of Group 1 (n = 3) received 
dexmedetomidine 1 µg/kg/hr from T30 until T60 (period A) and 1.75 µg/kg/hr from T90 until T120 (period B). In ponies of Group 2 (n = 3) the order of the infusion 
rates was reversed. Data are represented as mean ± SD. 
* Value after dexmedetomidine 1 µg/kg/hr significantly different from respective baseline values (p < 0.05). § Value after dexmedetomidine 1.75 µg/kg/hr
 
significantly 
different from respective baseline values (p < 0.05). 
# 
Significant differences were found between baseline periods (T30 and T90). 
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Body temperature (Table 3) 
Body temperature decreased significantly between the two baseline measurements (0.3 
± 0.1°C from T30 to T90). Body temperature decreased significantly during all 
treatments and periods. No differences between treatments or periods were found. 
 
Blood analyses (Table 3) 
There were some statistically significant differences between the baseline periods in 
parameters from blood analyses. Arterial oxygen tension (PaO2) and PCV both 
decreased [4.3 ± 2.8 kPa (33 ± 21 mmHg); 2 ± 2% respectively] from T30 to T90. 
Packed cell volume decreased significantly [mean decrease of 2 ± 0% (p = 
0.02)] at the end of the 1 µg/kg/hr CRI compared with the respective baseline values. 
The 1 µg/kg/hr CRI had little influence on the PaO2 in both treatment groups [(16.1 ± 
6.3 versus 16.5 ± 6.3 kPa (121 ± 47 versus 124 ± 47 mmHg) in treatment 1, 7.2 ± 2.9 
versus 7.7 ± 3.7 kPa (54 ± 22 versus 58 ± 28 mmHg) in treatment 2]. In contrast, the 
1.75 µg/kg/hr CRI induced significant decreases in arterial and venous PO2 [overall 
mean decrease of 3 ± 1 kPa (26 ± 8 mmHg) (p = 0.02) and 1 ± 0 kPa (5 ± 2 mm Hg) (p 
= 0.03) respectively]. No differences between the two CRI rates were found. 
 At T60, after period A (T30 to T60), PCV was significantly lower [mean 
decrease of 2 ± 0% (p = 0.04)]. Venous pH decreased significantly [mean decrease of 
0.02 ± 0.00 (p < 0.02)] at T120, after period B (T90 to T120) compared with baseline 
values. No differences between the two periods were found. 
 
Other calculated values (Table 3) 
When comparing the two baseline periods using paired t-tests significant decreases in 
CaO2 (18 ± 10 mL/L), CvO2 (19 ± 9 mL/L) and DO2 (0.46 ± 0.31 mL/kg/min) were 
found. 
Arterial oxygen content, CvO2 and DO2 were significantly lower [mean decrease 
of 7 ± 2 mL/L (p = 0.04), 13 ± 4 mL/L
 
(p < 0.02) and 0.97 ± 0.39 mL/kg/min
 
(p < 
0.002) respectively] at the end of the 1 µg/kg/hr CRI compared with the baseline values. 
After the 1.75 µg/kg/hr CRI, only the decreases in CvO2 and DO2 were significant 
[mean decrease of 12 ± 3 mL/L (p = 0.01) and 1.21 ± 0.46 mL/kg/min (p = 0.01) 
respectively]. No differences between the two doses were found. 
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 At T60, after period A (T30 to T60), CaO2, CvO2 and DO2 were significantly 
lower [mean decrease of 12 ± 3 mL/L (p = 0.03), 14 ± 4 mL/L (p = 0.02) and 1.37 ± 
0.32 mL/kg/min (p = 0.01) respectively] compared with the respective baseline values. 
Only CvO2 and DO2 were significantly decreased at T120, after period B (T90 to T120) 
[mean decreases of 11 ± 4 mL/L (p = 0.04) and 0.86 ± 0.39 mL/kg/min
 
(p < 0.01) 
respectively]. No differences between periods were found. 
 
 
 
 
 
 
Chapter 1  
  
     
 
Table 3: Other parameters in six isoflurane anaesthetized ponies supplemented with constant rate infusions of dexmedetomidine. 
Values Differences Unit Group Period A Period B   
 
      T30 T60 T90 T120 T150 
Body temperature *, §, # °C 1 36.2 ± 0.3 36.0 ± 0.2 35.8 ± 0.2 35.6 ± 0.2 35.5 ± 0.2 
   
2 36.1 ± 0.3 36.0 ± 0.3 35.9 ± 0.2 35.8 ± 0.2 35.6 ± 0.2 
Venous pH 
  
1 7.48 ± 0.06 7.47 ± 0.05 7.47 ± 0.04 7.46 ± 0.04 7.47 ± 0.05 
   
2 7.47 ± 0.06 7.46 ± 0.05 7.46 ± 0.03  7.44 ± 0.03 7.44 ± 0.02 
Venous PCO2 
 
kPa 1 5.6 ± 0.8 5.6 ± 1.2 5.7 ± 1.0 6.0 ± 1.2 5.6 ± 1.0 
   
2 6.0 ± 1.2 6.1 ± 0.9 6.1± 0.4 6.5 ± 0.8 6.7 ± 0.2 
Venous PCO2 
 
mmHg 1 42 ± 6 42 ± 9 43 ± 8 45 ± 9 42 ± 8 
   
2 45 ± 9 46 ± 7 46 ± 3 49 ± 6 50 ± 2 
Venous PO2 § kPa 1 6.1 ± 2.6  4.8 ± 1.0 5.0 ± 0.9 4.2 ± 0.5 4.5 ± 0.5 
   
2 4.3 ± 0.0 3.7 ± 0.2 3.4 ± 0.5 3.3 ± 1.1 3.5 ± 1.2 
Venous PO2 § mmHg 1 46 ± 20 36 ± 8 38 ± 7 32 ± 4 34 ± 4 
   
2 32 ± 0 28 ± 2 26 ± 4 25 ± 8 26 ± 9 
Arterial pH 
  
1 7.50 ± 0.05 7.50 ± 0.05 7.49 ± 0.04 7.49 ± 0.04 7.49 ± 0.05 
   
2 7.50 ± 0.09 7.50 ± 0.06 7.49 ± 0.03 7.48 ± 0.04 7.47 ± 0.03 
Arterial PCO2 
 
kPa 1 5.3 ± 0.8 5.3 ± 0.8 5.3 ± 0.7 5.6 ± 0.8 5.6 ± 0.8 
   
2 5.6 ± 1.3 5.3 ± 1.2 5.6 ± 0.8 5.9 ± 0.7 6.1 ± 0.3 
Arterial PCO2 
 
mmHg 1 40 ± 6 40 ± 6 40 ± 5 42 ± 6 42 ± 6 
   
2 42 ± 10 40 ± 9 42 ± 6 44 ± 5 46 ± 2 
Arterial PO2 §, # kPa 1 16.1 ± 6.3 16.5 ± 6.3 13.1 ± 4.3 10.5 ± 3.6 10.4 ± 6.1 
   
2 12.8 ± 5.9 8.5 ± 3.7 7.2 ± 2.9 7.7 ± 3.7 8.4 ± 4.1 
Arterial PO2 §, # mmHg 1 121 ± 47 124 ± 47 98 ± 32 79 ± 27 78 ± 46 
   
2 96 ± 44 64 ± 28 54 ± 22 58 ± 28 63 ± 31 
Arterial oxygen content *, # mL/L 1 133 ± 17 124 ± 13  116 ± 14 113 ± 11 112 ± 21 
   
2 122 ± 23 108 ± 11 103 ± 13 98 ± 20 100 ± 17 
Venous oxygen content *, §, # mL/L 1 109 ± 23 93 ± 22 92 ± 21 80 ± 19 61 ± 57 
   
2 85 ± 13 73 ± 18 63 ± 7 53 ± 18 54 ± 15 
Venous admixture 
 
% 1 42 ± 21 29 ± 9 38 ± 14 33 ± 13 39 ± 27 
   
2 30 ± 3 40 ± 20 40 ± 12 38 ± 5 35 ± 5 
Oxygen delivery index *, §, # mL/kg/min 1 8.03 ± 1.92 6.83 ± 1.61 6.67 ± 2.24 5.68 ± 2.71 6.00 ± 2.42 
   
2 6.65 ± 0.87 5.10 ± 0.62 5.22 ± 1.22 4.49 ± 1.13 4.62 ± 0.97 
Oxygen consumption index 
 
mL/kg/min 1 1.51 ± 1.16 1.75 ± 0.80 1.44 ± 0.87 1.57 ± 0.72 1.41 ± 0.80 
   
2 1.98 ± 0.2 1.72 ± 0.67 1.98 ± 0.22 1.88 ± 0.46 1.98 ± 0.34 
Packed cell volume *, # % 1 28 ± 4 26 ± 3 25 ± 4 24 ± 3  25 ± 4 
 
    2  26 ± 6 25 ± 6  25 ± 7  24 ± 8  24 ± 7 
* Value after dexmedetomidine 1 µg/kg/hr significantly different from respective baseline values (p < 0.05). § Value after dexmedetomidine 1.75 µg/kg/hr
 
significantly 
different from respective baseline values (p < 0.05). 
# 
Significant differences were found between baseline periods (T30 and T90). 
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Recovery 
Extubation times were 11.67 ± 4.16 and 11.00 ± 3.61 minutes for treatments 1 and 2 
respectively. Time to standing ranged between fifteen and thirty minutes. For ponies of 
treatment 1 mean time to standing was 20.33 ± 3.06 minutes while the recovery time in 
group 2 was 17.00 ± 3.46 minutes. All ponies had good recoveries (scores 1 or 2) with 
minimal or no ataxia. 
 
Discussion 
The present study aimed at identifying cardiopulmonary effects of two different CRI 
rates of dexmedetomidine in isoflurane anesthetized ponies. Overall, the results of the 
present study demonstrated that a CRI of dexmedetomidine can be applied without 
major side effects in isoflurane anesthetized ponies. Moreover, both infusion rates 
induced similar cardiopulmonary effects. Although statistical differences were detected 
for some parameters such as HR and CI, these differences were small and probably of 
only limited importance in healthy animals. 
The design of the present study, aimed at reducing the time period of the 
experiment and limiting the number of anaesthetic episodes per pony, imposed some 
limitations. The results obtained may have been influenced by the simultaneous 
administration of other anaesthetic drugs used for premedication and induction. 
However, the main objective of the present study was to evaluate the effects of a CRI of 
dexmedetomidine in experimental ponies under standardized conditions, using an 
anaesthetic protocol that can be routinely applied in clinical patients. Nevertheless, the 
effects of time, possible carry-over effects between the two periods and differences in 
body conformation between ponies may have had a major impact on the data.  
Theoretically, a loading dose of dexmedetomidine should be included into the 
protocol of the CRI in order to quickly achieve adequate plasma concentrations. 
However, no loading dose was given, as it is probable that the administration of a bolus 
of dexmedetomidine before each infusion would have caused major cardiopulmonary 
changes which would have overshadowed the effects of the CRI and potential 
differences between the CRI rates. Furthermore, the cardiovascular effects of a bolus of 
an 2-agonist might be dangerous during a relatively deep level of isoflurane 
anaesthesia (FE´ISO of 1.50 %) used in the present study, which would also be hard to 
Chapter 1  
  
111 
 
justify during clinical anaesthesia in horses. In the clinical situation, the dose 
administered for premedication is usually regarded as the loading dose. In the present 
study, dexmedetomidine was administered as premedication fifteen minutes before 
induction of anaesthesia. Although this would have had an effect on the 
cardiopulmonary system, the effects of dexmedetomidine after IV injection were 
reported to be short-lasting (Bettschart-Wolfensberger et al. 2005). Consequently, the 
effects of the dexmedetomidine administered as premedication in the present study 
should have been minimal by T30, when the first CRI was initiated. Nevertheless, with 
a loading dose administered forty five minutes before initiating the CRI, steady state 
plasma concentrations should still have been reached earlier than if no loading dose had 
been given at all. 
Cardiovascular function was only evaluated at the end of each infusion period of 
thirty minutes as during the initial stages of the infusion plasma concentrations of 
dexmedetomidine would have been low. Rough calculations using the available 
pharmacokinetic data in ponies (Bettschart-Wolfensberger et al. 2005) suggest that a 
steady state can only be reached after about eighty to hundred minutes. Although steady 
state plasma concentrations probably were not reached by the end of the infusion 
periods, most of the recorded values appeared to change mainly during the initial phase 
of the infusion and were quite stable towards the end of that time period, suggesting that 
most of the effects were maximal at that time. 
Possible carry-over effects between infusion periods may have occurred in the 
present study design. To exclude this possibility T30 and T90 were compared using 
paired t-tests for the different parameters. Cardiovascular parameters were similar at 
these points, except for minor changes in HR and RAP. Changes in arterial blood gases 
(PaO2 and PCV) and calculated values (CaO2, CvO2 and DO2) were minimal and could 
be explained by the effect of time. Although the pharmacokinetics of dexmedetomidine 
in isoflurane anaesthetized ponies have not been investigated, its cardiovascular effects 
after a bolus injection in standing ponies were short lasting (Bettschart-Wolfensberger 
et al. 2005), suggesting that a washout period of thirty minutes after the end of a first 
CRI was acceptable. This assumption was confirmed in the present study by the 
comparable baseline values recorded in the two time periods. 
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Isoflurane affects cardiovascular function and these changes are influenced by 
the duration of anaesthesia. However, in a study in horses in which, following sedation 
with romifidine, anaesthesia was induced with ketamine and maintained with isoflurane, 
systemic vascular resistance (SVR) increased gradually over time while CI decreased 
progressively (Raisis et al. 2005). Ringer et al. (2007) investigated the effects of a CRI 
of medetomidine in horses undergoing anaesthesia for clinical purposes. Over time, 
SVR and arterial blood pressures increased as did CI, albeit it from an initial low level 
which possibly resulted from the effect of the bolus of medetomidine used for initial 
sedation. In the present study, these temporal effects may also have influenced the data 
obtained, although randomization of the order of treatments should have minimized this 
effect. In a clinical setting, FE´ISO would be lower than that used in the present study 
due to considerable isoflurane-sparing effects of dexmedetomidine. This might favour 
lower CRI rates with regards to haemodynamic performance, as a higher isoflurane 
requirement will somewhat obtund the increase in SVR, resulting in decreased cardiac 
work and myocardial oxygen consumption for the same level of CI. 
The cardiovascular effects of ketamine used for induction of anaesthesia should 
also be considered, as these may again have influenced measured values, especially the 
ones recorded at T30 which were used as baseline. Although ketamine´s direct effect on 
the heart is depressant (Graf et al. 1995), it has been shown to increase the sympathetic 
efferent activity, hereby increasing HR, arterial blood pressure (Wong & Jenkins 1974) 
and myocardial oxygen consumption (Bålfors et al. 1983). Nevertheless, these 
stimulating effects may have been counteracted in the present study by the 
dexmedetomidine sedation or even the administration of midazolam. 
In equine anaesthesia, maintenance of cardiac performance is of major 
importance to guarantee a sufficient muscle blood flow and oxygenation, thereby 
reducing the potential risk of post-anaesthetic myopathy (Lee et al. 1998). Good oxygen 
delivery is also critical to prevent tissue hypoxia. After thirty minutes of anaesthesia, a 
marked decrease in PaO2 was present in all ponies. It is suggested that this was due to 
ventilation/perfusion mismatch as the ponies used in the present study were round 
bellied and relatively fat and heavy body weight ponies are prone to these problems 
(Moens 1989). 
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The sedation dose used in these experimental ponies was based on studies where 
7 µg/kg medetomidine was estimated to be equipotent to 3.5 µg/kg dexmedetomidine 
(Bettschart-Wolfensberger et al. 2005). All ponies were well sedated, with the typical 
lowering of the head, and the degree of ataxia was acceptable. Induction of anaesthesia 
with the standard drugs and subsequent endotracheal intubation were uneventful. 
No effective calculations were performed to obtain the optimal dose needed for 
CRI of dexmedetomidine. Dexmedetomidine CRI dosages have not been reported for 
equines previously. Similar studies in standing horses with, after an initial bolus dose, a 
medetomidine infusion rate of 3.5 µg/kg/hr gave good sedation and resulted in stable 
blood levels of the drug with acceptable cardiopulmonary effects and reduced the MAC 
of desflurane (Bettschart-Wolfensberger et al. 1999a, b; 2001). Based on the above 
mentioned equipotent doses of medetomidine and dexmedetomidine, we chose two 
different infusion rates: 1.75 µg/kg/hr dexmedetomidine was estimated as being 
equivalent to 3.5 µg/kg/hr medetomidine, while a lower infusion rate of 1 µg/kg/hr was 
also studied. Future pharmacokinetic studies are justified to determine whether constant 
and effective plasma levels can be achieved with both doses. 
In this present study no clear differences between the two CRI rates were found. 
This might be due to a ‘ceiling’ of both the positive and negative effects of the 
dexmedetomidine CRIs. Indeed, the analgesic and sedative effects have their upper 
limits, whereby increasing the dose only extends the duration of sedation and analgesia. 
Such an effect has been described also for the cardiovascular side effects of different 
doses of romifidine (Pypendop & Verstegen 2001). Consequently, cardiovascular 
effects may already occur at a low CRI dose, without further dose related increases. 
Cardiovascular function was well maintained in both treatments of ponies 
receiving a CRI of dexmedetomidine. Overall, HR significantly decreased with both 
infusion rates, as a typical effect of the α2-agonists. Activation of 2b-receptors has been 
reported to induce an initial surge in vascular resistance followed by a reflex 
bradycardia (Maze & Tranquili 1991; Maze & Fujinaga 2000; Guimarães & Moura 
2001). More recently, it has been shown that 2-agonists additionally induce 
bradycardia by central mechanisms (Enouri et al. 2008; Honkavaara et al. 2008). 
However, the observed decrease in HR was minimal and no periods of severe 
bradycardia or atrio-ventricular blocks were observed in the ponies. The decrease in HR 
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was significantly more pronounced by the end of period A (from T30 to T60) compared 
to the end of period B (from T90 to T120) in both treatments but this difference was not 
of clinical relevance (2 beats/min). 
Baseline MAP values were low in the present study compared to those 
considered acceptable during clinical anaesthesia. This was presumed to be due to the 
deep level of isoflurane anaesthesia (FE´ISO 1.50%) and resultant decrease in SVR 
(Rödig et al. 1996). No surgical stimulation was performed which may have 
counteracted this decrease. Decreased cardiac compensation could also explain the low 
arterial pressures observed in the present study. Indeed, inhibitory effects of 
dexmedetomidine on release of norepinephrine (Ebert et al. 2000) may potentiate 
depressive influences induced by the volatile agents (vasodilation and myocardial 
depression). 
Arterial pressure increased after infusion of dexmedetomidine, the most 
probable cause being vasoconstriction induced by the activation of 2b-adrenoceptors on 
endothelial smooth muscle, resulting in an increase in SVR (Maze & Tranquili 1991; 
Maze & Fujinaga 2000; Guimarães & Moura 2001). Mean arterial pressure and SVR 
increased significantly in period B compared with baseline values. Differences between 
both infusion rates and periods were not observed. However, the increases in MAP and 
SVR were only significant for period B and not for period A and so this is most likely 
explained by the accumulation of dexmedetomidine over the two infusion periods of 
thirty minutes and by time related changes. Compared to the respective baseline values, 
CI decreased in both treatment groups of ponies receiving dexmedetomidine CRIs, 
mainly attributable to a decrease in HR. Both 1 and 1.75 µg/kg/hr CRIs induced a 
decrease in CI, which returned to baseline values during the ‘washout’ period when no 
dexmedetomidine was administered. 
In the present study significant decreases in CI and DO2 occurred after the 
dexmedetomidine CRIs, but these decreases were approximately 10% of baseline 
values. Such decreases are usually well tolerated in healthy anaesthetized horses under 
clinical conditions. Also under clinical circumstances, the concentrations of isoflurane 
would have been reduced once dexmedetomidine infusion commenced. Nevertheless, 
caution should be taken in compromised horses. Even more, the observed decrease in 
arterial and venous PO2 throughout the anaesthesia in the present study might also have 
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an influence on the other parameters. The purpose of using an FiO2 of 55% was to 
reduce the degree of atelectasis which might occur (Marntell et al. 2005) but in this case 
it was not successful in avoiding substantial pulmonary right to left shunting. In a 
clinical case the FiO2 would have been increased. 
 In both treatments, core temperature decreased significantly over time. This is as 
expected under anaesthesia. However, the average decrease was about 1°C over 150 
minutes in all ponies, which was clinically acceptable. 
Recovery remains a critical phase in equine anaesthesia. In the present study all 
ponies had good recoveries with minimal or no ataxia, despite the fact the animals did 
not receive additional sedation before the recovery period. Oxygen was supplemented 
during the recovery period at a flow rate of 8 L/min via the endotracheal tube and 
nasally after extubation. Although switching from oxygen to room air is normally well 
tolerated by most horses, it was deemed prudent in these ponies to supplement oxygen 
during recovery because of the low PaO2 values measured during anaesthesia (Hubbell 
2005). 
In conclusion, the results of this study demonstrated that dexmedetomidine CRIs 
administered during isoflurane anaesthesia caused statistically significant 
cardiopulmonary effects typical of 2-agonists. However, at the doses used, changes 
were small and within acceptable clinical range, despite isoflurane administration being 
at > one MAC. Further studies are justified to evaluate the analgesic properties and 
anaesthetic-sparing effects of both doses of a dexmedetomidine CRI, and also the 
cardiopulmonary status of horses when such CRIs are administered together with the 
minimal dose of isoflurane necessary to allow surgery. 
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Abstract 
Objective To investigate the influence of a dexmedetomidine constant rate infusion 
(CRI) in horses anaesthetized with isoflurane. 
Study design Prospective, randomized, blinded, clinical study. 
Animals Forty adult healthy horses (weight mean 491 ± SD 102 kg) undergoing 
elective surgery. 
Methods After sedation [dexmedetomidine, 3.5 μg/kg intravenously (IV)] and 
induction IV (midazolam 0.06 mg/kg, ketamine 2.2 mg/kg), anaesthesia was maintained 
with isoflurane in 55-60% oxygen. Horses were ventilated and dobutamine was 
administered when hypoventilation [arterial partial pressure of CO2 > 8.00 kPa (60 
mmHg)] and hypotension (mean arterial pressure < 70 mmHg) occurred respectively. 
During anaesthesia, horses were randomly allocated to receive a CRI of 
dexmedetomidine (1.75 μg/kg/hour) (D) or saline (S). Monitoring included end-tidal 
isoflurane concentration, cardiopulmonary parameters, and need for dobutamine and 
additional ketamine. All horses received 0.875 μg/kg dexmedetomidine IV for the 
recovery period. Age and weight of the horses, duration of anaesthesia, additional 
ketamine and dobutamine, cardiopulmonary data (ANOVA), recovery scores (Wilcoxon 
Rank Sum Test), duration of recovery (t-test) and attempts to stand (Mann-Whitney 
test) were compared between groups. Significance was set at p < 0.05. 
Results Heart rate (HR) and arterial partial pressure of oxygen were significantly lower 
in group D compared to group S. An interaction between treatment and time was 
present for cardiac index, oxygen delivery index and systemic vascular resistance 
(SVR). End-tidal isoflurane concentration and HR significantly increased over time. 
Packed cell volume, systolic, diastolic and mean arterial pressure, arterial oxygen 
content, stroke volume index and SVR significantly decreased over time. Recovery 
scores were significantly better in group D, with fewer attempts to stand and 
significantly longer times to sternal position and first attempt to stand. 
Conclusions and clinical relevance A dexmedetomidine CRI produced limited 
cardiopulmonary effects, but significantly improved recovery quality. 
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Introduction 
Inhalation anaesthesia is frequently used in long surgical procedures in horses and 
carries a higher risk of mortality compared with humans and small domestic animals 
(Johnston et al. 2002). Since many causes of peri-anaesthetic death can be a 
consequence of cardiovascular depression, combination anaesthetic protocols are often 
used to reduce the required amount of inhalants and the associated cardiovascular 
effects (Steffey & Howland 1978) in an attempt to achieve ʻbalanced anaesthesiaʼ. 
Currently, balanced anaesthesia has reached new dimensions with the use of inhalation 
anaesthetics in combination with short-acting anaesthetic adjuvants. The theory is that 
the combination of different anaesthetics will act synergistically regarding to desired 
effects, but not with respect to side-effects (Tonner 2005). 
 Combination anaesthesia in horses aims at maintaining good intraoperative 
cardiopulmonary function and minimizing the pain associated with surgery, both of 
which should result in calmer and more coordinated recoveries (Bettschart-
Wolfensberger & Larenza 2007). The use of lidocaine (Doherty & Frazier 1998), 
ketamine (Muir & Sams 1992) and various 2-agonists (Wagner et al. 1992; Neges et al. 
2003; Kuhn et al. 2004; Devisscher et al. 2010; Schauvliege et al. 2011) as constant rate 
infusions (CRIs) have been described in clinical and in experimental equine anaesthetic 
procedures. These CRIs were reported to provide a sufficient level of analgesia, an 
increase in anaesthetic depth and a reduction of the minimum alveolar concentration 
(MAC) of the inhalation agents (Steffey & Pascoe 1991; England & Clarke 1996; 
Bettschart-Wolfensberger et al. 2001). 
Alpha2-agonists are used frequently in combination anaesthetic protocols in 
horses, although when these agents are used for sedation, especially after bolus 
administration, classic side effects including bradycardia, arrhythmias, decreases in 
cardiac output (   ) and increases in systemic vascular resistance (SVR) have been 
documented extensively (England & Clarke 1996; Yamashita et al. 2000). In contrast, 
cardiac output indexed to weight (CI) and systemic vascular resistance indexed to 
weight (SVRI) did not differ from presedation values under steady state conditions 
when medetomidine was used as a CRI in ponies (Bettschart-Wolfensberger et al. 
1999). Furthermore, recovery quality was significantly better when horses undergoing 
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elective surgery received a medetomidine CRI during isoflurane anaesthesia compared 
to a lidocaine CRI (Ringer et al. 2007). 
Dexmedetomidine, the dextro-rotary and active enantiomer of the racemic 
mixture medetomidine (Vickery & Maze 1989), has marketing authorisation in small 
animal practice and is one of the most potent and selective 2-agonist commercially 
available. Results of previous studies showed that dexmedetomidine offers some 
sedative and analgesic benefits over racemic medetomidine in dogs (Kuusela et al. 
2000, 2001). Furthermore, dexmedetomidine was reported to have a shorter half-life 
compared to medetomidine in both dogs (Kuusela et al. 2000) and ponies (Bettschart-
Wolfensberger et al. 2005). Dexmedetomidine also significantly reduces the MAC of 
isoflurane in humans (Aantaa et al. 1997) and dogs (Pascoe et al. 2006). 
In ponies, dexmedetomidine was shown to be redistributed more rapidly than in 
humans due to a larger volume of distribution (Bettschart-Wolfensberger et al. 2005). 
Consequently, dexmedetomidine has been suggested to be an ideal agent for CRIs in 
equine anaesthesia. Preliminary studies in experimental ponies in our clinic (Marcilla et 
al. 2010) showed that two different CRI rates, 1 and 1.75 μg/kg/hr, after sedation with 
dexmedetomidine (3.5 μg/kg), caused statistically significant cardiopulmonary effects 
typical of 2-agonists, although cardiovascular function remained within clinically 
acceptable limits. However, the arterial partial pressure of oxygen (PaO2) recorded in 
those anaesthetized ponies, had a tendency to be low. To date, dexmedetomidine has 
been used under clinical conditions as a CRI in dogs (Uilenreef et al. 2008) and in small 
ruminants (Kästner et al. 2007), but not in horses. 
In our clinic, we have investigated the effects of a CRI of romifidine (Devisscher 
et al. 2010) and of detomidine (Schauvliege et al. 2011) when given to anaesthetized 
horses. The aim of this current study was to evaluate the cardiopulmonary and possible 
isoflurane sparing effects and the influence on recovery quality of a dexmedetomidine 
CRI of 1.75 μg/kg/hr in healthy anaesthetized horses undergoing elective surgery in 
which anaesthesia is being maintained with isoflurane. 
 
Materials and methods 
The experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of the University of Ghent (2009/22). 
Chapter 2  
  
124 
 
Animals and instrumentation 
Forty adult client-owned horses [American Society of Anesthesiologists (ASA) 
category I or II] aged between seven months and sixteen years old, weighing 491 ± 102 
kg (mean ± SD), which had been referred for elective surgery (soft tissue or orthopaedic 
procedures) lasting more than one hour, were included in the study. Horses undergoing 
head or neck surgery were excluded because of difficulty in evaluation of clinical 
parameters related to anaesthetic depth. 
 The horses were assigned randomly to group D (dexmedetomidine) or group S 
(saline). Food but not water was withheld for twelve hours before general anaesthesia. 
Pre-anaesthetic examinations were performed the evening before the surgical procedure. 
All the anaesthetic procedures were performed by the same investigator (MGM) who 
was unaware of the treatment given. 
Dexmedetomidine (3.5 μg/kg, IV) (Dexdomitor, Pfizer Animal Health, Belgium) 
was given for sedation, after a 12-gauge × 80mm (Intraflon 2, Ecouen, France) or a 14-
gauge × 55 mm (Vasocan Braunüle Luerlock, B. Braun Melsungen AG, Germany) 
catheter was placed in the jugular vein. If the horse was not adequately sedated, an 
additional dose of dexmedetomidine (between 1/4 or 1/2 of the initial dose) was given 
before induction of anaesthesia. Seven to ten minutes following administration of the 
sedative dose of dexmedetomidine, anaesthesia was induced with midazolam (0.06 
mg/kg, IV) (Dormicum, Roche, Belgium) and ketamine (2.2 mg/kg, IV) (Anesketin, 
Eurovet, Belgium) together in the same syringe. 
After tracheal intubation (24-30 mm OD tracheal tube, Willy Rusch AG, 
Germany), the horses were hoisted onto a surgical table covered with soft foam rubber 
pillows (twenty cms), and positioned as required for the planned surgical procedure. 
The endotracheal tube was connected to a large animal anaesthetic unit (Matrx medical 
Inc., NY, USA mounted on a Sulla 909V, Dräger, Germany) with an out-of-circuit 
vaporizer (Drägerwerk AG, Germany) and a large animal ventilator (Smith respirator 
LA 2100, model 2002, Veterinary Technics/BDO-Medipass, The Netherlands). 
Connection to the anaesthetic circuit was considered as time 0 (T0). Anaesthesia was 
maintained with isoflurane (Isoflo, Abbott Laboratories Ltd, UK) in a mixture of 
oxygen (O2) and air, so as to maintain the inspired O2 fraction (FiO2) between 55 and 
60%. Horses placed in lateral recumbency were allowed to breathe spontaneously. If the 
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arterial partial pressure of carbon dioxide (PaCO2) was higher than 8 kPa (60 mmHg), 
PaO2 lower than 13.3 kPa (100 mmHg) or respiratory rate (RR) lower than 4 
breaths/min for more than three minutes in laterally recumbent animals intermittent 
positive pressure ventilation (IPPV) was applied, using an ʻassisted-controlledʼ 
respiration mode with a tidal volume of 10 mL/kg, peak inspiratory pressure close to 
1.96 kPa (20 cmH2O), inspiratory time of 2.2 seconds and RR close to 8 breaths/min. 
All parameters were adapted to maintain PaCO2 between 4.66 and 6.00 kPa (35 and 45 
mmHg). Horses placed in dorsal recumbency were ventilated immediately after 
positioning on the table as previously described. During anaesthesia, anaesthetic depth 
was adjusted by altering the inspired isoflurane concentration according to assessment 
of clinical parameters (respiration, cardiovascular parameters and ocular signs). A 
ketamine bolus was administered to deepen anaesthesia if the horses showed nystagmus 
or moved. 
Arterial access was achieved by catherization of the facial artery (22-gauge 
Vasocan Braunüle Luer Lock, B. Braun Melsungen AG, Germany). This was used to 
obtain arterial blood for analysis, for withdrawal of blood for the lithium dilution     
measurements, and for invasive measurement of arterial blood pressures. The pressure 
monitoring system was zeroed at the level of the right atrium. 
Inspiratory and expiratory CO2, O2 and isoflurane concentrations were measured 
using a calibrated, methane-insensitive, multi-gas analyser (Datex Ohmeda, S/5, D-
LCC15-03, OR, USA). This monitor was also used to record the ECG (base-apex lead), 
systolic (SAP), diastolic (DAP), mean arterial pressures (MAP), peripheral arterial 
saturation by pulse oximetry (probe placed on the tongue) and body temperature using 
an oesophageal probe. 
Cardiac output was measured with the lithium dilution technique (LiDCOplus 
Haemodynamic Monitor, LiDCO Ltd., UK). A bolus of lithium chloride (4.5 μmol/kg) 
was injected through the jugular venous catheter for each measurement. Haemoglobin 
concentration was estimated from the packed cell volume (PCV) [Hb (g/dL) = 34 × 
PCV (L/L); Linton et al. 2000] measured at T15. Intraoperatively, all horses received 
flunixin meglumine (1.1 mg/kg, IV) (Endofluxin 50, Ecuphar, Belgium) and 
intramuscular procaine benzylpenicillin (15000 IU/kg) (Pen-30, V.M.D., Belgium). 
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Experimental design 
As soon as the endotracheal tube was connected to the anaesthetic circuit (T0), group D 
received a CRI of dexmedetomidine (1.75 μg/kg/hr) while group S received a saline 
CRI of equivalent volume and rate. The syringes were prepared by one of the co-
authors, while the main anaesthetist (MGM) was unaware of the treatment. Constant 
rate infusions were administered using a syringe driver (Ohmeda 9000, BOC Health 
care, UK) and were maintained until the end of anaesthesia. Lactated Ringer’s solution 
(Ringer Lactate, Vetoflex, Bioluz, France) was administered IV for the duration of 
anaesthesia at a rate of 10 mL/kg/hr. A urinary catheter was placed in all the horses. 
Values for inspiratory and expiratory CO2, O2, isoflurane, heart rate (HR), SAP, 
MAP, DAP, and body temperature were recorded at five minute intervals throughout 
anaesthesia. Cardiac output was measured and arterial blood samples were collected for 
immediate analysis at fifteen minute intervals (ABL5, Radiometer, Denmark). 
Cardiac output, CI, stroke volume (SV), stroke volume indexed to weight (SVI), 
arterial content of oxygen (CaO2) and oxygen delivery index to weight (DO2I) were 
calculated using standard formulae as listed in previous work from our laboratory 
(Schauvliege et al. 2008). 
Total doses of additional boluses of ketamine and dobutamine infusion rates 
were recorded. Dobutamine (Dobutamine EG, NV Eurogenerics, Belgium) was infused 
to maintain MAP above 70 mmHg, starting at a rate of 0.5 μg/kg/min and then adjusting 
the rate as required. The administration rate of dobutamine over time was calculated for 
each horse according to the individual body weight and the duration of anaesthesia. 
At the end of the surgical procedure, all horses received 0.875 μg/kg 
dexmedetomidine, before they were transported to a padded recovery box where they 
were allowed to recover without assistance. Oxygen was administered (from 8 to 15 
L/min depending on the size of the horse) initially through the endotracheal tube and, 
after extubation, nasally. The endotracheal tube was removed once the horses were able 
to swallow. Following extubation, the doors of the recovery box were closed, and 
recoveries were observed from outside via the continuous images sent by a video 
camera. Extubation time, time to sternal recumbency, time to stand were recorded, and 
recovery quality scored on a scale of 1-5 (Table 1). All the recoveries were observed 
continuously and scored by the same blinded anaesthesist (MGM). 
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Table 1: Scoring system used to grade recoveries. 
Score Description 
1 One attempt to stand, no ataxia. 
2 One to two attempts to stand, some ataxia. 
3 More than two attempts to stand but quiet recovery. 
4 More than two attempts to stand, excitation. 
5 Severe excitation. Horse injured. 
 
Statistical analysis 
Data was tested for normality of distribution by the Kolmogorov-Smirnov test. The age 
and weight of the horses, duration of anaesthesia and total doses of additional ketamine 
and required dobutamine were compared between treatment groups using ANOVA. 
The duration of anaesthesia did not exceed sixty minutes in several horses, and 
therefore only the cardiopulmonary data for sixty minutes after anaesthetic induction 
were analyzed. This analysis used a mixed model analysis of variance with treatment, 
time and their interaction as fixed effects and horse as random effect. Recovery scores 
and duration were compared between treatments using a Wilcoxon rank sum test and t-
test respectively. A Mann-Whitney test was used to compare the number of attempts to 
stand in the recovery. For all analyses the significance level was set at 5%. Results are 
presented as mean ± SD unless otherwise stated. 
 
Results 
Age (for group S and D respectively, 4 ± 4 and 6 ± 4 years) and weight (469 ± 95 and 
513 ± 107 kg) of the horses and duration of anaesthesia (97 ± 28 and 105 ± 44 minutes) 
did not differ statistically between groups. In group S and D, respectively sixteen and 
thirteen horses were placed in dorsal recumbency while four and seven were positioned 
in lateral recumbency. All four horses placed in lateral recumbency in group S were 
able to breathe spontaneously, maintaining PaCO2 lower than 8 kPa (60 mmHg) during 
anaesthesia. In contrast, only one of seven horses in group D was able to breathe 
spontaneously. All other horses were mechanically ventilated. No significant 
differences between groups in FiO2 were found. 
Eleven horses (three in group S and eight in group D) (27.5%) received an 
additional dose of dexmedetomidine to obtain an acceptable level of sedation prior to 
anaesthesia. 
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Details of surgical interventions are shown in Table 2. 
 
Table 2: Types of surgeries performed in group S (n = 20) and group D (n = 20). 
Group D received a constant rate infusion of dexmedetomidine (1.75 μg/kg/hr), 
group S an equivalent volume and rate of saline.  
Type of surgery Group S Group D 
Arthroscopy 11 10 
Cryptorchid 3 3 
Sarcoid excision 1 2 
Umbilical hernia 1 1 
Wound 1 1 
Sarcoid cryosurgery 0 1 
Arthrodesis 0 1 
Funiculitis 1 0 
Street nail 0 1 
Penis amputation 1 0 
Varus deformation 1 0 
 
Isoflurane concentrations, ketamine and dobutamine administration (Figure 1) 
Overall, the end-tidal isoflurane concentration (FE´ISO) increased over time from (p = 
0.0001). No significant differences between groups were found (Fig. 1). Twelve horses 
in group S and eight horses in group D received additional doses of ketamine. The total 
dose in these horses was 0.82 ± 0.41 and 0.57 ± 0.3 mg/kg for horses in group S and D, 
respectively (p = 0.16). In both groups, seven horses needed one dose of extra ketamine; 
doses ranging from 0.3 to 1 mg/kg in group S and from 0.3 to 0.9 mg/kg in group D. 
Two horses in group S needed two doses (0.5 mg/kg), two needed three doses (0.4-0.6 
mg/kg) and one horse four extra doses (0.2-0.4 mg/kg). In group D only one horse 
required a second dose (0.5 mg/kg). Extra doses of ketamine were administered when 
horses showed nystagmus or moved. Only one horse in each group moved during 
anaesthesia. 
Nine horses in group S (mean dose 0.11 ± 0.06 μg/kg/min) and five horses in 
group D (mean dose 0.13 ± 0.15 μg/kg/min) received a dobutamine CRI during the 
anaesthetic period. These mean doses did not differ significantly between groups (p = 
0.6). 
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§ Changes over time (p < 0.05) were present. 
 
Figure 1: End-tidal isoflurane concentration (FE´ISO) (in percentage) in forty 
horses anaesthetized with a standard isoflurane protocol for elective surgery. 
Horses in group S (n = 20) received a constant rate infusion of saline and horses in 
group D (n = 20) received dexmedetomidine 1.75 μg/kg/hr. 
 
Cardiopulmonary system (Tables 3-4 & Figures 2-5) 
Overall, HR in beats/min was significantly lower (p = 0.02) in group D (33 ± 4) 
compared with group S (37 ± 6 ) (Fig. 2). An interaction between treatment and time 
was found for CI (p = 0.02) (Fig. 3), DO2I (p = 0.02) (Fig. 4) and SVR (p = 0.04). 
Statistical analysis also showed an increase in HR (p < 0.0001) and a decrease in SAP, 
DAP and MAP (p < 0.0001), SVI (p = 0.003) and SVR (p = 0.005) over time. 
Overall, PaO2 was significantly lower in group D (20 ± 7 kPa; 150 ± 53 mmHg) 
than in group S (25 ± 9 kPa; 188 ± 68 mmHg) (p = 0.02) (Fig. 5). Packed cell volume 
decreased over time (p < 0.0001). 
Hypoxaemia (PaO2 < 8 kPa; < 60 mmHg) occurred only in four horses (three in 
group S and one in group D), and for short periods of time, mostly after the first hour of 
anaesthesia. 
An interaction between treatment and time was found for DO2I (p = 0.02) (Fig. 
4). Arterial oxygen content decreased significantly over time (p = 0.03).  
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Table 3: Cardiovascular parameters (mean ± SD) in forty anaesthetized horses 
undergoing elective surgery.  
Values Differences Unit Group T15 T30 T45 T60 
SAP 
§
 mmHg S 119 ± 12 107 ± 10 105 ± 16 107 ± 15 
   
D 122 ± 17 114 ± 20 107 ± 22 106 ± 20 
MAP 
§
 mmHg S 95 ± 13 84 ± 11 82 ± 16 86 ± 15 
   
D 98 ± 17 91 ± 19 86 ± 20 83 ± 19 
DAP 
§
 mmHg S 81 ± 12 70 ± 11 69 ± 17 72 ± 15 
   
D 83 ± 15 78 ± 18 73 ± 20 71 ± 18 
SVR 
§, #
 dyne/sec/cm
5
 S 260 ± 45 209 ± 43 223 ± 86 244 ± 103 
   
D 263 ± 82 252 ± 76 233 ± 89 223 ± 81 
SI 
§
 mL/kg S 1.8 ± 0.4 1.9 ± 0.4 1.7 ± 0.4 1.7 ± 0.4 
   
D 1.9 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 
Systolic (SAP), mean (MAP) and diastolic (DAP) pressures, systemic vascular resistance (SVR) and stroke index (SI) 
in forty anaesthetized horses undergoing elective surgeries. Horses in group S (n = 20) received a CRI of saline and 
horses in group D (n = 20) received dexmedetomidine 1.75 μg/kg/hr. 
§ Changes over time (p < 0.05); 
#
Interaction treatment*time (p < 0.05). 
 
 
Table 4: Other cardiopulmonary and systemic parameters in forty anaesthetized 
horses for elective surgery (mean ± SD values). 
Values Differences Unit Group T15 T30 T45 T60 
Body temperature  
§, #
 °C S 37.1 ± 0.5 37.0 ± 0.6 36.8 ± 0.6 36.8 ± 0.7 
   
D 37.0 ± 0.4 36.9 ± 0.4 36.8 ± 0.4 36.7 ± 0.4 
Arterial pH 
  
S 7.43 ± 0.05 7.43 ± 0.05 7.42 ± 0.06 7.42 ± 0.05 
   
D 7.41 ± 0.05 7.42 ± 0.05 7.42 ± 0.05 7.41 ± 0.03 
Arterial PCO2  
kPa S 5.9 ± 0.8 5.9 ± 0.9 6 ± 0.9 6 ± 0.7 
   
D 6 ± 0.8 6 ± 0.8 6 ± 0.9 6 ± 0.7 
Arterial PCO2  
mmHg S 44 ± 6 44 ± 7 45 ± 7 45 ± 5 
   
D 45 ± 6 45 ± 6 45 ± 7 45 ± 5 
CaO2 
§
 ml/L S 143 ± 13 140 ± 11 140 ± 11 140 ± 14 
   
D 142 ± 17 139 ± 15 137 ± 18 134 ± 17 
PCV 
§
 % S 30 ± 3 29 ± 3 29 ± 2 29 ± 3 
      D 30 ± 3 29 ± 3 29 ± 4 28 ± 3 
Body temperature, arterial blood gas results, arterial oxygen content (CaO2) and packed cell volume (PCV) in 40 
anaesthetized horses undergoing elective surgeries.  
Horses in group S (n = 20) received a constant rate infusion of saline and horses in group D (n = 20) received 
dexmedetomidine 1.75 μg/kg/hr. 
§ Changes over time (p < 0.05); 
#
Interaction treatment*time (p < 0.05). 
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* Significant differences between treatments (p < 0.05). A significant increase over time was present in 
both groups (p < 0.05). 
 
Figure 2: Heart rate in forty horses anaesthetized with a standard isoflurane 
protocol for elective surgery. Horses in group S (n = 20) received a constant rate 
infusion of saline and horses in group D (n = 20) received dexmedetomidine 1.75 
μg/kg/hr. 
 
Interaction treatment*time was present (p < 0.05). 
 
Figure 3: Cardiac index in forty horses anaesthetized with a standard isoflurane 
protocol for elective surgery. Horses in group S (n = 20) received a constant rate 
infusion of saline and horses in group D (n = 20) received dexmedetomidine 1.75 
μg/kg/hr. 
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Interaction treatment*time was present (p < 0.05). 
 
Figure 4: Oxygen delivery index in forty horses anaesthetized with a standard 
isoflurane protocol for elective surgery. Horses in group S (n = 20) received a 
constant rate infusion of saline and horses in group D (n = 20) received 
dexmedetomidine 1.75 μg/kg/hr. 
 
 
 
*Significant differences between treatments (p < 0.05). 
 
Figure 5: Arterial partial pressure of oxygen in forty horses anaesthetized with a 
standard isoflurane protocol for elective surgery. Horses in group S (n = 20) 
received a CRI of saline and horses in group D (n = 20) received dexmedetomidine 
1.75 μg/kg/hr. 
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Recovery scores and times (Tables 5 & 6) 
Recovery scores were significantly better in group D (p = 0.03) than in group S. Horses 
in group D needed fewer attempts to stand (p = 0.04). Times to sternal recumbency (p = 
0.03) and first attempt to stand (p = 0.04) were significantly longer in group D 
compared with group S. 
 
Table 5: Recovery scores in forty horses anaesthetized for elective surgery. Horses 
in group S (n = 20) received a constant rate infusion of saline and horses in group 
D (n = 20) received dexmedetomidine 1.75 μg/kg/hr. 
 
Group S Group D 
Score 1 9 15 
Score 2 9 6 
Score 3 3 0 
Significant differences between groups (p < 0.05) were found. 
 
Table 6: Recovery times (in minutes) in forty horses anaesthetized for elective 
surgery. Horses in group S (n = 20) received a constant rate infusion of saline and 
horses in group D (n = 20) received dexmdetomidine (1.75 µg/kg/hr). 
 
Differences Group S Group D 
Extubation time 
 
19 ± 7 21 ± 5 
Time to sternal recumbency * 25 ± 8 31 ± 8 
First attempt to stand * 29 ± 11 36 ± 10 
Standing time 
 
32 ± 10 37 ± 11 
Extubation to sternal recumbency 
 
6 ± 6 10 ± 7 
Sternal to standing time 
 
7 ± 7 6 ± 5 
*
 Significant differences between groups (p < 0.05). 
 
Discussion 
In the present study, a CRI of dexmedetomidine given to horses during isoflurane 
anaesthesia had limited cardiopulmonary effects, but failed to reduce the dose of 
isoflurane required for maintenance. Recovery from anaesthesia was statistically (but 
not clinically) significantly longer after the dexmedetomidine CRI, but was of better 
quality. 
The design of the present study had limitations, especially to detect anaesthetic-
sparing effects of dexmedetomidine. This may have been due to difficulty in correct 
assessment of depth of anaesthesia. Ringer et al. (2007) reported that, on the basis of the 
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classical parameters and ocular signs usually used to judge depth of anaesthesia, horses 
at the ʻideal depthʼ appear more lightly anaesthetized when a CRI of medetomidine is 
used. They suggested that horses anaesthetized with medetomidine and assessed as 
ʻlightʼ by the anaesthetist, did not respond to noxious stimuli. In previous studies carried 
out in our clinic using methods similar to those used here, we failed to demonstrate an 
isoflurane sparing effect of CRIs of romifidine or detomidine in horses undergoing 
routine surgical procedures (Devisscher et al. 2010; Schauvliege et al. 2011). An 
experimental ‘MAC reduction study’ is required to determine if there are isoflurane 
sparing effects of dexmedetomidine in horses. 
The dose of dexmedetomidine used for pre-anaesthetic sedation of the horses 
was based on previous studies where 7 μg/kg medetomidine was estimated to be 
equipotent to 3.5 μg/kg dexmedetomidine (Bettschart-Wolfensberger et al. 2005). In our 
previous experimental study (Marcilla et al. 2010), this dose produced an adequate level 
of sedation. However, in the present study, with clinical cases involving different types 
of horses of varying temperaments, the level of sedation was insufficient in eleven of 
forty horses and an additional dose of dexmedetomidine was required. Thus slightly 
higher doses than those used in this study might be preferable in order to obtain 
acceptable sedation in individual patients, as adequate sedation is essential prior to 
induction with ketamine. Induction of anaesthesia and subsequent endotracheal 
intubation were uneventful. 
In our previous study, the cardiopulmonary effects of two different CRIs of 
dexmedetomidine were compared (1 and 1.75 μg/kg/hr) in experimental ponies 
(Marcilla et al. 2010). The protocol involved a total of 150 minutes of anaesthesia with 
isoflurane, during which there were periods of infusion of dexmedetomidine at one of 
the dose rates tested, and periods of ‘control’ with no dexmedetomidine CRI. Thus the 
results are not strictly comparable with this current study, which examined only sixty 
minutes of anaesthesia, involved lower FE´ISO and included surgical stimulation. In the 
experimental study, with both administration rates, typical 2-agonist associated 
cardiovascular effects were recorded, but cardiovascular function remained within 
clinically acceptable limits in all the ponies. However, arterial hypoxaemia was present 
in four of six ponies. It was considered that this was because of the conformation of the 
ponies, resulting in alveolar collapse during anaesthesia, causing right-to-left shunting 
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in the pulmonary circulation (Nyman & Hedenstierna 1989), which has been shown to 
be more pronounced in fat, round bellied horses (Moens 1989). Cardiovascular function 
was comparable with both dexmedetomidine administration rates in ponies, possibly 
due to the occurrence of a ‘ceiling effect’. On this basis, the higher of the doses tested 
was used in the present study, as it was hypothesized that it would provide more 
sedation, analgesia, and isoflurane sparing effects compared to the lower dose, without 
causing more pronounced cardiovascular depression. 
In this present study, cardiovascular function was well maintained in group D. 
Overall, HR was significantly lower compared with group S, a typical side effect of 2-
agonists. The observed decrease in HR was minimal and no periods of severe 
bradycardia were observed. Only two out of forty horses showed second degree atrio-
ventricular blocks, and there was no need for treatment. Heart rate increased over time 
in both groups, probably due to a gradual waning of the effects of the dexmedetomidine 
administered for premedication. The cardiopulmonary effects of dexmedetomidine have 
been shown to be short lasting and should be minimal after thirty minutes, while the 
plasma concentration should be below the minimal level of detection (0.05 ng/mL) 
within sixty to ninety minutes (Bettschart-Wolfensberger et al. 2005). Arterial blood 
pressures (ABPs) decreased over time in both groups, again probably due to a gradually 
diminishing effect of the dose of dexmedetomidine used for premedication, but also 
possibly partly due to the increase in FE´ISO that occurred over time, although this 
increase was small and unlikely to be clinically significant. Although ABP tended to be 
higher in group D, the difference with group S was not statistically significant. In part, 
this may be explained by the use of dobutamine to maintain MAP above 70 mmHg in 
both groups, although the difference in dobutamine used between groups was not 
statistically significant. 
An interaction between treatment and time was found for CI. A peak at T30 
occurred in group S, compared to the values at T15 and T45, while CI remained stable 
for group D. A possible explanation is that surgical intervention usually started close to 
thirty minutes after anaesthesia induction, and it is possible that the sedation and 
analgesia provided by the infusion of dexmedetomidine blunted the autonomic response 
to noxious stimulation. An interaction between treatment and time was also observed 
for DO2I (Fig. 4), which changed over time in a similar way as CI, demonstrating the 
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clear relationship between both variables. In agreement with these findings, the need for 
additional doses of ketamine tended to be lower and less frequent in horses in group D. 
It is also interesting to note that although FE´ISO was similar in both groups, CI was not 
significantly different between treatments, so was not adversely affected by the 
dexmedetomidine infusion despite the decrease in HR. This contrasts with the results of 
the experimental studies (Marcilla et al. 2010) in which dexmedetomidine CRI resulted 
in a significant decrease in CI. 
Arterial partial pressure of oxygen was statistically significantly lower in group 
D compared with group S (Fig. 5), but always in the range to fully saturate 
haemoglobin, and therefore there was no clinical significance and CaO2 was comparable 
in both groups. In conscious horses, 2-agonists do cause a small, but usually 
significant, fall in PaO2 (England & Clarke 1996), but the cause has not been 
definitively proven. In the present study most horses were ventilated, so inadequate 
ventilation was not the cause. Interestingly, all four horses in group S positioned in 
lateral recumbency were able to maintain PaCO2 below 8 kPa (60 mmHg) and PaO2 
above 13.3 kPa (100 mmHg) without the use of mechanical ventilation. In contrast, in 
group D, six out of seven laterally recumbent horses needed mechanical ventilation, 
suggesting that an infusion of dexmedetomidine may reduce respiratory drive in 
isoflurane anaesthetized horses. A previous study with medetomidine in isoflurane 
anaesthetized horses (Kalchofner et al. 2006) reported that only three out 300 horses 
needed mechanical ventilation. However, in that study mechanical ventilation was only 
initiated when apnea longer than one minute occurred.  
Recovery remains a critical phase in equine anaesthesia. The experimental 
ponies in our previous study received CRI of dexmedetomidine during anaesthesia, but 
no additional sedation at the end of anaesthesia. They recovered well with minimal or 
no ataxia (Marcilla et al. 2010). However, it is possible that there was a ʻlearning 
effectʼ, as the ponies had been already anaesthetized for different trials. In the present 
study, all horses in both groups received dexmedetomidine IV (0.875 μg/kg) prior the 
recovery period, this dose being comparable to the 2 μg/kg of IV medetomidine that has 
been previously described for use under clinical circumstances (Ringer et al. 2007). 
For the evaluation of the recovery scores, the same experienced anaesthesist, 
unaware of the group, evaluated the recoveries from the video images. Although the 
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scale used was simple, studies comparing such as scale with more complex scales 
appeared to have demonstrated that all are equally reliable in assessing recovery quality 
after general anaesthesia in horses (Vettorato et al. 2010). In the present study recovery 
was of good quality in both groups, but both had received extra sedation at this time. 
However, the recovery was scored to be better in group D, the horses having fewer 
attempts to stand and taking significantly longer times to sternal recumbency and to 
their first attempt to stand than did horses in group S. Moreover, after extubation horses 
in group D tended to stay in lateral recumbency for a longer period before going to the 
sternal position, suggesting that they had recovered from anaesthesia but were more 
sedated than horses in group S.  
In conclusion, the results of the present study demonstrated that a 
dexmedetomidine CRI at 1.75 μg/kg/hr, given to healthy isoflurane anaesthetized horses 
undergoing surgery, failed to reduce the FE´ISO required to maintain anaesthesia under 
the conditions of this clinical trial, but had no clinically relevant effects on the 
cardiovascular system. Although PaO2 was significantly lower in group D, DO2I did not 
differ between groups. The horses receiving dexmedetomidine CRI took longer to 
recover but the recovery quality was better than that of group S. Experimental studies 
are required to find if, and at what dose, a dexmedetomidine CRI can reduce the MAC 
of isoflurane in horses. 
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Summary 
Reasons for performing study Dexmedetomidine has been administered in the equine 
as a constant rate infusion (CRI) during inhalation anaesthesia preserving optimal 
cardiopulmonary function with calm and coordinated recoveries. Inhalant anaesthetic 
sparing effects have been demonstrated in other species but not in horses. 
Objectives To determine the effects of a CRI of dexmedetomidine on the minimum 
alveolar concentration (MAC) of sevoflurane in ponies. 
Methods Six healthy adult ponies were involved in this prospective, randomized, 
crossover, blinded, experimental study. Each pony was anaesthetized twice (three-
weeks washout period). After induction with sevoflurane in oxygen (via nasotracheal 
tube), the ponies were positioned on a surgical table (T0) and anaesthesia was 
maintained with sevoflurane (expired sevoflurane fraction 2.5%) in 55% oxygen. The 
ponies were randomly allocated to treatment D [intravenous (IV) dexmedetomidine 3.5 
µg/kg (T10-T15) followed by a CRI of dexmededomidine at 1.75 µg/kg/hr] or treatment 
S (bolus and CRI of saline at the same volume and rate as treatment D). After T60, 
MAC determination, using a classic bracketing technique, was initiated. Stimuli 
consisted of constant-current electrical stimuli at the skin of the lateral pastern region. 
Triplicate MAC estimations were obtained and averaged in each pony. Monitoring 
included pulse oximetry, electrocardiography, anaesthetic gas monitoring, arterial blood 
pressure measurement and arterial blood gases. Normocapnia was maintained by 
mechanical ventilation. Analysis of variance (treatment and period as fixed factors) was 
used to detect differences between treatments (α = 0.05). 
Results An IV dexmedetomidine CRI decreased mean ± SD sevoflurane MAC from 
2.42 ± 0.55% to 1.07 ± 0.21% (mean MAC reduction 53 ± 15%).  
Conclusions and clinical relevance A dexmedetomidine CRI at the reported dose 
significantly reduces the MAC of sevoflurane. 
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Introduction 
Balanced anaesthetic techniques are often used to reduce the required amount of 
inhalants and their associated cardiovascular effects (Steffey & Howland 1978). Alpha2-
agonists produce sedation and analgesia in all species and have been shown to reduce 
inhalational anaesthetic requirements when administered as a bolus (Steffey et al. 2000) 
or as a constant rate infusion (CRI) in horses (Wagner et al. 1992; Bettschart-
Wolfensberger et al. 2001; Neges et al. 2003; Kuhn et al. 2004), although clear 
minimum alveolar concentration (MAC) reductions were not always reported 
(Devisscher et al. 2010; Schauvliege et al. 2011; Marcilla et al. 2012). However, their 
classic side effects in horses (bradycardia, arrhythmias, a decrease in cardiac output and 
an increase in vascular resistance (England & Clarke 1996; Yamashita et al. 2000) 
should be considered.  
The use of dexmedetomidine, currently the most selective 2-agonist agent, has 
been reported in ponies at the dose of 3.5 µg/kg (Bettschart-Wolfensberger et al. 2005). 
Its use as a CRI experimentally in ponies (at rates of 1 and 1.75 µg/kg/hr) (Marcilla et 
al. 2010) and clinically in horses (1.75 µg/kg/hr) (Marcilla et al. 2012) after a sedative 
dose of 3.5 µg/kg has also been studied. In ponies, dexmedetomidine has been shown to 
be a rapidly redistributed and short-acting sedative drug, with a rapid initial decline of 
the drug concentration, which indicates that plasma levels can be rapidly adjusted to the 
needs of the patients (Bettschart-Wolfensberger et al. 2005). These characteristics 
encourage the use of dexmedetomidine as a CRI in equine balanced anaesthetic 
techniques. 
In the present MAC study, sevoflurane was chosen because of its low blood 
solubility, which facilitates a quick induction and recovery, as well as more rapid 
changes in anaesthetic depth compared with other volatile agents (Brown 1995). 
Additionally, sevoflurane has an acceptable smell and induces a smooth induction of 
anaesthesia without breath holding or signs of airway irritation (Aida et al. 1994). The 
MAC of sevoflurane in horses has been reported to be 2.31 ± 0.11% (Aida et al. 1994), 
2.42 ± 0.24% (Rezende et al. 2011) and 2.84 ± 0.16% (Steffey et al. 2005) in different 
studies. This volatile agent is presently used in the equine (Matthews et al. 1999; 
Rezende et al. 2011) although its use is not licensed. 
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The objective of the present study was to determine the MAC of sevoflurane in 
anaesthetized ponies when receiving a CRI of dexmedetomidine or a CRI of saline by 
using a constant-current (CC) noxious stimulation (Levionnois et al. 2009). 
 
Materials and methods 
The experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of the University of Ghent (2011/059). 
 
Animals and instrumentation 
Six healthy ponies (five geldings and one mare) aged 12.7 ± 2.8 years and weighing 294 
± 51 kg were included in this study. The left carotid artery had been transposed to a 
subcutaneous (SC) position at least seven years before the experiments. Food (not 
water) was withheld for twelve hours before anaesthesia. 
 A 14-gauge intravenous (IV) catheter (Venocan, Kruuse, Denmark)
 
was placed 
in the left jugular vein following SC administration of 0.5 mL mepivacaine 2% 
(Scandicaine, Astrazeneca, Belgium). A nasotracheal silicone tube (Endo-Tracheaal Sil 
V-PET-14/16, Vtrade, Belgium) was inserted into the trachea, via the nose, using 
lidocaine gel (Xylocaine, Astrazeneca, Belgium) and silicone spray (Silikonspray, 
Kirchner & Wilhelm GmbH & Co. KG, Germany) to facilitate placement. 
Preanaesthetic medication was not administered. A rope twitch was placed on the nose 
during nasotracheal intubation of the less cooperative ponies. 
 The ponies were manually restrained against the wall of the recovery box by two 
anaesthetists, while head and tail ropes were used for additional support (another two 
persons). Cotton was placed inside the ears to reduce auditory stimuli. The nasotracheal 
tube was connected to a circle system (Large Animal Ventilator Dräger AV, North 
American Dräger, PA, USA) with a 30 L reservoir bag, using plastic breathing hoses of 
3.5 m length and 55 mm internal diameter. Anaesthesia was induced with 5% 
sevoflurane (Sevorane, Abbott, Belgium) in 8 L/min
 
oxygen. The induction time (time 
from connection to the anaesthetic machine to lateral recumbency) and expired 
sevoflurane fraction (FE´SEVO) at the moment of induction were recorded. 
 After induction of anaesthesia, the ponies remained in lateral recumbency while 
inhaling sevoflurane to deepen the plane of anaesthesia, for three to five minutes. They 
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were then hoisted onto a surgical table covered with soft foam rubber pillows, and 
positioned in right lateral recumbency. The nasotracheal tube was then connected to a 
large animal anaesthetic unit (Matrx, Matrx Medical Inc., NY, USA mounted on a Sulla 
909V, Dräger, Germany) and a large animal ventilator (Smith respirator LA 2100 model 
2002, Veterinary Technics/BDO-Medipass, The Netherlands). Anaesthesia was 
maintained with sevoflurane in oxygen/air with an inspired oxygen fraction (FiO2) of 
55%. The sevoflurane vaporizer setting was adjusted to maintain an FE´SEVO of 2.5% 
for the first hour of anaesthesia. Respiration mode was ‘assisted-controlled’, with a tidal 
volume of 10 ml/kg, respiratory rate of 10 breaths/min, peak inspiratory pressure of 
1.96 kPa (20 cmH2O) and inspiration time of 1.8 seconds. Positive end expiratory 
pressure (PEEP) of 0.49 kPa (5 cmH2O) was applied by means of a home-made, plastic, 
water-filled cylinder, in which the distal end of the expiratory limb was positioned five 
cm below the water surface. The settings were adjusted to maintain arterial partial 
pressure of carbon dioxide (PaCO2) between 6.67 and 8.00 kPa (50 and 60 mmHg) . 
 Lactated Ringer´s solution (Hemofiltratie BH 504, Dirinco, The Netherlands) 
was infused during the whole anaesthetic (3 ml/kg/hr). A urinary catheter was placed. 
 A 22-gauge catheter (Venocan, Kruuse, Denmark) was placed in the left carotid 
artery and connected to a pressure transducer (at the level of the right atrium and zeroed 
to atmospheric pressure) to record arterial blood pressures. Two additional catheters 
were placed (left facial and metatarsal arteries), and non-invasive blood pressure cuffs 
on the tail, both metacarpal and right metatarsal arteries for the performance of a 
parallel study. Blood samples were withdrawn every twenty to thirty minutes from the 
facial arterial catheter for blood gas analysis [pH, standard base excess (SBE) and 
arterial partial pressures of oxygen (PaO2) and carbon dioxide] (ABL5, Radiometer, 
Denmark). Packed cell volume was determined by centrifugation. 
 Inspiratory and expiratory carbon dioxide, oxygen and sevoflurane 
concentrations were continuously measured using a methane-insensitive, 
multiparameter monitoring device (Datex Ohmeda, S/5, D-LCC15-03, OR, USA), 
which was calibrated before every procedure (QUICK CAL
TM
 Calibration gas 
Desflurane, GE Healthcare Finland Oy, Finland) and also used to record the 
electrocardiogram, systolic, diastolic and mean arterial pressures, peripheral arterial 
saturation by pulse oximetry (probe on the tongue) and body temperature by a nasal 
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probe. A warm-water blanket was placed under the ponies (Aquamatic K Thermia 
Model RK-625, Gorman-Rupp Industries Div., OH, USA) and the room temperature 
maintained at 23 °C in order to reduce heat loss. 
 According to our protocol, dobutamine would be infused to maintain the mean 
arterial pressure > 65 mmHg in case of hypotension (mean arterial pressure < 60 
mmHg) and the FiO2 would be increased if hypoxaemia occurred (PaO2 < 60 mmHg), 
but these measures were not needed in any of the ponies. 
 
Experimental design 
Each pony was anaesthetized twice and was administered treatment S (saline) or D 
(dexmedetomidine), with a three weeks washout period. The order of the treatments was 
randomized.  
Once the ponies were positioned on the table (T0), anaesthesia was maintained 
for sixty minutes (T60) with sevoflurane at an FE´SEVO of 2.5%. At T10, the ponies 
received an IV bolus of dexmedetomidine (3.5 µg/kg) (Dexdomitor, Orion Corporation, 
Finland) (treatment D) or a bolus of saline at the same volume (treatment S) over a 
period of five minutes (T10-T15). From T15 onwards, a CRI of dexmedetomidine was 
administered (1.75 µg/kg/hr) (treatment D) or a saline CRI at the same volume and rate 
(treatment S), until the end of the anaesthesia. 
 
Determination of MAC 
A CC electrical stimulation was used for MAC determination (Levionnois et al. 2009). 
Two electrodes (Neuroline 70005-J/12, Ambu GmbH, Germany) were placed on the 
shaved and degreased skin of the lateral aspect of the distal pastern region of the left 
forelimb with an interelectrode distance of one cm. Both electrodes were connected to 
an electrical stimulator (Grass S88, Grass Medical Instruments, MA, USA) equipped 
with a CC unit (Grass Constant Current Unit, Grass Technologies, RI, USA) to ensure 
delivery of CC stimuli despite possible variations in interelectrode resistance. The 
stimuli consisted of a twenty five millisecond train of five one millisecond CC (forty 
milliampere) square-wave pulses. The trains of five were delivered at a frequency of 5 
hertz. The resistance between the electrodes was measured before each stimulation 
using a multimeter (Digital multimeter, VC260, Voltcraft, Conrad Electronic SE, 
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Germany). If it increased above three kiloohms, the electrodes were replaced to ensure 
discharge of a current of forty milliampere. Further details of the equipment used have 
been previously reported (Spadavecchia et al. 2003). 
After sixty minutes of anaesthesia using 2.5% FE´SEVO, the first CC noxious 
stimulus was applied. The response to electrical stimulation was evaluated by the main 
anaesthetist (MGM), who was unaware of the treatment and was not allowed to observe 
the monitored variables (only clinical assessment of anaesthetic depth). The response to 
the electrical stimuli was considered positive when a gross purposeful movement of 
head, limbs or tail occurred and/or swallowing or generalized muscle tremors were 
observed following a CC noxious stimulus. Gross purposeful movement without CC 
stimulation was also considered a positive response. A negative response was where 
none of the described movements occurred, whereas nystagmus and changes to 
physiological parameters were considered as negative responses as well. If the reaction 
was negative, the FE´SEVO was decreased by 0.2% and maintained for twenty minutes 
before a further stimulation. If the response was positive, the FE´SEVO was increased 
by 0.2% and maintained for twenty minutes prior to further stimulation. The MAC was 
determined as the average of the lowest concentration preventing a positive response 
and the highest concentration allowing a positive response. After the first MAC 
estimation the FE´SEVO was again increased or decreased in steps of 0.2% (second 
estimation of MAC value). For the third estimation of MAC, increases or decreases of 
FE´SEVO were made in steps of 0.1%. 
Each MAC determination was corrected to standard atmospheric pressure. The 
final MAC value was determined as the mean of the three estimations. Local 
tetracycline spray (Chlortetra Spray, Eurovet, Belgium) was applied to the stimulated 
area at the end of the experiment. No skin lacerations or wounds were noticed. 
 
Recording of cardiopulmonary variables and arterial blood gases 
Cardiopulmonary values were recorded every ten minutes, while arterial blood gases 
were determined every twenty-thirty minutes. The mean of the three values recorded 
before each MAC estimation (i.e. recorded immediately before each electrical 
stimulation for first, second and third MAC estimations) was additionally calculated. 
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Recovery period 
After determination of the third MAC value and once the ponies were breathing 
spontaneously, they received a bolus of dexmedetomidine (0.875 µg/kg) and were 
transported to a padded recovery box. Oxygen was insufflated (8 L/min) through the 
nasotracheal tube and nasally after extubation. Intranasal phenylephrine (Phenylephrine 
10%, Théa Pharma, Belgium) was administered into both nostrils whilst still intubated 
to reduce post-anaesthetic upper airway obstruction. After swallowing, the nasotracheal 
tube was removed. The ponies were allowed to recover with manual support of the tail. 
Extubation time, time to sternal recumbency and time to stand were recorded. 
Recoveries were scored as previously described (Marcilla et al. 2010) by the main 
anaesthesist, who was unaware of the administered treatment. 
 
Data analysis 
Analysis of variance with treatment and period as fixed factors was used to detect 
differences between treatments (α = 0.05). Correctness of the model was confirmed by 
analysis of the residuals: the Kolmogorov-Smirnov test indicated a normal distribution 
of the standardized residuals, while equality of variances and absence of outliers in the 
data set were confirmed using a scatterplot of the studentized residuals versus the 
predicted values. 
 
Results 
Placement of the nasotracheal tube was possible in all ponies without sedation within 
two to three minutes with minimal resistance, although a nose twitch was needed in 
some of them. Inflation of the cuff, lubricated with lidocaine gel, initially resulted in a 
few (1-3) attempts to cough, but was well tolerated afterwards.  
Induction of anaesthesia was smooth with minimal struggling in five of the six 
ponies. Mean induction time in those ponies was 8.8 ± 2.3 minutes after connection to 
the anaesthetic machine, while mean ± SD FE´SEVO values of 2.12 ± 0.14% were 
required to achieve lateral recumbency.  
Pony number 3, a relatively nervous female, panicked and struggled when signs 
of ataxia occurred. For safety reasons, 1 mg/kg xylazine (Xyl-M, VMD, Belgium) was 
administered IV. After this, induction of anaesthesia was uneventful. The bolus of the 
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test drug was administered forty minutes after xylazine in order to avoid possible 
interferences with MAC determination. The remainder of the anaesthesia was the same 
as in the other ponies, with a first stimulus forty five minutes after administration of the 
drug bolus. The same sedative protocol was used for the second treatment in that pony. 
 
Determination of MAC (Table 1)  
Table 1 includes the individual MAC values for treatment S and D. The sevoflurane 
MAC values (mean ± SD) of treatment D (1.07 ± 0.21%) were significantly lower 
compared to treatment S (2.42 ± 0.55%). The sevoflurane MAC reduction induced by 
the dexmedetomidine CRI ranged between 34 and 79%, with a mean value of 53 ± 15%. 
 From the thirty six MAC estimations (three per pony), fourteen were negative 
responses to stimuli and twenty two were positive responses (fifteen were clear, 
purposeful movements in response to the electrical stimuli or the inflation of a non-
invasive blood pressure cuff and the remaining seven positive reactions were considered 
spontaneous movements).  
 
Table 1: Individual (mean and range) and overall mean (± SD) sevoflurane 
minimum alveolar concentration (MAC) values (%) and percentage reduction of 
sevoflurane MAC.  
 
Pony 
 
Treatment S 
 
Treatment D 
Percentage 
MAC Reduction 
1 3.52  (3.48-3.53) 0.74  (0.71-0.76) 79 
2 2.21  (1.8-2.44) 0.99  (0.96-1.01) 55 
3* 2.34  (2.17-2.62) 1.02  (1-1.05) 56 
4 2.21  (2.2-2.25) 1.06  (0.96-1.11) 52 
5 2.23  (2.22-2.27) 1.28  (1-1.45) 43 
6 1.99  (1.96-2.01) 1.32  (1.15-1.4) 34 
    
Mean ± SD 2.42 ± 0.55 1.07 ± 0.21 53 ± 15 
Ponies received either a bolus of saline followed by a constant rate infusion (CRI;  
treatment S) or a bolus of dexmedetomidine followed by a CRI (treatment D).  
*Pony 3 received 1 mg/kg bwt xylazine (IV) prior to induction. 
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Cardiopulmonary system and body temperature (Table 2) 
Throughout anaesthesia, cardiopulmonary function was well maintained within 
acceptable limits in all the ponies receiving both treatments. 
 
Table 2: Cardiopulmonary parameters, body temperature and duration of 
anaesthesia in six sevoflurane anaesthetized ponies.  
Variable Unit  Treatment S Treatment D 
Heart rate beats/min 42 ± 5 36 ± 3 
Systolic arterial pressure mmHg 141 ± 15 104 ± 7 
Mean arterial pressure mmHg 114 ± 8 83 ± 4 
Diastolic arterial pressure mmHg 94 ± 6 69 ± 4 
Arterial pH   - 7.36 ± 0.04 7.42 ± 0.02 
Standard base excess mmol/L 5 ± 3 9 ± 1 
 PaCO2 kPa 7.2 ± 1 7 ± 1 
 mmHg 54 ± 4 52 ± 4 
 PaO2 kPa 14.3 ± 6.1 15.9 ± 5.7 
 mmHg 107 ± 46 119 ± 43 
Body temperature °C 37.0 ± 0.7 36.4 ± 0.6 
Duration of anaesthesia min 178 ± 32 330 ± 32 
Ponies received either a bolus of saline followed by a CRI (treatment S) or a bolus of 
dexmedetomidine followed by a CRI (treatment D). Values were obtained at the time of 
MAC determination (mean±SD). 
 
Duration of anaesthesia (Table 2) and recovery (Table 3) 
Total anaesthesia times (mean ± SD) were significantly shorter for treatment S (178 ± 
32 minutes) compared with treatment D (330 ± 32 minutes). 
Recovery qualities for all twelve anaesthetic procedures were graded as score 1 
(1 attempt to stand, no ataxia). Mean (± SD) extubation time (treatment S 8 ± 4 versus 
treatment D 9 ± 4 minutes), time to sternal recumbency (treatment S 22 ± 5 versus 
treatment D 23 ± 10 minutes) and time to stand (treatment S 29 ± 4 versus treatment D 
27 ± 9 minutes) were comparable between treatments. 
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Table 3: Extubation, sternal and standing times (in minutes) and number of 
attempts to stand in six anaesthetized ponies.  
Pony Treatment Extubation Time Time to sternal Time to stand Attemps to stand 
1 S 5 20 30 1 
1 D 7 13 23 1 
2 S 15 27 32 1 
2 D 8 33 38 1 
3* S 7 29 30 1 
3* D 15 30 30 1 
4 S 2 17 32 1 
4 D 7 10 15 1 
5 S 10 20 22 1 
5 D 5 19 20 1 
6 S 7 20 25 1 
6 D 12 30 35 1 
Ponies received either a bolus of saline followed by a constant rate infusion (CRI; treatment S) or a bolus 
of dexmedetomidine followed by a CRI (treatment D).
*
Pony 3 received 1 mg/kg bwt xylazine (IV) prior 
induction. 
 
Discussion 
The results of this study show that a dexmedetomidine bolus followed by a CRI of 
dexmedetomidine at the reported doses significantly reduces the MAC of sevoflurane 
(mean ± SD reduction of 53 ± 15%), although individual differences were found.  
Induction of anaesthesia by halothane (Bennett et al. 2004), isoflurane (Steffey 
et al. 2000), sevoflurane (Aida et al. 1994) and desflurane (Tendillo et al. 1997) via face 
mask has been used in MAC studies in the equine in order to avoid the possible impact 
of other drugs. To avoid pollution of the working place and to minimize struggling with 
the ponies, nasotracheal intubation was preferred over the mask induction technique. To 
the authors´ knowledge this technique has never been described for MAC studies in the 
equine. 
In the present study, stepwise (0.2%) increases or decreases in FE´SEVO were 
quickly obtained, minimizing the duration of anaesthesia. The new level of FE´SEVO 
was maintained for twenty minutes before the next stimulus was applied. This period 
was shorter than in most similar studies, so it might be hypothesized that the interval 
was too short to assure a good agreement between the end-tidal and arterial sevoflurane 
concentration. However, the difference between the inspiratory and expiratory 
sevoflurane concentrations was never higher than 10%, suggesting that the difference 
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between the end-tidal and arterial sevoflurane concentration was minimal. Indeed, 
factors which produce errors in the estimation of arterial anaesthetic partial pressure 
from end-tidal pressure analysis usually also contribute to large inspired to end tidal 
differences (Eger & Bahlman 1971). 
Five of the six ponies tolerated the assisted induction technique quite well. One 
relatively nervous female pony panicked severely once she became ataxic during the 
induction of anesthesia. In order to reduce the risk for both the pony and the 
investigators, xylazine was administered. Once a good level of sedation was achieved, 
induction with sevoflurane by the nasotracheal tube was performed without problems. 
Xylazine was chosen due to its short duration of action (Yamashita et al. 2000), 
although dexmedetomidine would also have been a viable alternative (Bettschart-
Wolfensberger et al. 2005). To further reduce any influence of the administered sedative 
drug in that pony, the application of the first stimulus was delayed ninety minutes after 
the xylazine administration, a time sufficient to allow the MAC sparing effect of 
xylazine to have worn off (Steffey et al. 2000).  
The MAC of an inhaled anaesthetic has been defined as the concentration 
required to prevent gross movement in response to a defined supramaximal noxious 
stimulus and has been used to compare the potencies of volatile anaesthetic agents (Eger 
et al. 1965). The MAC is affected by multiple factors (Eger et al. 1965; Regan & Eger 
1976; Yamashita et al. 2009), such as differences in MAC determination methodology 
[type of stimulus (Steffey et al. 2000; Levionnois et al. 2009), place of stimulation 
(Doherty & Frazier 1998; Steffey et al. 2000; Bettschart-Wolfensberger et al. 2001) or 
definition of responses (Aida et al. 1994)], which may be responsible for the collection 
of different MAC values in different studies. To avoid influences in the present study, 
the ponies of the same bodyweight and age were used in a crossover study design and 
premedication was avoided (only one pony required sedation). Normocapnia was 
maintained by using mechanical ventilation, while PEEP and a warm-water blanket 
were used in order to reduce the risk of hypoxaemia (Wilson & McFeely 1991; Moens 
& Böhm 2011) and hypothermia respectively. Although the experiment was performed 
near sea level, a correction to standard atmospheric pressure was made to compensate 
for possible differences in ambient pressure. 
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The most common stimulus in equines is an electrical stimulation of the oral 
mucosal membranes (Aida et al. 1994; Tendillo et al. 1997; Steffey et al. 2000; Rezende 
et al. 2011). A similar stimulus has also been described over the palmar digital nerve 
using subcutaneous electrodes (Doherty & Frazier 1998) and at the coronary band by 
acupuncture needles (Bettschart-Wolfensberger et al. 2001). Quite recently, CC surface-
electrode stimulation was shown to result in more repeatable MAC estimations and 
clearer reactions compared with two constant-voltage stimuli (Levionnois et al. 2009). 
In the present study, the surface electrodes were placed on the shaved and degreased 
skin over the lateral aspect of the distal pastern region of the left forelimb. All MAC 
determinations per pony and per session were close together, confirming the reportedly 
high repeatability of MAC determinations using the CC stimulation technique. 
In most studies, only gross, purposeful movements induced by a stimulus are 
accepted as positive responses (Doherty & Frazier 1998; Bennett et al. 2004). In the 
present experiment, nystagmus and physiological parameter modifications, such as 
increases in heart rate and arterial blood pressure, were not considered as positive 
reactions, but in contrast with most MAC studies, swallowing, muscle tremors and any 
movements of head, limbs, ears or tail were all considered as positive responses. No 
attempts were made to distinguish between purposeful movements and a classic 
withdrawal reflex, because the distinction between them can be subtle and is often 
subjective. Moreover, withdrawal reflexes, swallowing, etc. were considered as positive 
responses because they are not tolerated under clinical circumstances either. The 
objective of the present study was to determine the MAC at which a surgical depth of 
anaesthesia is reached. This classification of the responses to electrical stimuli was 
similar to the one used by Aida et al. (1994), who rated the responses on a two-point 
scale, positive or negative.  
 The MAC value of sevoflurane during treatment S was 2.42 ± 0.55%, which is 
similar to that reported in horses (Aida et al. 1994; Steffey et al. 2005; Rezende et al. 
2011), despite the use of a different definition of MAC. In order to reduce the amount of 
volatile anaesthetics used and to minimize their cardiovascular depressant effects, 
several MAC studies with different 2-agonists have been performed in horses. Single 
boluses of xylazine reduced the MAC of isoflurane (Steffey et al. 2000) and halothane 
(Bennett et al. 2004). A romifidine CRI significantly reduced the expiratory isoflurane 
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concentration in one clinical study (Kuhn et al. 2004), whereas another failed to find a 
clear reduction of the anaesthetic requirement (Devisscher et al. 2010). Detomidine 
reduced the MAC of halothane by 33% when infused continuously (Wagner et al. 
1992), although no reduction was found in isoflurane anaesthetized horses (Schauvliege 
et al. 2011). A medetomidine CRI reduced the MAC of desflurane by 28% in 
experimental ponies (Bettschart-Wolfensberger et al. 2001) and about 20% in isoflurane 
anaesthetized clinical horses (Neges et al. 2003). 
A bolus of dexmedetomidine followed by a CRI failed to reduce the isoflurane 
requirements in our previous clinical study (Marcilla et al. 2012). In contrast, a very 
clear and significant MAC reduction was found here. It is interesting to note that all of 
the studies in which no difference in the end-tidal anaesthetic agent concentration could 
be demonstrated, were blinded clinical trials (Devisscher et al. 2010; Schauvliege et al. 
2011; Marcilla et al. 2012). A possible reason might be that horses receiving infusions 
of 2-agonists at the ʻideal depthʼ appeared to be more lightly anaesthetized on the basis 
of the classical parameters and ocular signs used to judge depth of anaesthesia (Ringer 
et al. 2007). Consequently, it becomes difficult to detect reductions in volatile 
anaesthetic requirements if the anaesthetist is unaware of the treatment and evaluates 
anaesthetic depth based on clinical parameters (Marcilla et al. 2012). 
Throughout anaesthesia, cardiopulmonary function and arterial blood gases were 
clinically acceptable. Further studies are necessary to evaluate the effects of 
dexmedetomidine in addition to sevoflurane in comparison with pure sevoflurane 
anaesthesia at the respective MAC levels, with detailed cardiopulmonary assessment. 
Values before MAC estimation, as shown in table 2, are not compared statistically 
between both treatments as duration of anaesthesia was significantly longer during 
treatment D and cardiopulmonary function may change over time (Gasthuys et al. 1990; 
Steffey et al. 1990).  
In order to avoid potential hypoxaemia, mechanical ventilation combined with 
PEEP was applied (Wilson & McFeely 1991; Moens & Böhm 2011), while an FiO2 of 
55% was maintained to avoid atelectasis (Marntell et al. 2005). Although the PaO2 
values were still lower than theoretically expected, the mean arterial PaO2 was higher 
than 13.3 kPa (100 mmHg) in both treatments, and individual PaO2 values were never 
below 8 kPa (60 mmHg).  
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 All the ponies received a low dose of dexmedetomidine before the recovery and, 
despite a rather long duration of anaesthesia, all recoveries were very good and 
uneventful. Differences in recovery times and qualities were not found in this study, 
probably because these ponies had been anaesthetized previously and were used to 
recover from anaesthesia. 
 In conclusion, dexmedetomidine administered as a bolus followed by a CRI at 
the dose and rate reported here significantly decreased the MAC of sevoflurane by 53 ± 
15% (mean ± SD). 
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Abstract 
Objective To compare the effects of a constant rate infusion (CRI) of dexmedetomidine 
and morphine to those of morphine alone on the minimum end-tidal sevoflurane 
concentration necessary to prevent movement (MACNM) in ponies.  
Study design Prospective, randomized, crossover, blinded, experimental study. 
Animals Five healthy adult gelding ponies were anaesthetised twice with a three weeks 
washout period.  
Methods After induction of anaesthesia with sevoflurane in oxygen (via nasotracheal 
tube), the ponies were positioned on a surgical table (T0), and anaesthesia was 
maintained with sevoflurane (FE´SEVO 2.5%) in 55% oxygen. Monitoring included 
pulse oximetry, electrocardiography and measurement of anaesthetic gases, arterial 
blood pressure and body temperature. The ponies were mechanically ventilated and 
randomly allocated to receive IV treatment M [morphine 0.15 mg/kg (T10-T15) 
followed by a CRI (0.1 mg/kg/hr)] or treatment DM [dexmedetomidine 3.5 µg/kg plus 
morphine 0.15 mg/kg (T10-T15) followed by a CRI of dexmedetomidine 1.75 µg/kg/hr 
and morphine 0.1 mg/kg/hr]. At T60, a stepwise MACNM determination was initiated 
using constant current electrical stimuli at the skin of the lateral pastern region. 
Triplicate MACNM estimations were obtained and then averaged in each pony. Analysis 
of variance was used to detect differences between treatments ( = 0.05). 
Results Sevoflurane-morphine MACNM was 2.79 ± 0.73%. The addition of a continuous 
infusion of dexmedetomidine significantly reduced sevoflurane MACNM to 0.89 ± 
0.22% (mean MACNM reduction 67 ± 11%).  
Conclusion and clinical relevance Co-administration of dexmedetomidine and 
morphine CRIs significantly reduced the MACNM of sevoflurane compared with a CRI 
of morphine alone at the reported doses. 
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Introduction 
Morphine is a µ-opioid receptor agonist that has been used during equine anaesthesia 
mainly to provide analgesia. Its use has been considered controversial due to the 
potential occurrence of dangerous behaviour, cardiopulmonary disturbances, respiratory 
depression in anaesthetised horses (Steffey et al. 2003) and a reduction of 
gastrointestinal motility (Roger et al. 1985). However, clinical studies reported minimal 
haemodynamic and ventilatory changes (Mircica et al. 2003; Clark et al. 2005), 
improvement of the recovery qualities (Mircica et al. 2003; Love et al. 2006; Clark et al. 
2008) and no increased incidence of post surgical colic (Mircica et al. 2003).  
With regard to the effects of morphine on anaesthetic agent requirements, horses 
undergoing elective surgical procedures receiving a morphine constant rate infusion 
(CRI) tended to receive fewer and lower doses of additional anaesthetic drugs (Clark et 
al. 2005). In contrast, IV boluses of morphine at two different doses increased, 
decreased or did not change the minimum alveolar concentration (MAC) of isoflurane 
in anaesthetized horses (Steffey et al. 2003). The influence of a morphine infusion on 
the MAC of volatile agents has not been reported in horses. 
Alpha2-agonists are often combined with opioids in standing horses to achieve 
neuroleptoanalgesia, producing synergistic analgesic effects (Clarke & Paton 1988), 
resulting in reliable sedation and stable cardiorespiratory function (Solano et al. 2009). 
However, under general anaesthesia, the concurrent IV bolus administration of two 
doses of morphine failed to further reduce the MAC of halothane compared to xylazine 
alone in adult horses (Bennett et al. 2004). An IV dexmedetomidine CRI decreased the 
mean ± SD MAC of sevoflurane in ponies from 2.42 ± 0.55 to 1.07 ± 0.21% (Gozalo-
Marcilla et al. 2013) but, to date, the effect on MAC of adding a dexmedetomidine CRI 
to a morphine infusion has not been studied.  
Traditionally, the concept of the MAC is defined as the alveolar concentration of 
volatile anaesthetic agent at which 50% of the patients do not respond with purposeful 
movement to a supramaximal noxious stimulus (Merkel & Eger 1963). Differentiation 
between purposeful versus nonpurposeful movement is sometimes difficult and 
subjective. Derivatives of the traditional MAC such as the minimum end-tidal 
concentration of sevoflurane necessary to prevent movement (MACNM), have therefore 
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been described in the literature. From a clinical standpoint, MACNM may be more 
relevant than the traditional MAC (Seddighi et al. 2011, 2012). 
The main objectives of this study were to determine and compare the MACNM 
values of sevoflurane in experimental ponies receiving a CRI of morphine alone or 
combined with dexmedetomidine. 
 
Materials and methods 
The experiment was approved by the Local Ethical Committee of the Faculty of 
Veterinary Medicine of the University of Ghent (2011/168). 
 
Animals and instrumentation 
Five healthy gelding ponies, aged 13 ± 3 years, weighing 294 ± 57 kg with body 
condition scores of four out of five (Carroll & Huntington 1988) were included in this 
trial. 
Food, but not water, was withheld for twelve hours. Induction and maintenance 
of anaesthesia, fluid therapy and monitoring was performed as described by Gozalo-
Marcilla et al. (2013). Briefly, anaesthesia was induced in the recovery box with 
sevoflurane (Sevorane, Abbott, Belgium) in oxygen via a nasotracheal tube. After 
induction, the ponies were positioned on a surgical table in right lateral recumbency. 
General anaesthesia was maintained with sevoflurane in oxygen/air [inspired oxygen 
fraction (FiO2) of 55%]. The ponies were mechanically ventilated [intermittent positive 
pressure ventilation (IPPV) with tidal volume of 10 mL/kg and positive end-expiratory 
pressure (PEEP) of 0.49 kPa (5 cmH20)] to maintain the arterial partial pressure of 
carbon dioxide (PaCO2) between 6.67-8.00 kPa (50-60 mmHg). Lactated Ringer´s 
solution (Hemofiltratie BH 504, Dirinco, The Netherlands) was infused IV (3 mL/kg/hr) 
and a urinary catheter was placed. 
 Monitoring included electrocardiography, pulse oximetry, anaesthetic gas 
monitoring, invasive (transposed carotid artery) and non-invasive (right metacarpal 
artery) blood pressure (S/5 D-LCC15-03, Datex Ohmeda, OR, USA) and body 
temperature by a nasal probe. Arterial blood samples were withdrawn for blood gas 
analysis [pH, standard base excess and arterial partial pressures of oxygen (PaO2) and 
PaCO2 (ABL5, Radiometer, Denmark)]. A warm-water blanket was placed under the 
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ponies, bubble wrap was used to cover the ponies and the room temperature was 
maintained at 23°C. 
 According to our protocol, dobutamine would be infused to maintain the mean 
arterial pressure (MAP) over 65 mmHg in case MAP decreased below 60 mmHg and 
the FiO2 would be increased if severe hypoxaemia was present (PaO2 below 60 mmHg). 
 
Experimental design 
Each pony was anaesthetised twice for treatment M (morphine) or DM 
(dexmedetomidine plus morphine), in a randomized order with a three weeks washout 
period. The main anaesthetist (MGM) was unaware of the treatment. 
 Once on the table (T0), anaesthesia was maintained for sixty minutes (T60) with 
sevoflurane at an expired fraction (FE´SEVO) of 2.5%. At T10, the ponies received an 
IV bolus of morphine (0.15 mg/kg) (Morphine.HCl, Sterop, Belgium), combined with 
either a bolus of dexmedetomidine (3.5 µg/kg) (Dexdomitor, Orion Corporation, 
Finland) (treatment DM) or an equivalent volume of saline (treatment M), over five 
minutes (T10-T15). The different boluses were administered slowly by hand. From T15 
onwards, a morphine CRI was administered (0.1 mg/kg/hr), combined with 
dexmedetomidine (1.75 µg/kg/hr) (treatment DM), or saline, at the same volume and 
rate (treatment M) until the end of the anaesthesia.  
 
MACNM determination 
The MACNM of sevoflurane was determined applying constant current (CC) electrical 
stimuli to the skin of the lateral pastern region by means of an electrical stimulator 
(Grass S88, Grass medical instruments, MA, USA) equipped with a CC unit (Grass 
Constant Current Unit, Grass Technologies, RI, USA).  
At T60, the first CC stimulus was applied as previously described by Gozalo-
Marcilla et al. (2013). The response to electrical stimulation was assessed by the blinded 
anaesthetist who was allowed only to monitor reflex suppression, muscle tone and gross 
response to noxious stimulation. Positive reactions were considered gross purposeful 
movements, swallowing, generalized muscle tremors, movement of the head, limbs, 
ears or tail, or spontaneous movements without electrical stimulation. Nystagmus and 
physiological parameter modifications were considered negative responses. If the 
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reaction was negative, the FE´SEVO was decreased by 0.2%. Once this level was 
reached, it was maintained for twenty minutes before the next stimulation. This process 
was repeated until a positive response was obtained. If the first stimulus elicited a 
positive response, FE´SEVO was increased in 0.2% steps until a negative response was 
obtained. The MACNM was determined as the average of the lowest concentration 
preventing a positive response and the highest allowing a positive response. Triplicate 
MACNM estimations were obtained, corrected to standard atmospheric pressure and 
averaged in each pony. The correction to standard atmospheric pressure (MAC x PB / 
101.325 kPa; where PB was the ambient barometric pressure at the moment of each 
MAC estimation) was performed as reported by Mama et al. (1999), and using the data 
available from the Royal Meteorological Institute (RMI) of Belgium, which monitors 
hourly the exact PB at a location close to our institution. 
 
Recording of cardiopulmonary variables and arterial blood gases 
Cardiopulmonary values were recorded every ten minutes and arterial blood gas 
samples collected every twenty to thirty minutes. Cardiovascular data was recorded 
immediately before and arterial blood gases immediately after each electrical 
stimulation. For both cardiopulmonary variables and arterial blood gases, the mean of 
the 3 values recorded respectively before and after each MACNM estimation was 
calculated. 
 
Recovery period 
After the determination of the third MACNM value, CRIs and sevoflurane were 
discontinued and once breathing spontaneously, the ponies received dexmedetomidine 
(0.875 µg/kg, IV) and were transported to the recovery box. Oxygen was insufflated (8 
L/min) and intranasal phenylephrine (Phenylephrine 10%, Théa Pharma, Belgium) was 
administered into both nostrils to reduce post anaesthetic upper airway obstruction, with 
the nasotracheal tube in place. After swallowing, the nasotracheal tube was removed. 
Recoveries were manually assisted and scored by the same blinded anaesthetist using a 
scale of 1-5 (Table 1). Furthermore, recovery times including times to extubation and 
times to regain sternal recumbency and standing position were recorded.  
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Table 1: Scoring system used to grade recovery after sevoflurane anaesthesia in 
five adult ponies. 
 
Score Description 
1 One attempt to stand, no ataxia. 
2 One to two attempts to stand, some ataxia. 
3 More than two attempts to stand but quiet recovery. 
4 More than two attempts to stand, excitation. 
5 Severe excitation. Pony injured. 
 
Statistical analysis  
For the sevoflurane MACNM values, analysis of variance with treatment and period as 
fixed factors was used to detect differences between treatments ( = 0.05). As 
correctness of the model could not be confirmed by analysis of the residuals 
(Kolmogorov-Smirnov test) a non-parametric test for paired samples (Wilcoxon signed-
rank test) was performed. Analyses of variance were used to compare duration of 
anaesthesias and total amount of morphine administered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  
  
169 
 
Results 
MACNM determination 
Sevoflurane MACNM values (mean ± SD) for treatments M and DM were 2.79 ± 0.73% 
and 0.89 ± 0.22% respectively, indicating a mean MACNM reduction of 67 ± 11% 
(ranging from 53 to 78%) as shown in Table 2. 
 The responses were clear in all the ponies after electric stimulation, except for 
ponies 1 and 3 during treatment M, in which maintenance of anaesthesia was more 
difficult, with frequent spontaneous movements and fighting against the ventilator.  
 
Table 2: Individual mean MACNM values (%) for sevoflurane with a morphine 
infusion (treatment M) and for sevoflurane with morphine and dexmedetomidine 
infusions (treatment DM) in five adult ponies. 
Pony Treatment M Treatment DM % MACNM reduction 
1 4.07  0.89  78 
2 2.48  0.74  70 
3 2.56  0.62  76 
4 2.21  1.04  53 
5 2.65  1.15  57 
    
Mean±SD 2.79 ± 0.73 0.89 ± 0.22 67 ± 11 
Values corrected to one atmosphere at sea level (760 mmHg). 
 
Cardiopulmonary system  
Heart rate and arterial blood pressures were maintained within acceptable limits. No 
dobutamine was required in any of the ponies receiving either treatment. During 
treatment M, PaO2 in pony 1 decreased below 60 mm Hg (down to 48 mmHg at T150). 
In this case, the FiO2 was increased to 100%, but no change in PaO2 was observed (50 
mmHg at the end of the anaesthetic, at T240). Moreover, moderate hypoxaemia (PaO2 
60-80 mmHg) occurred in ponies 3 and 4 receiving treatment M. When receiving 
treatment DM moderate hypoxaemia was present in pony 1 while pony 4 showed a mild 
degree of hypoxaemia (80-90 mmHg). No significant differences in PaO2 were observed 
between treatments. Cardiopulmonary data are shown in Table 3.  
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Table 3: Cardiopulmonary parameters, body temperature and duration of 
anaesthesia in five sevoflurane anaesthetized ponies (mean ± SD) that received a 
morphine infusion (treatment M) or a morphine and dexmedetomidine infusion 
(treatment DM). 
Variable Unit  Treatment M Treatment DM 
Heart rate beats/min 45 ± 2 37 ± 5 
Systolic arterial pressure mmHg 139 ± 23 132 ± 23 
Mean arterial pressure mmHg 118 ± 20 106 ± 17 
Diastolic arterial pressure mmHg 101 ± 16 90 ± 16 
Arterial pH  7.42 ± 0.03 7.42 ± 0.02 
Standard base excess mmol/L 7 ± 2 9 ± 1 
 PaCO2 kPa 6.7 ± 0.7 7.1 ± 0.1 
 mmHg 50 ± 5 53 ± 1 
 PaO2 kPa 12.4 ± 7.2 16.5 ± 7.6 
 mmHg 93 ± 54 124 ± 57 
Body temperature °C 37.3 ± 0.4 37.1 ± 0.5 
Duration of anaesthesia min 168 ± 56 333 ± 35 
Partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2). 
Values were obtained from three data collection periods before minimal alveolar concentration no 
movement (MACNM) determination (mean ± SD).  
 
Duration of anaesthesia, total amount of morphine administered, and recovery 
times and quality 
Duration of anaesthesia (mean ± SD) was shorter for treatment M than treatment DM 
(168 ± 56 versus 333 ± 35 min) (Table 3). The total amount (mean ± SD) of morphine 
received per pony per anaesthesia was 0.43 ± 0.09 and 0.71 ± 0.06 mg/kg for treatments 
M and DM respectively (p < 0.001). 
 No significant differences were found in the recovery times (Table 4). All 
recoveries were scored as 1 (one attempt to stand, no ataxia) except for pony 1 after 
treatment M, where the recovery was scored as 2 (two attempts, slight ataxia) and signs 
of excitement and over-reactions to stimuli were observed until two hours after the end 
of the anaesthesia. After standing, pony 3, which had received treatment M (morphine 
only), walked in circles in the recovery box until two hours after anaesthesia. 
 
 
Chapter 4  
  
171 
 
Table 4: Time (mean ± SD) to extubation, sternal and standing and recovery scores 
in five sevoflurane anaesthetized ponies that received a morphine infusion 
(treatment M) or a morphine and dexmedetomidine infusion (treatment DM). 
Pony Treatment Extubation time 
(minutes) 
Time to sternal 
(minutes) 
Time to stand 
(minutes) 
Recovery scores 
1 M 12 13 16 2 
2 M 7 20 21 1 
3 M 7 14 17 1 
4 M 9 11 14 1 
5 M 8 8 9 1 
Mean ± SD M 9 ± 2 13 ± 4 15 ± 4  
      
1 DM 9 9 14 1 
2 DM 5 16 16 1 
3 DM 10 10 21 1 
4 DM 4 10 11 1 
5 DM 1 2 7 1 
Mean ± SD DM 6 ± 4 9 ± 5 14 ± 5  
 
 
Discussion 
The results of this study show that co-administration of dexmedetomidine and morphine 
CRIs significantly reduces the MACNM of sevoflurane compared with a CRI of 
morphine alone at the reported doses (mean ± SD reduction of 67 ± 11%).  
When determining the MACNM values in the present study, not all the responses 
were clear movements after electrical stimulation, and in ponies 1 and 3 during 
treatment M, maintenance of anaesthesia was more difficult, with the occurrence of 
generalized muscle tremors and fighting against the ventilator. These differences may 
be explained by a combined analgesic, excitatory and locomotor stimulant effect of 
morphine in horses (Kamerling et al. 1989), with possible inter-individual differences. 
Furthermore, the findings of two research papers studying the effects of opioids in 
horses (Pascoe et al. 1993; Steffey et al. 2003) suggested that the MAC technique may 
not be able to differentiate between arousal of the central nervous system (CNS) or 
stimulation and suppression of response to noxious stimulation (i.e. analgesia). Co-
administration of dexmedetomidine seems to avoid these reactions, most probably due 
to its sedative properties. 
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One of the limitations of this study is that it was performed under experimental 
conditions in healthy animals. It cannot be excluded that the effects of morphine might 
be different in clinical patients undergoing surgery with pre-existing pain and caution 
should be taken when interpreting these results. However, it is generally accepted that 
the results of MAC studies are useful in predicting the required end-tidal anaesthetic 
agent concentration that will result in a surgical depth of anaesthesia in patients (Quasha 
et al. 1980). Another important limitation is the absence of a control (saline) group. 
Ideally, four different treatments (treatments M and DM, as well as treatments S and D) 
would have been included, all administered in a randomized order, to describe the 
effects of a morphine CRI on the MACNM, either when administered alone or combined 
with dexmedetomidine. However, since MACNM with treatments S and D had already 
been determined in a previous experiment in the same ponies, under identical 
circumstances and less than five months before the present experiment (Gozalo-Marcilla 
et al. 2013), it was considered unethical to repeat treatments S and D. Although a 
statistical comparison was therefore only made between treatments M and DM, in the 
authors’ opinion it still remains interesting to compare the present results to those of our 
previous report. 
The MACNM value (mean ± SD) for treatment M obtained in this study was 2.79 
± 0.73%, which is somewhat higher than the value obtain under the same conditions 
when receiving saline (2.42 ± 0.55) (Gozalo-Marcilla et al. 2013). Individually, the 
MAC of four out of five ponies was higher when receiving morphine compared to 
saline and did not change in the remaining pony (pony 4). Administration of boluses at 
low and high doses of morphine (0.25 mg/kg and 2.0 mg/kg, respectively) increased, 
decreased or did not influence the MAC of isoflurane in horses, which does not support 
the routine use of morphine as an anaesthetic adjuvant in horses (Steffey et al. 2003). 
The influence of morphine on MAC thus appears to be less consistent in the equine than 
in other species (Steffey et al. 1994), and Steffey et al. (2003) were unable to identify 
any specific characteristic that would allow them to predict each horse´s individual 
MAC response to morphine administration. 
Compared to the use of morphine alone, the co-administration of 
dexmedetomidine and morphine CRIs produced a significant reduction of the 
sevoflurane MACNM by 67 ± 11%. A reduction was found in all the ponies, which 
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ranged between 53 and 78%. Moreover, during treatment DM the MACNM was even 
lower (0.89 ± 0.22 %) than during treatment D in our previous report (1.07 ± 0.21 %). 
Therefore, it appears likely that dexmedetomidine reduces the excitatory CNS effects of 
a morphine CRI in anaesthesized horses, but perhaps preserves, or even enhances, 
morphine’s analgesic effects. In standing horses, the administration of 2-agonists and 
opioids produces synergistic analgesic effects, with reduced adverse side effects (Clarke 
& Paton 1988; Solano et al. 2009). Intraoperatively, the addition of dexmedetomidine to 
morphine in human patients resulted in superior analgesia, significant morphine sparing 
and less morphine-induced nausea, without additional sedation and untoward 
haemodynamic changes (Lin et al. 2009).  
With regard to the recovery times, no significant differences were found 
between treatments. Possibly, administration of dexmedetomidine (0.875 µg/kg, IV) 
prior to recovery in both treatment groups masked potential differences. However, the 
times to sternal recumbency and to standing in both groups were shorter when 
compared to the values of our previous study with saline and dexmedetomidine CRIs 
(Gozalo-Marcilla et al. 2013). This may be related to the use of morphine, since, Clark 
et al. (2008) reported shorter times from the first recovery movement to the time at 
standing in horses receiving a bolus and an infusion of morphine at the dose and rates 
reported here. Surprisingly, the addition of dexmedetomidine to morphine did not 
increase but shortened the recovery times in all but one pony, despite the considerably 
longer duration of anaesthesia. Possibly, this finding can be attributed to the effects of 
morphine accumulation. Although the morphine plasma concentration was not 
determined in the present study, the duration of general anaesthesias, and consequently 
the cumulative doses of morphine, were significantly higher in ponies during treatment 
DM. It may be hypothesized that the sedative effects of dexmedetomidine were 
overcome by the larger accumulated dose of morphine, leading to CNS stimulation, 
accelerating return from anaesthesia with recovery times becoming shorter.  
In addition to the difficulties for maintenance of general anaesthesia, pony 1 
required two attempts to stand after treatment M and showed excitement and ataxia with 
over-reaction to stimuli for up to two hours after anaesthesia. Although pony 3 after 
treatment M needed only one attempt to stand with no ataxia (score 1), he later showed 
clear signs of box-walking for up to two hours after treatment M. The simultaneous 
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infusion of dexmedetomidine during treatment DM seemed to avoid these reactions, as 
all the ponies recovered well (all score 1) and did not show any sign of excitation or 
box-walking during the recovery period. In the study reported by Steffey et al. (2003), 
IV morphine at 2.0 mg/kg produced dangerous recoveries but not at low doses. Good 
recoveries were described in horses receiving lower doses (0.1-0.2 mg/kg, IV) (Mircica 
et al. 2003; Love et al. 2006) and after a bolus and a CRI at the dose and rates reported 
here (Clark et al. 2008). No box-walking was observed during the post-operative 
periods after saline or dexmedetomidine infusions (Gozalo-Marcilla et al. 2013) and 
after single morphine boluses (Mircica et al. 2003; Love et al. 2006) or infusions (Clark 
et al. 2008).  
 Although comparison of cardiopulmonary function between both CRIs, 
including cardiac output, mixed venous blood gases, etc., would have been interesting, 
this was not the primary aim of the study and this comparison would have been difficult 
due to the large difference in duration of anaesthesia. Heart rate and arterial blood 
pressures were maintained within clinically acceptable limits (Table 3). However, 
despite IPPV and PEEP, severe hypoxaemia (PaO2 = 48 mmHg) was present in pony 1 
receiving treatment M. Consequently, 100% oxygen was administered, but PaO2 
remained low. Presence of severe hypoxaemia could have an influence on MACNM 
values, but this only has been reported with PaO2 values lower than 40 mmHg (Steffey 
& Mama 2007). Moreover, although mean (± SD) values of PaO2 were lower in ponies 
receiving morphine, no statistically significant difference was found between 
treatments. In previous studies, horses receiving morphine had lower PaO2 values 
(Steffey et al. 2003; Love et al. 2006), mainly related to hypoventilation, although no 
differences were found when morphine was administered as a CRI (Clark et al. 2005). 
Furthermore, ventilation/perfusion mismatch related to the high body condition score of 
the ponies (Moens 1989) may have been a contributing factor, exacerbating hypoxaemia 
in the present study, as all five ponies were classified as fat according to the body 
condition scoring reported by Carroll & Huntington (1988).  
In conclusion, co-administration of dexmedetomidine and morphine CRIs 
significantly reduced the MACNM of sevoflurane compared with a CRI of morphine 
alone. Furthermore, the combination of both drugs could be used in equine anaesthesia, 
thus reducing the needs of inhalant agents and possibly enhancing analgesia. Potential 
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CNS stimulation should be considered when using a morphine CRI alone, since 
generalized and uncontrolled spontaneous movements in the intraoperative period and 
excitation, overreaction to stimuli and box-walking during the recovery period could be 
present after prolonged infusions.  
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Abstract 
Twenty adult healthy horses undergoing elective surgery were involved in this 
prospective, blinded, clinical study. Horses were randomly allocated to receive a 
constant rate infusion (CRI) of morphine or dexmedetomidine. After induction, 
anaesthesia was maintained with isoflurane in oxygen/air and mechanical ventilation 
applied. The end-tidal isoflurane concentration (FE´ISO) was initially set at 0.9% and 
adjusted by the anaesthetist, to maintain a light surgical plane of anaesthesia, according 
to an objective flow-chart. Cardiopulmonary function was well maintained with both 
treatments. Less ketamine was required, FE´ISO was lower after one hour and more time 
was spent in an ‘ideal’ plane of anaesthesia in horses receiving dexmedetomidine, with 
better recoveries. One horse receiving morphine developed post-operative colic and 
pulmonary oedema and two showed box-walking behaviour. This study showed that a 
dexmedetomidine CRI produced a more stable anaesthetic depth, reduced isoflurane 
requirements and better recoveries, without post-operative complications compared with 
a morphine CRI. 
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Introduction 
The use of intravenous (IV) constant-rate infusions (CRIs) of 2-agonists has been 
widely studied in horses (Bettschart-Wolfensberger et al. 2001; Devisscher et al. 2010; 
Schauvliege et al. 2011; Pöppel et al. 2012). Dexmedetomidine, the dextro-rotary and 
active enantiomer of the racemic mixture medetomidine, is currently the most potent 
and selective 2-agonist which is commercially available for use in humans and small 
animals. Experimental studies in isoflurane anaesthetized ponies showed that 
dexmedetomidine at two different rates maintained cardiovascular function within 
clinically acceptable limits and produced the typical cardiopulmonary effects of 2-
agonists, while the arterial partial pressure of oxygen (PaO2) tended to be low (Marcilla 
et al. 2010). In a blinded clinical study involving forty healthy isoflurane anaesthetized 
horses undergoing elective surgery, dexmedetomidine (3.5 µg/kg followed by a CRI 
1.75 µg/kg/hr) produced no clinically relevant effects on the cardiovascular system 
compared with a placebo group. Although PaO2 was significantly lower in horses 
receiving dexmedetomidine, oxygen delivery indexed to weight (DO2I) was comparable 
between groups (Marcilla et al. 2012). Moreover, a dexmedetomidine infusion 
improved the quality of the recovery. Although no reduction in expiratory fraction of 
isoflurane (FE´ISO) was demonstrated, a minimal alveolar concentration (MAC) study 
performed in six ponies showed that the same protocol reduced the MAC of sevoflurane 
by 53 ± 15% (mean ± SD) (Gozalo-Marcilla et al. 2013a). As a dexmedetomidine CRI 
causes minor cardiopulmonary effects, improves recovery quality and reduces the MAC 
of inhalant agents, the proposed protocol could be useful for clinical equine balanced 
anaesthesia (Bettschart-Wolfensberger & Larenza 2007).  
 The use of systemically administered opioids in horses to provide analgesia 
remains controversial (Bennett & Steffey 2002; Clutton 2010). Some authors reported 
that morphine administered IV can induce dangerous behaviour in conscious (Combie et 
al. 1979) and anaesthetized horses (Steffey et al. 2003), causing post-operative colic 
(Roger et al. 1985) and respiratory depression (Steffey et al. 2003). In contrast, other 
investigators reported minimal haemodynamic and ventilatory changes (Mircica et al. 
2003; Clark et al. 2005) without an increased incidence of post-operative colic (Mircica 
et al. 2003). Even more, improved recovery qualities were observed (Mircica et al. 
2003; Love et al. 2006; Clark et al. 2008) after boluses and CRIs of morphine in horses 
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undergoing elective surgical procedures. With regard to anaesthetic sparing effects, the 
IV administration of boluses of morphine at two different doses (Steffey et al. 2003) 
failed to reduce the MAC of isoflurane. Moreover, the mimimum end-tidal 
concentration to prevent movement (MACNM) value of sevoflurane obtained in 
experimental ponies receiving a morphine CRI (0.15 mg/kg/hr after loading dose 0.1 
mg/kg) was higher than the one obtained under the same conditions when receiving 
saline (Gozalo-Marcilla et al. 2013b). Both studies were performed in healthy, pain-free 
horses under experimental conditions, where the applied electrical stimulation was 
qualitatively different from classic surgical nociception (Clutton 2010). In contrast, 
clinical equine patients under a morphine CRI tended to receive fewer and lower doses 
of additional anaesthetic drugs, although this was not of statistical significance (Clark et 
al. 2005). 
 The aim of the present study was to evaluate and compare the cardiopulmonary 
function and recovery quality of clinically healthy horses undergoing elective surgery 
either receiving a morphine or a dexmedetomidine CRI at the doses reported by Clark et 
al. (2005) and Marcilla et al. (2012) respectively. Additionally, the hypothesis that 
maintenance of stable anaesthetic depth in horses receiving a CRI of dexmedetomidine 
would be easier compared with horses receiving a morphine CRI, requiring a lower 
FE´ISO and less additional ketamine was investigated. 
 
Materials and methods 
The study was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (2010/177). 
 
Animals and instrumentation 
After obtaining written owner consent, data from twenty adult healthy horses [American 
Society of Anesthesiologists (ASA) category I or II] undergoing elective surgery (soft 
tissue and orthopaedic procedures) lasting more than one hour were included in this 
clinical study. The horses were aged between ten months and fifteen years old, 
weighing 466 ± 117 kg (mean ± SD). Head or neck surgeries were excluded due to the 
difficulty of assessment of the clinical parameters related to anaesthetic depth. 
Respecting the current EU laws of medication in animals, horses classified as ‘food 
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producing animals’ were excluded as dexmedetomidine is not licensed for use in the 
horse. 
 The horses were randomly allocated to receive treatment M (morphine) or 
treatment D (dexmedetomidine). Food, but not water, was withheld for twelve hours 
before anaesthesia and pre-anaesthetic examinations were performed the evening before 
the surgical procedure. All the anaesthetic procedures were performed by the same 
anaesthetist (MGM), who was unaware of the treatment. All medication syringes were 
prepared by one of the co-authors. Sedation scores, depth of anaesthesia and recovery 
scores were evaluated by the same blinded anaesthetist. 
 The horses in treatment M received for sedation dexmedetomidine (3.5 µg/kg, 
IV) (Dexdomitor, Orion Corporation, Finland) plus morphine (0.15 mg/kg, IV) 
(Morphine.HCl, Sterop, Belgium) and those in treatment D received dexmedetomidine 
(3.5 µg/kg, IV) plus a bolus of saline of equivalent volume as morphine in treatment M. 
Depth of sedation was scored as 0 (no sedation), 1 (slight sedation), 2 (good sedation) or 
3 (deep sedation). After sedation, a 12-gauge x 80 mm catheter (Intraflon 2, Ecouen, 
France) was placed in the jugular vein. If required, additional doses of 
dexmedetomidine (1/4 to 1/2 of the initial dose) were given to achieve an adequate level 
of sedation prior to anaesthetic induction. Anaesthesia was induced seven to ten minutes 
after sedation, with midazolam (0.06 mg/kg) (Dormicum, Roche, Belgium) and 
ketamine (2.2 mg/kg) (Anesketin, Eurovet, Belgium) IV mixed in the same syringe. 
After orotracheal intubation (24-30 mm OD tracheal tube, Willy Rusch AG, 
Germany) the horses were hoisted on a surgical table covered with soft foam rubber 
pillows (twenty cms) and positioned according to the planned surgical procedure. The 
endotracheal tube was connected to a large animal anaesthetic unit (Matrx Medical Inc., 
NY, USA mounted on a Sulla 909V; Dräger, Germany) with an out-of-circuit vaporizer 
(Drägerwerk AG, Germany) and a large animal ventilator (Smith respirator LA 2100, 
model 2002, Veterinary Technics/BDO-Medipass, The Netherlands). Connection to the 
anaesthetic circuit was considered as the beginning of anaesthesia (T0). Anaesthesia 
was maintained with isoflurane (Isoflo, Abbott Laboratories Ltd, UK) in a mixture of 
oxygen (O2) and air to maintain the inspired O2 fraction (FiO2) between 55 and 60%. 
All the horses were mechanically ventilated immediately after positioning on the table. 
Intermittent positive pressure ventilation (IPPV) was applied, using an assisted-
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controlled respiration mode, with a tidal volume of 10 mL/kg, peak inspiratory pressure 
close to 1.96 kPa (20 cm H2O), inspiratory time of around 2.2 seconds and respiratory 
rate near to 8 breaths/min. All parameters were adapted to maintain arterial partial 
pressure of carbon dioxide (PaCO2) between 4.66 and 6.00 kPa (35-45 mmHg).  
Inspiratory and expiratory CO2, O2 and isoflurane concentrations were measured 
using a calibrated, methane-insensitive, multiparameter monitoring device (S/5, D-
LCC15-03, Datex Ohmeda, OR, USA). This monitor was also used to record the 
electrocardiogram (base-apex lead), systolic (SAP), diastolic (DAP) and mean arterial 
pressures (MAP), peripheral arterial saturation by pulse oximetry (probe on the tongue) 
and body temperature by a nasal probe. 
 Catheterization of the facial artery was performed in all horses (22-gauge 
Vasocan Braunüle Luer Lock; B. Braun Melsungen AG, Germany) to obtain arterial 
blood for analysis, for withdrawal of blood for lithium dilution cardiac output 
measurements and for continuous invasive measurement of arterial blood pressures. The 
pressure monitoring system was zeroed at the level of the right atrium. 
 Cardiac output (   ) was determined using the lithium dilution technique 
(LiDCOplus Haemodynamic Monitor, LiDCO Ltd., UK). A bolus of lithium chloride 
(4.5 µmol/kg) was injected through the jugular catheter, while arterial blood for 
detection of lithium chloride by the LiDCO sensor (CM10 LiDCO sensor, LiDCO Ltd., 
UK) was withdrawn from the facial artery by the LiDCO Flow Regulator (CM 33 
LiDCO flow regulator, LiDCO Ltd., UK). Plasma sodium values were determined 
(AVL 9180 Electrolyte Analyzer, AVL Scientific Corporation, GA, USA) on a blood 
sample withdrawn from the right jugular vein before sedation and were entered into the 
LiDCOplus monitor to allow correct LiDCO measurements. Haemoglobin (Hb) 
concentration was estimated for each measurement from the packed cell volume (PCV) 
[Hb (g/dL) = 34 x PCV (L/L) (Linton et al. 2000)]. 
 Intraoperatively, all the horses received flunixin meglumine (1.1 mg/kg, IV) 
(Endofluxin 50, Ecuphar, Belgium) and intramuscular procaine benzylpenicillin (15000 
IU/kg) (Pen-30, V.M.D., Belgium). 
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Experimental design 
The vaporizer was adjusted to obtain an FE´ISO of 0.9% during the first ten minutes of 
general anaesthesia. Horses allocated to treatments M and D received at T0 a CRI of 
morphine (0.1 mg/kg/hr) and dexmedetomidine (1.75 µg/kg/hr) respectively. Constant 
rate infusions were administered by a syringe driver (Ohmeda 9000, BOC Health Care, 
UK) until the end of anaesthesia. Lactated Ringer´s solution (Hamofiltratie, Dirinco, 
The Netherlands) was administered IV (10 mL/kg/hr). A urinary catheter was placed in 
all the horses. 
 Instrumentation was completed by T10. Values for inspiratory CO2, O2, 
isoflurane, heart rate (HR), SAP, MAP, DAP and body temperature were recorded every 
five minutes. Cardiac output was measured and arterial blood samples collected at 
fifteen minutes intervals (ABL5, Radiometer, Denmark). 
 Cardiac output indexed to bodyweight (CI), stroke volume (SV), stroke volume 
indexed to bodyweight (SVI), systemic vascular resistance (SVR), arterial oxygen 
content (CaO2), oxygen delivery (DO2) and DO2I were calculated using standard 
formulae (Schauvliege et al. 2008).  
 
Maintenance of anaesthesia 
Dobutamine (Dobutamine EG, NV Eurogenics, Belgium) was infused to maintain MAP 
above 70 mmHg, starting at a rate of 0.5 µg/kg/min and adjusted as required. The 
FE´ISO was adjusted to maintain a light surgical plane of anaesthesia by the blinded 
anaesthetist, according to a scoring flow-chart adapted from Enderle et al. (2008) 
(Figure 1) in order to assess the depth of anaesthesia more objectively. After T10 
(FE´ISO = 0.9%), a scoring evaluation was performed every five minutes. For each 
scoring, the reference value was the previous score. The flow-chart ranges from scores -
2 (deep anaesthesia) to 4 (very light anaesthesia, limb movement present), where score 
0 was considered as the ‘ideal’ surgical plane of anaesthesia. The vaporizer setting was 
adjusted to provide a higher or lower FE´ISO according to occurrence of movement 
(scores 3 and 4), nystagmus (score 2), presence of palpebral reflex (scores -2 to 1) and 
absence of palpebral reflex (score -2). If a palpebral reflex was present, with no 
movement neither nystagmus (scores -2 to 1), scoring was mainly based on MAP values 
and the administration (or no administration) of dobutamine. If MAP was lower than 70 
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mmHg, the FE´ISO was reduced by 0.1% (score -1). If MAP was higher than 70 mmHg, 
the decision was based on changes in MAP compared to the previous value, while 
taking possible changes in the administration rate of dobutamine into account: if MAP 
was reduced by more than 15% compared with the previous scoring, a score of -2 was 
given and the FE´ISO was reduced by 0.2%. If MAP was reduced by 15% or less and a 
dobutamine infusion had been started or its rate increased during the last 5 minutes, a 
score -1 was given and the FE´ISO was reduced by 0.1%; if the administration rate of 
dobutamine had not changed in the last 5 minutes, the anaesthetic depth was considered 
ideal (score 0) and the FE´ISO was maintained constant. A score 0 was also given when 
MAP increased by less than 20% or when it increased by more than 20% when the 
dobutamine administration rate had been increased in the last 5 minutes. Increases in 
MAP by more than 20% without changes in the out changes in the dobutamine 
administration rate indicated too light anaesthesia (score 1) and FE´ISO was increased 
by 0.1%. If movement or nystagmus were present (scores 2 to 4), ketamine was 
administered IV as indicated in the flow-chart. Ketamine doses and dobutamine rates 
were calculated for each horse and corrected according to the individual body weight 
and anaesthesia duration. Percentages of the time of anaesthesia spent in each score 
were calculated for every horse from each treatment. 
 
Chapter 5  
  
188 
 
Movement ?
Limb movement ?
Nystagmus ?
YesNo
Yes
↑↑ FE ISO 0.2%
Ketamine 0.6 mg kg-1
Score 4No
↑↑ FE ISO 0.2%
Ketamine 0.4 mg kg-1
Score 3
Yes
↑ FE ISO 0.1%
Ketamine 0.2 mg kg-1
Score 2
No
Palpebral reflex?
No
↓ FE ISO 0.2%
Score -2
Yes
MAP < 70 mmHg?
Yes
↓ FE ISO 0.1%
Score -1
↓ FE ISO 0.2%
Score -2
FE ISO =
Score 0
No
MAP
↓ FE ISO 0.1%
Score -1
↑ FE ISO 0.1%
Score 1
↓ by > 15% ↓ = 
or 
by <15%
↑ by >20%
Dobutamine started
or increased?
Yes
Dobutamine started
or increased?
No
↑ by <20%
Yes
No
 
Figure 1: Flow-chart representing the scoring system used to adjust anaesthetic 
requirement in order to maintain a light surgical level of anaesthesia in twenty 
isoflurane anaesthetized hores undergoing elective surgery. Different questions are 
answered to obtain the score and the modification of the expiratory fraction of 
isoflurane (FE´ISO) every five minutes, with the value obtained five minutes earlier 
being the reference value, and MAP the mean arterial pressure. Adapted from 
Enderle et al. (2008). 
 
 
End of anaesthesia and recovery phase 
At the end of the surgery, the CRIs and mechanical ventilation were stopped. Once 
breathing spontaneously, dexmedetomidine (0.875 µg/kg, IV) was administered in all 
horses which were transported to a padded recovery box and allowed to recover without 
assistance. Oxygen was administered initially through the endotracheal tube and nasally 
after extubation. The endotracheal tube was removed once the horses were able to 
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swallow. The rest of the recovery was monitored from outside the recovery box using 
an infrared camera system. Recovery times (extubation time, time to sternal 
recumbency and time to stand) were recorded and recovery qualities scored on a scale 
of 1-6 (Table 1) by the same blinded anaesthetist. 
 
Table 1: Scoring system used to grade recoveries. 
Score Description 
1 One attempt to stand, no ataxia. 
2 One to two attempts to stand, some ataxia.  
3 More than two attempts to stand, calm recovery. 
4 More than two attempts to stand, not calm recovery. 
5 Several attempts to stand, excitation. 
6 Very bad recovery. 
 
 
Statistical analysis 
Data were tested for normality of distribution (Kolgomorov-Smirnov test). The age and 
weight of the horses, duration of anaesthesia, total doses of additional ketamine and 
dobutamine, sedation, depth of anaesthesia and recovery scores and recovery times were 
compared between treatments using a Wilcoxon rank sum test.  
  The duration of anaesthesia did not exceed sixty minutes in some horses. 
Consequently, only the data until T60 were analyzed. Differences between treatments 
were analyzed, overall and at T60 using a mixed model analysis of variance with horse 
as random effect and treatment, time and their interaction as categorical fixed effects. 
For all analyses the significance level was set at 5%.  
 
Results 
Age (5 ± 5 and 7 ± 5 years old, for treatment M and D respectively) and weight 
(treatment M 440 ± 125 kg and treatment D 491 ± 110 kg) did not differ statistically 
between groups. Nine horses were placed in dorsal recumbency and one in lateral 
recumbency in treatment M. Five horses receiving treatment D were placed in dorsal 
recumbency and the remaining five in lateral recumbency. Details of the surgical 
interventions are represented in Table 2.  
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Table 2: Types of surgeries performed in horses receiving treatment M (n = 10) 
and treatment D (n = 10). Horses allocated in treatment M received a bolus of 
dexmedetomidine (3.5 µg/kg) plus morphine (0.15 mg/kg) IV followed by a CRI of 
morphine (0.1 mg/kg/hr). Horses allocated in treatment D received a bolus of 
dexmedetomidine (3.5 µg/kg) plus an equivalent volume of saline instead of 
morphine IV followed by a CRI of dexmedetomidine (1.75 µg/kg/hr). 
 
Type of surgery Treatment M  Treatment D 
Arthroscopy 4 6 
Cryptorchid 2 0 
Umbilical hernia 2 0 
Tenoscopy 1 0 
Sarcoid excision 1 0 
Street nail 0 2 
Castration 0 1 
Sarcoid cryosurgery 0 1 
 
 
Level of sedation and sedation scores 
Sedation scores were significantly lower (less sedation) in treatment M compared with 
treatment D (p = 0.042). Eight horses (six receiving treatment M and two treatment D) 
required an additional dose of dexmedetomidine to assure an acceptable level of 
sedation. 
 
Isoflurane concentrations (Figure 2), anaesthetic depth scores (Figure 3) and 
requirements of ketamine and dobutamine  
Although there was a significant influence of time on the FE´ISO (p = 0.009), no 
significant overall differences in FE´ISO were found between treatments. However, at 
T60, FE´ISO values were significantly (p = 0.012) lower in horses receiving treatment D 
compared to treatment M. Because the difference was gradually increasing over time, an 
additional statistical comparison was performed at T90 for the seven horses that were 
anaesthetized for ninety minutes or more (four treatment M versus three treatment D). 
At this time point, FE´ISO values tended to be lower in horses receiving treatment D, 
but the difference was not significant (p = 0.069). 
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 Horses receiving treatment D spent significantly more time (in percentage) at 
score 0 compared to horses of treatment M (97.4% versus 79.7% respectively) (p < 
0.001). Moreover, horses receiving treatment M spent significantly more time at score -
1 than those receiving treatment D (7% versus 1.7% respectively) (p = 0.043).  
Nine horses receiving treatment M required additional doses of ketamine, 
whereas only two in treatment D received ketamine. The mean amount of ketamine 
administered (in µg/kg/min) was significantly higher in treatment M (8.71 ± 5.72) 
(mean ± SD) versus treatment D (0.71 ± 1.58) (p = 0.001). 
Six horses receiving treatment M and three horses receiving treatment D 
required dobutamine. The mean dose of dobutamine administered in horses receiving 
treatment M and D was 0.04 ± 0.04 and 0.01 ± 0.02 µg/kg/min (mean±SD) respectively. 
This difference was not statistically significant (p = 0.116).  
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*
Significant differences between treatments at T60 (p < 0.05). Changes over time were present (p < 0.05). 
Statistical analysis was not performed after T60. 
 
Figure 2: End-tidal isoflurane concentration (FE´ISO) (in percentage) (mean ± SD) 
in twenty horses anaesthetized with a standard isoflurane protocol for elective 
surgery. Horses in treatment M (n = 10) received a CRI of morphine (0.1 
mg/kg/hr) and horses in treatment D (n = 10) received dexmedetomidine at 1.75 
µg/kg/hr. 
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*Significant differences between treatments (p < 0.05). 
 
Figure 3: Distribution of the anaesthetic time (in percentage) (mean values) spent 
at the different anaesthetic depth scores in twenty horses anaesthetized with a 
standard isoflurane protocol for elective surgery. Horses in treatment M (n = 10) 
received a CRI of morphine (0.1 mg/kg/hr) and horses in treatment D (n = 10) 
received dexmedetomidine at 1.75 µg/kg/hr. 
 
 
Cardiopulmonary system (Tables 3 & 4) 
Overall, MAP (p = 0.031) and DAP (p = 0.025) were significantly higher whereas CI 
and SVI were significantly lower (p = 0.009 and p = 0.028, respectively) in horses 
receiving treatment D. 
 Statistical analysis also demonstrated gradual decreases over time of SAP, MAP, 
DAP, SVR and CaO2 (p < 0.0001) in both treatments. 
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Table 3: Cardiovascular parameters (mean ± SD) in twenty anaesthetized horses 
undergoing elective surgery using two different protocols. 
Value Differences Unit Treatment T15 T30 T45 T60 
HR 
 
beats/min M 34 ± 5 34 ± 4 34 ± 5 34 ± 4 
   
D 34 ± 5 32 ± 3 33 ± 5 34 ± 5 
SAP # mmHg M 122 ± 12 103 ± 9 102 ± 13 105 ± 21 
   
D 126 ± 14 118 ± 12 115 ± 13 114 ± 16 
MAP *, # mmHg M 99 ± 9 80 ± 9 79 ± 13 82 ± 20 
   
D 104 ±15 97 ± 14 92 ± 15 93 ± 17 
DAP *, # mmHg M 85 ± 9 65 ± 9 66 ± 15 68 ± 20 
   
D 89 ± 14 82 ± 14 79 ± 15 79 ± 14 
SVR # dyne/sec/cm5 M 334 ± 79 241 ± 66 251 ± 79 275 ± 109 
   
D 394 ± 159 344 ± 105 313 ± 117 294 ± 102 
CI * mL/kg/min M 53.9 ± 9.8 60.7 ± 9.4 56.8 ± 11.0 54.7 ± 10.2 
   
D 45.0 ± 9.3 45.8 ± 9.3 48.0 ± 4.9 48.5 ± 6.1 
SVI * mL/kg M 1.6 ± 0.2 1.8 ± 0.3 1.7 ± 0.3 1.6 ± 0.3 
      D 1.4 ± 0.3 1.4 ± 0.2 1.5 ± 0.2 1.5 ± 0.3 
Heart rate (HR), systolic (SAP), mean (MAP) and diastolic arterial pressures (DAP), systemic vascular 
resistance (SVR), cardiac output indexed to weight (CI) and stroke volume indexed to weight (SVI) in twenty 
horses undergoing elective surgery. Horses receiving treatment M were infused a CRI of morphine (0.1 
mg/kg/hr) and horses receiving treatment D a CRI of dexmedetomidine (1.75 µg/kg/hr). 
*Overall significant differences between treatments (p < 0.05). # Changes over time (p < 0.05). 
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Table 4: Other cardiopulmonary and systemic parameters in twenty anaesthetized horses for elective surgery (mean±SD). 
 
Values Differences Unit Treatment T15 T30 T45 T60 
Body tª # °C M 37 ± 0.6 37 ± 0.4 36.9 ± 0.4 36.8 ± 0.4 
   D 37 ± 0.5 37 ± 0.5 36.9 ± 0.4 36.9 ± 0.4 
Arterial pH   M 7.42 ± 0.05 7.42 ± 0.05 7.42 ± 0.06 7.41 ± 0.06 
   D 7.46 ± 0.11 7.43 ± 0.03 7.43 ± 0.03 7.43 ± 0.04 
Arterial PCO2  mmHg M 45 ± 6 46 ± 7 47 ± 8 49 ± 9 
   D 44 ± 6 45 ± 4 45 ± 4 47 ± 4 
Arterial PCO2  kPa M 6 ± 0.9 6 ± 0.9 6.2 ± 1.1 6.5 ± 1.2 
   D 5.9 ± 0.8 6 ± 0.5 6 ± 0.5 6.2 ± 0.6 
Arterial PO2  mmHg M 201 ± 78 193 ± 69 185 ± 63 163 ± 53 
   D 180 ± 79 171 ± 79 177 ± 76 177 ± 67 
Arterial PO2  kPa M 26.8 ± 10.4 25.7 ± 9.2 24.6 ± 8.4 21.8 ± 7 
   D 24 ± 10.5 22.8 ± 10.5 23.9 ± 10.1 23.6 ± 8.9 
CaO2 # mL/L
 M 143 ± 15 136 ± 16 131 ± 14 128 ± 16 
   D 141 ± 15 137 ± 17 133 ± 15 129 ± 12 
DO2I  mL/kg/min
 M 7.7 ± 1.8 8.3 ± 1.6 7.5 ± 1.8 7.1 ± 1.9 
   D 6.3 ± 1.3 6.3 ± 1.7 6.4 ± 1 6.2 ± 1.1 
PCV # % M 29 ± 3 28 ± 3 27 ± 3 26 ± 3 
   D 29 ± 3 28 ± 3 27 ± 3 27 ± 2 
Body temperature (body tª), arterial blood gas results, arterial oxygen content (CaO2), oxygen delivery indexed to weight (DO2I), and packed cell volume (PCV) in twenty 
anaesthetized horses undergoing elective surgery. Horses receiving treatment M were infused a CRI of morphine (0.1 mg/kg/hr) and horses receiving treatment D a CRI of 
dexmedetomidine (1.75µg/kg/hr). # Changes over time (p < 0.05).
Chapter 5  
  
196 
 
Recovery scores (Table 5) and times 
Recovery scores were significantly better in horses receiving treatment D (p = 0.015), 
with less attempts to stand (p = 0.015). No differences in recovery times were found 
between treatments. 
  
Table 5: Recovery scores in twenty horses anaesthetized for elective surgery. 
Horses receiving treatment M (n = 10) were infused a CRI of morphine (0.1 
mg/kg/hr) and horses in group D (n = 10) a CRI of dexmedetomidine (1.75 
µg/kg/hr) during anaesthesia. 
Score Treatment M Treatment D 
1 1 6 
2 5 3 
3 0 1 
4 2 0 
5 2 0 
6 0 0 
*
Significant differences between treatments were found (p = 0.015). 
 
Post-anaesthetic period 
One horse of treatment M developed signs of colic and pulmonary oedema (foamy nasal 
discharge and tachypnoea, confirmed by ultrasound) three hours after the surgical 
procedure. No episodes of airway obstruction were noticed during recovery. Urine 
production during anaesthesia was approximately eight litres. The horse was 
successfully treated [furosemide (Dimazon, Intervet, Belgium) (0.6 mg/kg, IV, TID); 
hyoscine butylbromide (Buscopan, Boehringer Ingelheim, Belgium) (0.2 mg/kg, IV, 
SID) and ipratropium bromide (Atrovent, Boehringer Ingelheim, Belgium) (0.7 µg/kg, 
via aerosol, QID] and returned to normal condition two days after anaesthesia.  
Moreover, two horses showed box-walking behaviour after receiving treatment 
M for up to two hours. 
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Discussion 
In the present study, the cardiopulmonary function was maintained at clinically 
acceptable levels with both morphine and dexmedetominde CRIs. A reduction of the 
required maintenance dose of isoflurane was demonstrated after one hour of anaesthesia 
in horses receiving treatment D compared to treatment M. Ketamine was needed less 
often and recovery qualities were better in horses in treatment D, with less attempts to 
stand. One horse receiving treatment M developed post-operative colic and pulmonary 
oedema and two more horses showed box-walking. 
 A first limitation of the present study was the number of horses involved. Due to 
differences in recovery quality between the two groups and also because of the 
difficulty to maintain anaesthesia in some horses receiving morphine, it was decided to 
discontinue the trial after the first twenty horses. Although no overall differences were 
found in FE´ISO between the two protocols, significant differences could be 
demonstrated in different important parameters including the cardiopulmonary function, 
recovery quality, additional ketamine used and the isoflurane requirements at T60, 
suggesting that the number of horses, and the power of the study, were sufficient to 
make clear end conclusions. Another limitation was the duration of anaesthesia, which 
was only sixty minutes in several horses. Due to the effects of premedication and 
induction drugs and because the initial FE´ISO was the same in both groups, differences 
in cardiopulmonary function and parameters such as FE´ISO may only become clear 
after a longer anaesthetic period. Finally, the inclusion of a placebo group would have 
been of interest to compare the effects of both drugs on the cardiopulmonary and 
FE´ISO values, duration of recovery and recovery scores, but this was not the primary 
aim of the study since a comparison of the effects of both morphine (Clark et al. 2005) 
and dexmedetomidine (Marcilla et al. 2012) CRIs with those of saline had already been 
reported in clinically healthy horses. 
 Dexmedetomidine (3.5 µg/kg, IV) was used for sedation. This dose was based 
on the study by Bettschart-Wolfensberger et al. (2005) where 7 µg/kg of medetomidine 
was estimated to be equipotent to 3.5 µg/kg dexmedetomidine. However, in a clinical 
study using the same dose, additional dexmedetomidine doses were required to obtain a 
good sedative level before induction of anaesthesia in eleven out forty horses (27.5%) 
(Marcilla et al. 2012). In the results presented here, a similar pattern was observed, but a 
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larger proportion of the horses receiving dexmedetomidine plus morphine required an 
extra dose of dexmedetomidine compared to horses receiving dexmedetomidine alone 
(60% versus 20%). Although it is difficult to draw conclusions because of the limited 
number of horses in the present study, these results are nevertheless surprising and in 
disagreement with those of Clarke & Paton (1988), who reported that the use of an 
opiate together with an 2-agonist greatly reduced the response to stimulation and 
improved sedation in standing horses compared to the 2-agonist alone. It may be 
hypothesized that a stimulation of the central nervous system by morphine occurred, but 
signs of excitement were not observed in any of the horses receiving the morphine 
protocol. According to these findings and to those of our previous work (Marcilla et al. 
2012), an increase in the dosage of dexmedetomidine should be considered in order to 
obtain better level of sedation before induction of general anaesthesia. 
 One of the main reasons to start this clinical study was to have a comparison of 
the isoflurane requirements between both protocols. However, demonstrating a clear 
reduction in isoflurane requirements with 2-agonist CRIs in blinded clinical studies has 
shown to be difficult (Devisscher et al. 2010; Schauvliege et al. 2011; Marcilla et al. 
2012). The most logical explanation for this might be that 2-agonists have little effect 
on classical parameters that are used to assess anaesthetic depth, including ocular 
reflexes and position of the eye. A plane of anaesthesia that would normally appear light 
and possibly inadequate should be tolerated during these infusions. It therefore becomes 
less likely that a difference in isoflurane requirements will be demonstrated in blinded 
clinical studies. Consequently, an adaptation of the flow-chart from Enderle et al. 
(2008) was used in the present study, which has been described as ‘a relatively objective 
tool to titrate the concentration of isoflurane delivered to the patient for the anaesthetist, 
unaware of the combination being administered to the horse’.  
Although overall differences between treatments in FE´ISO were not present 
during the first sixty minutes of anaesthesia, the difference between both groups 
gradually became larger and was significant after sixty minutes. As explained earlier, 
this observation might be related to a gradual reduction of the effects of the 
premedication and induction drugs. After ninety minutes of anaesthesia, the difference 
was indeed even larger, but not significant, mainly due to the low number of horses 
exceeding one hour of anaesthesia. Nevertheless, the FE´ISO values of both treatments 
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were lower than the reported isoflurane MAC values for horses (Steffey et al. 1977, 
2003), supporting the idea that analgesia and/or additional central nervous system 
depression was provided by both CRIs. Dexmedetomidine infusions provide sedation 
and/or analgesia in other species (Franken et al. 2008; van Oostrom et al. 2011) and 
reduced the MAC of isoflurane in ponies under experimental conditions (Gozalo-
Marcilla et al., 2013a). In contrast, the demonstration of analgesia in horses receiving 
morphine is not so straightforward (Bennett & Steffey 2002; Clutton 2010), especially 
when performed in pain-free horses or ponies. Non-painful horses used in experimental 
studies where an electrical stimulation was applied and morphine was administered had 
a surprising increase of the MAC of the inhalant agent (Steffey et al. 2003), mainly due 
to central arousal overwhelming any analgesic action of the opioid (Bennett & Steffey, 
2002). In agreement with these reports, the results of the present study confirm that, at 
the doses used, the isoflurane requirements are lower during a dexmedetomidine CRI 
than during a morphine CRI in horses. 
 Horses of the dexmedetomidine group spent more time at anaesthetic score 0, 
which was considered as the ‘ideal’ depth of anaesthesia. When treatment M was 
infused, more adjustments according to the flow-chart had to be performed. Moreover, 
more ketamine was needed and an optimal level of anaesthesia was more difficult to 
achieve since nystagmus and/or movement occurred more often. In contrast, Clark et al. 
(2005) concluded that horses receiving morphine tended to receive fewer and lower 
doses of ketamine. In the study of Clark et al. (2005), halothane was administered at one 
MAC whereas in this study all the horses at T10 were anaesthetized with a 0.63 to 0.69 
MAC of isoflurane, according to the isoflurane MAC values of Steffey et al. (1977, 
2003).  
It may be argued that 0.9% isoflurane was not enough for an adequate 
anaesthetic maintenance when morphine was administered as a CRI, leading to a more 
unstable anaesthesia accompanied with intra-operative movements and additional doses 
of ketamine compared with treatment D. However, as soon as an FE´ISO of 0.9% was 
reached after induction of anaesthesia, the flow-chart was used, which allowed increases 
in FE´ISO when anaesthetic depth was deemed inadequate and which was primarily 
based on the usual signs to assess anaesthetic depth, such as palpebral reflexes, 
nystagmus, movement, etc. Our flow-chart was adapted from Enderle et al. (2008). 
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According to the latter, anaesthetic depth was never decreased in horses where a 
palpebral reflex was present. In our flow-chart, anaesthetic depth in such horses was 
decreased when arterial blood pressure decreased considerably compared to the 
reference value or when mean arterial pressure decreased below 70 mm Hg (despite the 
prescribed use of dobutamine in these cases). It may be argued that dexmedetomidine 
increases arterial blood pressure and therefore influenced the decision making in the 
flow-chart. However, higher blood pressures would rather lead to positive scores and 
thus prescribe an increase in anaesthetic depth, but in contrast, FE´ISO was lower during 
treatment D. 
 Cardiovascular function was maintained within physiological limits in all horses. 
Although arterial blood pressures were stable during both treatments, MAP and DAP 
were significantly lower in horses receiving morphine. Six horses from treatment M, but 
only three horses from treatment D required dobutamine to maintain MAP over 70 
mmHg. Cardiac index and SVI were lower in horses receiving only dexmedetomidine, 
although these differences were of limited relevance in clinically healthy horses. Since 
HR was comparable between groups, the decrease in CI was mainly due to a decrease in 
SVI. Although direct effects of 2-agonists on myocardial contractility are not common 
(Flacke et al. 1990), a decrease in SVI might be due to a combination of an increase in 
SVR, which leads to an increase in afterload together with decreased sympathetic tone 
(Bloor et al. 1992). Moreover, this increase in SVR, although not of statistical 
significance, led to the higher arterial blood pressures in horses receiving 
dexmedetomidine, mainly due to the activation of 2b-adrenoceptors on endothelial 
smooth muscle (Guimarães & Moura 2001). These increases in arterial blood pressures 
when administering dexmedetomidine are consistent with the findings of our previous 
clinical study (Marcilla et al. 2012). 
No significant differences were found in arterial blood gases. All the horses were 
mechanically ventilated from the beginning of the anaesthesia in order to more easily 
reach the different FE´ISO values required, which could have masked potential 
differences in pulmonary parameters. Previous reports showed that horses receiving 
dexmedetomidine had significantly lower PaO2 values compared to a control group, 
although DO2I and CaO2 were comparable in both groups (Marcilla et al. 2012). A 
morphine infusion had no effect on either PaCO2 or PaO2 (Clark et al. 2005), although 
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two out of six experimental ponies showed clear signs of hypoxaemia (Gozalo-Marcilla 
et al. 2013b).  
 Recovery remains a critical phase in equine anaesthesia. Better recoveries were 
seen in horses receiving treatment D, with less attempts to stand compared with those 
receiving treatment M, without significant differences in recovery times. Compared to 
saline, recovery qualities following a dexmedetomidine CRI were better (Marcilla et al. 
2012). After a morphine infusion, recoveries were characterized by fewer attempts to 
attain sternal recumbency and standing, with a shorter time from the first recovery 
movement to the time of standing (Clark et al. 2008). The authors of that study 
attributed the presence of ‘quieter’ recoveries to the analgesic effects of morphine. 
Again, the presence of a placebo group would have allowed us to find differences in 
recovery quality between dexmedetomidine and morphine compared to saline. As 
previously stated, it could be argued that horses in treatment M received an insufficient 
dose of isoflurane to maintain an adequate surgical plane of anaesthesia, therefore 
requiring higher amounts of ketamine, which could have led to worse recoveries 
(Bettschart-Wolfensberger et al. 1996; Bettschart-Wolfensberger & Larenza 2007). The 
administration of a small dose of dexmedetomidine in order to prevent complications 
during the recovery period (Santos et al. 2003) might explain the absence of differences 
in recovery times between groups.  
 No post-operative complications were observed in any of the horses receiving 
treatment D, as previously reported (Marcilla et al. 2012). One horse showed signs of 
colic and pulmonary oedema after treatment M. Although it is impossible to draw 
appropriate conclusions from one single case, opioids have previously been shown to 
produce constipation in the gastrointestinal tract, causing a prolonged depression of the 
intestinal propulsion (Roger et al. 1985). Nevertheless, no increase in the incidence of 
colic was reported after IV administration of boluses (Mircica et al. 2003) or infusions 
of morphine (Clark et al. 2005, 2008). Alpha2-agonists can also decrease intestinal 
motility, predisposing to ileus (Valverde 2010), but none of the horses of the present 
study, all receiving dexmedetomidine, or the twenty horses of our previous clinical 
study (Marcilla et al. 2012), showed any sign of intestinal discomfort. Interestingly, the 
horse showing signs of colic also developed clinical signs of pulmonary oedema, 
confirmed via ultrasound, returning to normal status in two days. Up to now, two cases 
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with postoperative pulmonary oedema in horses have been mentioned in literature 
where morphine was suggested to be a potential cause (Kaartinen et al. 2010). Although 
the reasons remain unclear, the authors concluded that fluid overload during anaesthesia 
could have been worsened by morphine-induced reduction in urine production and by 
potential morphine-induced changes in pulmonary permeability. In that study, the two 
horses produced only three and two litres of urine after total anaesthesia times of 5.3 
and four hours respectively, whereas the horse affected here produced eight litres after 
three hours of anaesthesia, suggesting that other factors could have been involved in the 
development of pulmonary oedema (Senior 2005). Furthermore, two other horses 
receiving treatment M showed clear signs of box walking after the recovery for up to 
two hours. This excitatory behaviour was also present in two of six experimental ponies 
receiving morphine infusions (Gozalo-Marcilla et al. 2013b) and after doses as high as 2 
mg/kg in experimental studies by Steffey et al. (2003), but not at lower doses (0.25 
mg/kg). No box-walking behaviour was reported after morphine administration after 
single boluses (Mircica et al. 2003; Love et al. 2006) or as a bolus followed by a CRI 
(Clark et al. 2005, 2008).  
 In conclusion, at the doses reported here and at the starting isoflurane value of 
0.9%, a dexmedetomidine CRI appeared to maintain a more stable light surgical depth 
of anaesthesia, with fewer and lower doses of additional ketamine and lower isoflurane 
requirements, especially at sixty minutes after induction of anaesthesia, compared with 
a morphine CRI. Furthermore, recovery qualities were significantly better with a lower 
number of attempts to stand in horses receiving treatment D. Post-operative 
complications such as pulmonary oedema, colic and box-walking were occasionally 
observed in morphine horses. 
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As mentioned in the introduction of this PhD, general anaesthesia in equines carries a 
higher risk of mortality compared with other species, volatile anaesthetic agents making 
the most significant contribution (Johnston et al. 2002). Consequently, the concept of 
equine balanced anaesthesia has been introduced. In summary, balanced anaesthesia in 
horses includes the combination of volatile anaesthetics with intravenous (IV) 
anaesthetics and/or locoregional anaesthetic techniques, in order to maintain a good 
intraoperative cardiopulmonary function followed by calm, smooth and coordinated 
recovery (Bettschart-Wolfensberger & Larenza 2007). The use of different drugs as IV 
constant rate infusions (CRIs) in order to reduce the amount of inhalant anaesthetic 
agent, and to provide additional sedation and analgesia has been reviewed in depth in 
the Section 1 of the general introduction. Although encouraging results have already 
been obtained, most commonly used drugs are accompanied with side effects. Lidocaine 
may produce ataxia in the recovery period and toxicosis may also occur. Excitatory side 
effects that can worsen the quality of the recoveries after ketamine infusions have been 
reported. Finally, the use of opioids in horses remains controversial and may be limited, 
mainly due to their inconsistent minimum alveolar concentration (MAC) reduction, 
central nervous system stimulation and reduced gastrointestinal motility. The search for 
the ideal drug combination for balanced anaesthesia in horses therefore continues. 
 Alpha2-agonists are potent sedatives and analgesics and their use as CRIs during 
equine general anaesthesia may reduce the MAC of inhalant agents and improve the 
recovery qualities. Although these agonists are not free of cardiovascular side effects, 
which can be of major importance in compromised patients, it seems possible that the 
impact on cardiovascular function would be limited due to their associated MAC 
reducing effects. Intraoperative infusions of different 2-agonists have become popular 
and, although not licensed for use in food producing horses, medetomidine has been 
widely studied in anaesthetized horses. Medetomidine is an equal mixture of two optical 
enantiomers, with dexmetomidine being entirely responsible for the sedative, analgesic 
and dose dependent anaesthetic sparing effects (Segal et al. 1988; Ansah et al. 1998; 
Kuusela et al. 2000). As reviewed in Section 2 of the general introduction, 
dexmedetomidine has been used in different species with promising results. 
Unfortunately, only one study described the cardiopulmonary effects and 
pharmacokinetics of dexmedetomidine after IV administration in experimental ponies 
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(Bettschart-Wolfensberger et al. 2005). In that study, it was stated that preliminary trials 
showed that 7 µg/kg medetomidine was equisedative to 3.5 µg/kg dexmedetomidine. 
Using this dose, dexmedetomidine induced similar cardiopulmonary changes compared 
to other 2-agonists, but of very short duration. The authors concluded that it is a 
rapidly redistributed and short-acting sedative drug with a rapid initial decline of drug 
concentration. Consequently, the inclusion of dexmedetomidine as part of balanced 
anaesthetic regimes was suggested by these investigators. 
Based on the above mentioned equipotencies between medetomidine and 
dexmedetomidine, we examined the cardiopulmonary effects of two different CRI rates 
of dexmedetomidine in isoflurane anaesthetized healthy ponies in our first 
experimental study. After sedation with dexmedetomidine (3.5 µg/kg, IV) and 
induction, the cardiopulmonary effects of two different CRI rates (1 and 1.75 µg/kg/hr) 
were evaluated in each pony to test their safety during isoflurane anaesthesia. Both rates 
produced statistically significant cardiovascular effects, typical for 2-agonists (i.e. 
decreases in heart rate, cardiac index and oxygen delivery index). The observed side 
effects were of limited clinical relevance despite maintenance of anaesthesia with an 
end-tidal isoflurane concentration higher than one MAC. 
However, there was a tendency for a lower arterial partial pressure of oxygen 
(PaO2). This observation may be due to either the occurrence of hypoventilation, 
diffusion impairment or ventilation/perfusion (     ) mismatch and shunting or a 
combination of these factors. In awake horses, 2-agonists were demonstrated to 
decrease respiratory rate (Daunt & Steffey 2002), but with an increase in tidal volume 
(Lavoie et al. 1992), keeping the alveolar ventilation and arterial blood gas values 
relatively constant (Lemke 2007). Hypoventilation may still occur in anaesthetized 
patients, mainly due to an increase in anaesthetic depth induced by the combination of 
an 2-agonist with the volatile anaesthetic agent (Steffey et al. 2000). However, since 
all the ponies were mechanically ventilated, hypoventilation can be excluded as a major 
cause of hypoxaemia. Diffusion impairment is very unlikely since it rarely occurs in 
healthy animals. Consequently, the hypoxaemia noticed in these experimental ponies 
was most likely due to       mismatch and shunting. It may be hypothesized that 
dexmedetomidine influenced pulmonary perfusion, but to the authors’ knowledge, 
deterioration of       matching and/or shunting have not been reported after 
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administration of 2-agonists. It is however well known that pulmonary function and 
oxygenation are often impaired in anaesthetized horses (Hall et al. 1968; Nyman & 
Hedenstierna 1989). This might be aggravated by the conformation of the ponies 
(Moens 1989), as they were ‘round bellied’ and relatively fat and heavy. Overall, no 
significant differences in the cardiopulmonary function were present between both CRI 
dexmedetomidine rates. Moreover, recoveries from general anaesthesia were good, with 
minimal ataxia. These findings might have been masked by a ‘learning effect’ as the 
ponies had been previously enrolled in other experimental studies. 
Unfortunately, the study design did have some important limitations. Potential 
carry-over effects of the dexmedetomidine CRI infused during the first period of the 
study may have influenced the cardiopulmonary parameters of the second period, 
despite the washout period of thirty minutes between both periods. Although not ideal, 
the study design and the relatively short washout period were included to limit the 
number of anaesthetic procedures per pony but also to reduce the total anaesthetic time 
in each individual pony. Ideally, each pony would have been anaesthetized twice 
receiving randomly each dexmedetomidine CRI rate. As described by Bettschart-
Wolfensberger et al. (2005), the cardiopulmonary effects of dexmedetomidine are short 
lasting, suggesting that a ‘washout period’ of thirty minutes after the end of the first 
CRI would have been justified. Furthermore, this assumption was confirmed by the 
comparable baseline values recorded at the beginning of both periods, suggesting that 
carry-over effects did not or minimally influenced our results. 
Moreover, it can be argued that the simultaneous administration of other 
anaesthetic drugs might also have influenced our results and it would have been better 
to induce anaesthesia with only a volatile agent, as described for the determination of 
the MAC in most species. However, ketamine and midazolam (or other 
benzodiazepines) are routinely used for induction of anaesthesia in horses and their 
cardiovascular influences are always present under clinical situations. Moreover, 
although the sympathetic stimulation characteristics of ketamine can have an effect on 
all the values but mainly the baseline values recorded after thirty minutes of anaesthesia, 
these stimulating effects may have been counteracted by the dexmedetomidine’s 
sedative effects or even the administration of midazolam. 
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The results of our first study suggested that both protocols produced 
cardiopulmonary effects typical of 2-agonists, although limited and within an 
acceptable clinical range. In conclusion, both infusion rates are suggested to be useful in 
healthy, anaesthetized clinical horses. 
The second study was a blinded clinical trial in healthy equine patients 
undergoing elective surgeries in which we showed that a dexmedetomidine CRI can be 
safely used as an adjunct during isoflurane anaesthesia. The results of the first study 
were indicative that both rates produced similar cardiopulmonary effects, mainly due to 
the reported ceiling effect of the 2-agonists (Pypendop & Verstegen 2001). Indeed, 2-
agonists produce a dose related sedation and analgesia (Ansah et al. 1998; Slingsby & 
Taylor 1998), but beyond a certain dose only minimal changes on cardiopulmonary 
function can be expected. It was hypothesized that 1.75 µg/kg/hr dexmedetomidine 
would possibly provide more sedation and analgesia. Reports in rats (Bol et al. 1999), 
cats (Slingsby & Taylor 2008) and dogs (van Oostrom 2011) showed that the sedative 
effects of dexmedetomidine were reached at lower doses than those required for an 
adequate level of analgesia. Moreover, it has been stated that analgesia cannot be 
produced without sedation and sedation is not necessarily linked to comparative degrees 
of analgesia (Franken et al. 2008). In contrast, it may be argued that comparable degrees 
of sedation and analgesia were obtained with both rates of dexmedetomidine in our 
experimental first set up. Indeed, it remains unclear whether a ceiling effect for the 
sedation and analgesia did occur in our experimental ponies. Although this ceiling effect 
has been reported in dogs (van Oostrom 2011), and suggested in cats (Ansah et al. 
2000), up to now insufficient data are available to support this effect in horses and 
further studies are certainly justified. We preferred the higher dose as its equipotent 
dose of medetomidine was successfully used in horses. Medetomidine (7 µg/kg/hr) was 
suitable for prolonged use, providing a constant level of sedation (Bettschart-
Wolfensberger et al. 1999), together with clear MAC-sparing effects (Bettschart-
Wolfensberger et al. 2001; Neges et al. 2003). Additionally, a subjectively easier 
maintenance of a stable anaesthetic depth was reported when compared to horses 
receiving isoflurane alone (Neges et al. 2003). 
The results of our second study demonstrated that dexmedetomidine at a dose of 
1.75 µg/kg/hr can be safely used in isoflurane anaesthetized healthy equine patients. No 
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clinically relevant effects on the cardiovascular system were present compared to a 
control group. Although PaO2 was significantly lower in horses receiving 
dexmedetomidine, the mean values were over 100 mmHg and the oxygen delivery 
index did not differ between groups.  
An important finding concerning the clinical application of dexmedetomidine 
was the significantly improved recovery qualities. This observation might have been 
related to the significantly longer times these patients remained in the sternal recumbent 
position and the first attempt to stand, resulting in less residual effects of the 
anaesthetics on the motor function and coordination. This was not seen after romifidine 
(Devisscher et al. 2010) or detomidine CRIs (Schauvliege et al. 2011), most likely due 
to the extra inclusion of a small amount of the 2-agonist at the end of anaesthesia, 
masking potential differences (Schauvliege et al. 2011). However, better recoveries 
were observed in our clinical study, even when a small dose of dexmedetomidine was 
added, just prior to recovery, in both the saline and dexmedetomidine groups. 
Furthermore, the number of horses may have had an influence on the obtained results as 
well, since the clinical dexmedetomidine study had more statistical power compared to 
the other two studies (Devisscher et al. 2010, Schauvliege et al. 2011). To the authors´ 
knowledge, none of the other studies did compare the recovery qualities after a CRI 
medetomidine versus saline in anaesthetized horses. Horses receiving medetomidine did 
show better recoveries than those receiving lidocaine (Ringer et al. 2007), while 
medetomidine added to a lidocaine CRI improved the recovery qualities (Valverde et al. 
2010). 
The clinical protocol of the second study failed to show a reduction of 
isoflurane, which was in agreement with previous blinded studies using different 2-
agonist CRIs (Devisscher et al. 2010; Schauvliege et al. 2011). Horses receiving a 
medetomidine CRI were reported to be much ‘lighter’ compared to sole inhalational 
anaesthesia (Kalchofner et al. 2006) while equine patients were clinically assessed as 
‘light’ by the anaesthetist did not respond to noxious stimuli when medetomidine was 
being infused (Ringer et al. 2007). All these properties render it relatively difficult to 
find clear differences in the volatile requirements in a blinded study.  
Due to the limitations of blinded clinical studies, an experimental MAC study 
was performed in experimental ponies as third study in order to possibly detect MAC 
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reductions induced by a dexmedetomidine CRI. The six ponies used in the first trial 
were anaesthetized twice with sevoflurane and recieved randomly a saline placebo or a 
3.5 µg/kg dexmedetomidine bolus followed by a 1.75 µg/kg/hr CRI. The MAC of 
sevoflurane in our experimental ponies was 2.42 ± 0.55% which was similar to values 
reported in horses (Aida et al. 1999; Rezende et al. 2011). In this trial, we demonstrated 
that the inclusion of a dexmedetomidine CRI did significantly reduce the MAC of 
sevoflurane to 1.07 ± 0.21% (mean MAC reduction 53 ± 15%). 
In order to avoid possible interactions with other drugs, most of the equine MAC 
studies use a face mask delivering the volatile agent to induce anaesthesia (Aida et al. 
1994; Tendillo et al. 1997; Steffey et al. 2000). In order to avoid pollution of the 
working area and to minimize adverse reactions of the animals during inhalation of the 
gas mixture, the ponies were nasotracheally intubated as described in foals (Webb 
1984). To our knowledge, this is the first time that this method has been reported for 
MAC studies in adult ponies. However, one relatively nervous pony did panic when she 
became ataxic. Sedation with xylazine was needed to allow a smooth induction in this 
pony. It may be argued that this pony should have been excluded from the study since 
xylazine might have influenced MAC determinations. However, in that individual case, 
the first MAC determination was achieved after 120 and 300 minutes when receiving a 
saline or a dexmedetomidine CRI, respectively. Even though xylazine is accepted as a 
short acting 2-agonist, the sedative dose might influence the volatile anaesthetic 
requirements for at least three hours after injection (Steffey et al. 2000, Bennett et al. 
2004). Nevertheless, exclusion of that pony did not significantly alter the overall MAC 
values, which were 2.43 ± 0.62% and 1.08 ± 0.24% during the placebo and 
dexmedetomidine CRIs respectively (mean MAC reduction 53 ± 17%). 
Another remark that may arise is the non-traditional use of the term MAC. We 
stated that ‘the response to the electrical stimuli was considered positive when a gross 
purposeful movement of head, limbs or tail occurred and/or swallowing or generalized 
muscle tremors were observed following a constant-current (CC) noxious stimulus. 
Gross purposeful movement without CC stimulation was also considered a positive 
response’. Traditionally, MAC is defined as the alveolar concentration at which 50% of 
the patients do not respond with purposeful movement to a supramaximal noxious 
stimulus (Merkel & Eger 1963). According to this, non-purposeful movement is 
General discussion 
  
215 
 
permissible during MAC determinations. In our study, we used a different definition 
because non purposeful movement would not be allowed under clinical circumstances 
but also because differentiation between purposeful and non-purposeful movements 
remains confusing, making this process somewhat subjective (Seddighi et al. 2011). In 
fact, the definition applied in the present PhD fits better with the definition of the more 
recently proposed term ‘MAC-no movement’ (MACNM) which has been formulated as 
the lowest alveolar concentration of an anaesthetic that abolishes all movement 
(Seddighi et al. 2011, 2012). Indeed, the determination of MACNM instead of MAC was 
suggested to reduce the subjectivity of classic MAC studies and is more clinically 
relevant. In retrospect and taking the recent literature into account, the use of the term 
MACNM in both of our MAC studies would have been more appropriate. 
It is well known that the use of morphine remains controversial in equine 
anaesthesia (Bennett & Steffey 2002; Clutton 2010), and administration of IV boluses 
produced inconsistent changes in the MAC requirements of isoflurane (Steffey et al. 
2003). Although there was a tendency in clinical anaesthetized equine patients receiving 
a morphine CRI to require fewer and lower doses of additional anaesthetic drugs (Clark 
et al. 2005), the effects of a morphine CRI on the MACNM of volatile agents had not 
been reported. Due to the positive findings of our previous study and because the 
protocol was deemed suitable for use in further studies, we aimed to determine the 
effects of a morphine CRI on the MACNM of sevoflurane. Moreover, we hypothesized 
that the co-administration of a dexmedetomidine CRI may influence the MACNM 
values, probably reducing them. 
In the fourth study, five experimental ponies were anaesthetized with 
sevoflurane, as described in the third study, and they received randomly the morphine 
protocol described by Clark et al. (2005) (IV bolus 0.15 mg/kg followed by CRI at 0.1 
mg/kg/hr), alone or combined with our dexmedetomidine protocol. When receiving a 
CRI of morphine, the MACNM sevoflurane value was determined to be 2.79 ± 0.73%, 
whereas co-infusion of dexmedetomidine significantly reduced that value to 0.89 ± 
0.22% (mean MACNM reduction 67 ± 11%). The pony which needed sedation before 
induction of anaesthesia in the third study was excluded due to potential influences in 
the MACNM determination. 
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The most important limitation of the fourth study was the absence of a control, 
placebo group. Ideally, one larger MACNM study should have been performed, with 
each pony receiving the four treatments in a randomized order. Although both 
experiments were performed in the same ponies and within a period of five months, a 
direct statistical comparison between all four treatments was not made since the order of 
the treatments was not randomized, and the main anaesthetist was not fully blinded. In 
the author’s opinion, it was however deemed unethical to repeat the MACNM 
determinations for the dexmedetomidine and saline treatments in these ponies. Although 
the MACNM values obtained in the two studies are of value for further research, the only 
conclusion that can be made from our independent studies is that a CRI of 
dexmedetomidine significantly reduces sevoflurane´s MACNM values in ponies when 
added to saline or morphine infusions. 
A study including the four treatments might also have determined if a morphine 
infusion increases MACNM values of sevoflurane and/or if the addition of both 
dexmedetomidine and morphine further reduces the MACNM values compared to 
dexmedetomidine alone. However, although a direct statistical comparison between the 
four groups was not possible, it still remains of scientific interest to note that the MAC 
tended to increase when a CRI of morphine was infused, increasing the MAC of 
sevoflurane from 2.42 ± 0.55% to 2.79 ± 0.73%. At the same time, combination of both 
morphine and dexmedetomidine infusions further reduced the sevoflurane´s MAC 
compared to dexmedetomidine alone from 1.07 ± 0.21% to 0.89 ± 0.22%. Under 
clinical circumstances, co-administration of both CRIs would be of interest in order to 
reduce the MAC and potential side effects of the volatile anaesthetic, as 
dexmedetomidine seemed to alter the effect of morphine on MAC requirements. 
Interesting observations were made when morphine was administered as CRI 
compared to saline or dexmedetomidine alone. It is worth mentioning that the responses 
to the stimuli were different compared with the findings of the third study. Maintenance 
of anaesthesia was judged to be more difficult in two out of five ponies when receiving 
the morphine treatment, with the occurrence of generalized, almost uncontrollable 
muscle tremors, and ‘fighting’ against the ventilator. These differences were explained 
in the discussion by a combined analgesic, excitatory and locomotor stimulant effects 
attributed to the use of morphine in horses (Kamerling et al. 1989). Moreover, two 
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ponies showed after the morphine CRI a typical ‘box-walking’ behaviour for up to two 
hours after the end of anaesthesia, one of them with clear over-reactions to external 
stimuli. In both circumstances, co-infusion of dexmedetomidine seemed to avoid such 
reactions, most likely due to its sedative properties. Moreover, prolonged infusions of 
morphine with dexmedetomidine shortened the recovery times, which can possibly be 
attributed to the effects of morphine accumulation after prolonged CRIs. 
Finally, it has to be stated that the data obtained from the second MAC study 
should be interpreted carefully as stimulation of the central nervous system may result 
in MAC increases (Miller et al. 1968; Johnston et al. 1972). In the case of morphine, 
increases in MACNM can be induced by the central arousal overwhelming analgesic 
actions, which do not confirm the absence of analgesic effects (Bennett & Steffey 
2002). Moreover, electrical stimulation is probably qualitatively different from classic 
surgical nociception (Clutton et al. 2010). Although the demonstration of analgesia in 
horses receiving morphine is not so straightforward (Bennett & Steffey 2002; Clutton, 
2010), we hypothesized that in presence of surgical pain, morphine would exert more 
analgesic effects rather than producing central arousal, even producing MAC 
reductions. This assumption was based on previous encouraging reports with morphine 
infusions under clinical circumstances in horses (Mircica 2003; Clark et al. 2005, 2008; 
Love et al. 2006) and was the original idea to perform the following study. 
In order to compare both dexmedetomidine and morphine CRIs under clinical 
circumstances, we performed our fifth clinical trial to evaluate the influence on 
cardiopulmonary function, intraoperative anaesthetic stability and recovery quality in 
equine patients. With a dexmedetomidine CRI it was possible to maintain a more stable 
light surgical depth of anaesthesia, requiring less isoflurane or additional drugs. 
Furthermore, recovery qualities were significantly better, with a lower number of 
attempts to stand in horses receiving dexmedetomidine. Post-operative complications 
such as pulmonary oedema, colic and box-walking were only observed in horses 
receiving a morphine CRI. 
In this blinded, clinical trial not only a comparison between treatments with 
regard to the cardiopulmonary function and the recovery qualities was made. Moreover, 
the authors aimed to determine which protocol required less isoflurane and produced a 
more stable plane of anaesthesia. Although the MACNM of sevoflurane was higher in 
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our ponies when receiving a morphine CRI compared to dexmedetomidine, clinical 
studies showed that horses receiving the same protocol tended to receive fewer and 
lower doses of additional anaesthetics compared to a control group (Clark et al. 2005). 
As stated earlier, it remains difficult to detect potential MAC reductions when infusions 
of 2-agonists are used in blinded clinical studies. 
In order to overcome these drawbacks, we designed a flow-chart adapted from 
Enderle et al. (2008) described as ‘a relatively objective tool to titrate the concentration 
of isoflurane delivered to the patient for the anaesthetist, unaware of the combination 
being administered to the horse’. The application of this flow-chart was successfully 
performed by the main blinded anaesthetist. However, anaesthesia was easier to 
maintain at an ‘ideal’ plane, with less intraoperative movements in horses receiving a 
dexmedetomidine infusion. Moreover, less isoflurane and extra anaesthetic drugs were 
required. These results seem to support strongly the use of a dexmedetomidine versus a 
morphine infusion. Nevertheless, the results of this clinical study should be interpreted 
carefully. It may be discussed that the study design was not ideal, mainly because of the 
commencing maintenance of anaesthesia at an expiratory fraction of isoflurane (FE´ISO) 
of 0.9%. This value may have been sufficient when dexmedetomidine but not when 
morphine was infused, resulting in early arousal and a subsequently unstable plane of 
anaesthesia in the morphine group. Moreover, it cannot be excluded that central arousal 
effects might have been present on top of morphine´s analgesic properties, leading to 
intraoperative movements. Nevertheless, the flow-chart, did allow to increase the 
FE´ISO when the classical parameters used to evaluate anaesthetic depth in horses 
indicated a superficial plane of anaesthesia. In the authors’ opinion, this protocol 
therefore mimicked a clinical situation. In any case, when applying this relatively 
objective flow-chart we concluded that, when a dexmedetomidine CRI was 
administered, lower amounts of volatile agents are required to maintain a more stable 
and reliable plane of anaesthesia compared to a morphine CRI under clinical 
circumstances. 
Only twenty equine patients were included in this last clinical trial. Although the 
inclusion of forty horses was initially planned, the authors decided to stop the study 
after twenty animals as the overall maintenance of anaesthesia in horses receiving 
morphine was difficult, creating problems to the surgical team. Moreover, recovery 
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qualities were far from ideal with one horse developing colic and even pulmonary 
oedema after morphine infusion. However, it remains difficult to determine whether 
morphine was responsible for these symptoms. Although no overall differences were 
found in FE´ISO between the two protocols, significant differences could be 
demonstrated in important parameters including cardiopulmonary function, recovery 
quality, additional ketamine and the isoflurane requirements at T60, suggesting that the 
number of horses was sufficient to make clear end conclusions. Co-administration of 
both dexmedetomidine and morphine infusions may have led to better outcomes, 
providing the analgesic effects of morphine while avoiding the morphine side effects by 
the sedative properties of dexmedetomidine. 
An interesting finding of several of these studies is that the PaO2 values often 
tended to be lower when administering a dexmedetomidine CRI. Up to date, there is not 
a clear explanation for this. Differences in minute ventilation seem less likely, 
especially since mechanical ventilation was used in most horses and PaCO2 values were 
comparable between groups. It may be hypothesized that dexmedetomidine influences 
the hypoxic pulmonary vasoconstriction (HPV) reflex, a highly efficient mechanism in 
the pony that distributes blood flow from hypoxic regions in the lung to ventilated areas 
(Elliott et al. 1991). To the author´s knowledge, no studies are available on the effects of 
2-agonists on the HPV reflex. However, it seems possible that administration of 
dexmedetomidine elevated pulmonary arterial pressure, disturbing the HPV mechanism. 
This would contribute to impared arterial oxygenation, which was reported in horses 
after detomidine sedation (Nyman et al. 2009). In the latter study, significant reductions 
in blood flow and an increase in       mismatch were the major contributors to the 
alveolar-arterial oxygen tension difference. In contrast, studies in humans showed that a 
bolus of dexmedetomidine followed by a CRI did not adversely affect oxygenation 
during one-lung ventilation (Kernan et al. 2011). In fact, the authors concluded that its 
use as part of a balanced anaesthetic technique may improve oxygenation by allowing 
the use of lower concentrations of the inhaled agent, thereby limiting its effects on 
oxygenation (Marshall et al. 1984; Eisenkraft 1990). In our clinical study (Chapter 2), 
the FE´ISO was comparable between treatments (± 1.1 %). After determining that a 
dexmedetomidine CRI reduces the MACNM of inhalants (Chapter 3) and that general 
anaesthesia can be well maintained at FE´ISO values close to 0.9% (Chapter 5), it seems 
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of interest to examine the hypothesis of Kernan et al. (2011), comparing oxygenation in 
horses anaesthetized with different concentrations of inhaled agents while using a 
dexmedetomidine CRI. Furthermore, research investigating the effects of 
dexmedetomidine on the HPV reflex may be of value.  
Another timely point is the reliability of the method used to measure cardiac 
output (   ). In Chapters 1, 2 and 5     was measured by means of the lithium dilution 
method (LiDCO), a minimally invasive and accurate technique (Kurita et al. 1997; 
Linton et al. 1997) suitable for use in horses (Linton et al. 2000). However, a recent 
study showed that different drugs may influence the accuracy of the LiDCO sensor in 
vitro (Ambrisko et al. 2013). Therefore, although the LiDCO dilution technique was 
considered a valid method at the time of designing/performing these studies, the results 
should be interpreted carefully as potential interactions may occur. From the drugs used 
in our studies, ketamine may have interacted with the LiDCO sensor in vivo, 
dexmedetomidine seemed unlikely to cause bias and midazolam probably did have 
minimal or no interaction. However, although the results of Ambrisko et al. (2013) may 
be of clinical relevance, further research is required to confirm this hypothesis in vivo. 
 Based on the general results of this PhD thesis, it can be concluded that a 
dexmedetomidine CRI (1.75 µg/kg/hr) can be safely used in healthy anaesthetized 
horses, with minimal cardiopulmonary effects. Moreover, it improves the recovery 
quality and reduces the MACNM of inhalant agents. Dexmedetomidine can also be 
combined with a morphine CRI, reducing the MACNM of the volatile agent and 
theoretically preventing unwanted phenomena linked to the infusion of morphine. 
Finally, a dexmedetomidine CRI produced, under clinical circumstances using the 
design of our last study, a more stable anaesthetic depth, with less isoflurane 
requirements and better recoveries compared to a morphine CRI. Post-operative 
complications were more frequently seen in horses receiving morphine. Based on these 
results, the use of an infusion of dexmedetomidine seems to be promising from a 
clinical point of view, especially during surgical procedures requiring the use of a short-
acting sedative, with MAC-sparing effects and better recoveries (i.e. long orthopaedic 
procedures such as limb fracture repair). Limiting factors include the absence of a 
license for this drug in horses, which reduces its use to ‘non food producing animals’ 
and the higher economic costs compared with other registered 2-agonists. 
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Apart from these limitations, the results presented here are encouraging for 
further research. Dexmedetomidine and morphine CRIs may be combined in clinically 
healthy equine patients, providing analgesia by two different receptors, while the 
sedative effects of dexmedetomidine may reduce the potential side effects of morphine. 
Another direction for further investigation is the use of our protocol in compromised 
patients such as colic horses. As previously discussed, 2-agonists produce an important 
impact on cardiovascular function. However, combination with drugs such as 
phosphodiesterases III inhibitors may be beneficial, as they reduce the systemic vascular 
resistance and increase the cardiac output. The use of milrinone (Muir 1995) and 
enoximone (Schauvliege et al. 2007, 2008, 2009) has been already studied in horses and 
the simultaneous infusion with dexmedetomidine seems to be attractive and may be of 
benefit in colic horses. 
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It is well known that anaesthesia in horses carries a higher risk of mortality compared to 
other species. The different mortality rates reported in literature have been included in 
the general introduction. Overall, maintenance of general anaesthesia with volatile 
agents anaesthetics carries a higher risk of death compared with total intravenous 
anaesthetic protocols, mainly due to the cardiovascular depressant effects of the volatile 
agents. The different principles to treat cardiovascular depression during general 
anaesthesia in horses were also highlighted, introducing the concept of ‘balanced 
anaesthesia’. 
 The Section 1 of the general introduction includes a review of the different 
intravenous (IV) drugs that are commonly used as constant rate infusions (CRIs) in 
combination with volatile agents in anaesthetized horses. Lidocaine, ketamine and 
opioids can be administered in order to provide analgesia or to reduce the minimum 
alveolar concentration (MAC) of volatile anaesthetics, although their use is not free of 
side effects. Alpha2-agonists are potent sedatives and analgesics reducing the MAC of 
inhalant anaesthetics; the main concern is their impact on cardiovascular function. The 
pharmacokinetics of the most selective 2-agonists, medetomidine and 
dexmedetomidine, seem to favour their use in CRIs, mainly because of their very short 
lasting induced cardiopulmonary changes. 
An in depth review of the characteristics and use of dexmedetomidine was 
included in the Section 2 of the general introduction. This drug has been used not only 
in human but also in different veterinary species during inhalational anaesthesia, with 
promising results. Unfortunately, only one study investigated the use of 
dexmedetomidine in ponies, suggesting its use as a CRI for equine anaesthesia. 
The objectives of the PhD were defined in the scientific aims. In summary, we 
aimed to determine a safe dexmedetomidine dose(s) which was administered as sedative 
before induction of anaesthesia and as a CRI in combination with volatile agents during 
anaesthesia. A second aim was to determine the influence of dexmedetomidine on the 
MAC of sevoflurane when given alone or in combination with a morphine CRI. Finally, 
the third goal was to compare our proposed dexmedetomidine protocol with a morphine 
CRI under clinical circumstances in equine patients. 
The cardiopulmonary effects of two different CRIs of dexmedetomidine (1 and 
1.75 µg/kg/hr) were evaluated in six ponies in a prospective, randomized, experimental 
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study and incorporated in Chapter 1. After sedation with dexmedetomidine (3.5 µg/kg, 
IV) and induction with IV ketamine and midazolam (T0), anaesthesia was maintained 
with isoflurane [expiratory fraction of isoflurane (FE´ISO) 1.50 %] in an oxygen/air 
mixture (55% O2) for 150 minutes. Three ponies received dexmedetomidine CRIs of 1 
and 1.75 µg/kg/hr from T30 to T60 and T90 to T120 respectively. In the other three 
ponies, the order was reversed. 
Heart rate (HR), cardiac index (CI), arterial oxygen content (CaO2), venous 
oxygen content and oxygen delivery decreased significantly, whereas systemic vascular 
resistance, systolic arterial pressure and right arterial pressure significantly increased 
with both rates. No major differences were found between the two rates. It was 
concluded that although significant, the changes produced by both CRI rates of 
dexmedetomidine were small and within an acceptable clinical range. 
Since dexmedetomidine was found to be useful with minimal cardiopulmonary 
effects in healthy anaesthetized ponies, the use of the highest CRI rate (1.75 µg/kg/hr) 
was further investigated in equine patients under clinical circumstances and included in 
Chapter 2. The inclusion of this rate was justified not only because of the ‘ceiling 
effect’ of dexmedetomidine with regard to the cardiopulmonary function, but also due 
to a dose dependent increase in sedative and analgesic effects. A prospective, 
randomized, blinded, clinical study was performed to investigate the influence of a CRI 
of dexmedetomidine (1.75 µg/kg/hr) on the cardiopulmonary function and recovery 
quality in forty healthy, isoflurane anaesthetized horses undergoing elective surgery. All 
the horses were sedated with dexmedetomidine (3.5 µg/kg, IV) while anaesthesia was 
induced with IV ketamine and midazolam and maintained with isoflurane in 55-60% 
oxygen. The horses were randomly allocated to receive either a CRI of 
dexmedetomidine (1.75 µg/kg/hr) or saline. The main anaesthetist was unaware of the 
treatment. All the horses received a small dose of dexmedetomidine (0.875 µg/kg, IV) 
at the end of anaesthesia before the recovery period. 
Statistically significant decreases in HR and arterial partial pressure of oxygen 
(PaO2) were found in horses receiving a dexmedetomidine CRI. However, the decrease 
in HR was minimal, and no periods of severe bradycardia were observed. Despite this 
decrease, CI was not affected and was not significantly different between treatments. 
Although PaO2 was lower in horses receiving dexmedetomidine, it remained in the 
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range to fully saturate heamoglobin, with a comparable CaO2 between groups. Apart 
from the influence on the cardiopulmonary function, a dexmedetomidine CRI did not 
reduce the FE´ISO required to maintain anaesthesia but improved the recovery quality, 
with fewer attempts to stand and significantly longer times to sternal position and first 
attempt to stand. 
In order to prove a possible inhalant anaesthetic-sparing effects of the proposed 
dexmedetomidine protocol, a classic MAC study was performed (Chapter 3) using six 
healthy ponies in a prospective, randomized, crossover, blinded experimental study. 
Each pony was anaesthetized twice within a washout period of three weeks for either 
the dexmedetomidine protocol (3.5 µg/kg IV followed by a CRI at 1.75 µg/kg/hr) or the 
treatment saline. Induction of anaesthesia was performed with sevoflurane in oxygen by 
a nasotracheal tube and maintained with sevoflurane in 55% oxygen. Afterwards (T0, 
positioning on surgical table), the ponies received the appointed treatment and the MAC 
of isoflurane was determined after sixty minutes using a classic bracketing technique 
including constant-current electrical stimuli applied at the skin of the lateral pastern 
region. Triplicate estimations of the ‘MAC-no movement’ (MACNM) were obtained and 
averaged in each pony. The results obtained from this study showed that a 
dexmedetomidine CRI (1.75 µg/kg/hr) significantly reduces the mean ± SD sevoflurane 
MACNM from 2.42 ± 0.55 to 1.07 ± 0.21% (mean MACNM reduction 53 ± 15%). 
In view of the successful outcome and positive results obtained from the first 
MAC study, a second MAC study was additionally performed. The study included in 
Chapter 4 aimed to determine the MACNM of sevoflurane during a morphine CRI or a 
combination of both morphine and dexmedetomidine CRIs. The sevoflurane MACNM in 
five experimental ponies using a morphine CRI was 2.79 ± 0.73% while simultaneous 
infusion of dexmedetomidine significantly reduced sevoflurane MACNM to 0.89 ± 
0.22% (mean MACNM reduction 67 ± 11%). 
 Finally, a prospective, blinded, clinical study involving twenty horses 
undergoing elective surgeries was performed and reported in Chapter 5. Two different 
balanced anaesthetic protocols, dexmedetomidine and morphine CRIs, were studied 
with regard to cardiopulmonary function, isoflurane requirements and recovery 
qualities. Horses were randomly allocated to receive dexmedetomidine (3.5 µg/kg IV 
followed by a CRI at 1.75 µg/kg/hr) or morphine (dexmedetomidine 3.5 µg/kg plus 0.15 
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mg/kg morphine IV followed by a CRI of morphine 0.1 mg/kg/hr). Anaesthesia was 
induced in both groups with ketamine and midazolam and maintained with isoflurane in 
55-60% oxygen. In order to determine the isoflurane requirements during both 
protocols, a minimal FE´ISO of 0.9% was used after induction of anaesthesia, and then 
adjusted by the anaesthetist to maintain a light surgical plane of anaesthesia, according 
to an objective flow-chart. 
  Cardiopulmonary function remained stable in both groups. When the 
anaesthetized horses received a CRI of dexmedetomidine, less additonal ketamine was 
required, FE´ISO was lower after one hour and more time was spent in an ‘ideal plane’ 
of anaesthesia, together with better recoveries. Some complications were observed after 
infusion of morphine (one post-operative colic and pulmonary oedema and two box-
walking behaviours). In summary, a dexmedetomidine CRI in equine patients under 
clinical circumstances produced a more stable anaesthetic depth, with reduced 
isoflurane requirements and better recoveries, but also without post-operative 
complications compared with a morphine CRI. 
As an overall conclusion it can be stated that a dexmedetomidine CRI (1.75 
µg/kg/hr) can be safely used in healthy anaesthetized horses with minimal 
cardiopulmonary effects, producing a reduction of the isoflurane requirements, an easier 
maintenance of a stable plane of anaesthesia and longer but better recoveries. This 
dexmedetomidine protocol was also proven to be better compared to a morphine CRI in 
equine anaesthetized patients. 
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Het risico van algemene anesthesie is beduidend hoger bij paarden dan bij andere 
diersoorten. Verschillende mortaliteitspercentages werden in de literatuur reeds 
gerapporteerd, zoals beschreven in de algemene inleiding. Onderhoud van algemene 
anesthesie met volatiele anesthetica houdt bovendien een hoger risico in vergeleken met 
totaal intraveneuze anesthesie, vooral omwille van de meer uitgesproken 
cardiovasculaire depressie die optreedt. De verschillende principes die belangrijk zijn 
bij de behandeling van cardiovasculaire depressie werden bijkomend besproken, waarbij 
ook aandacht werd gegeven aan het concept van ‘balanced anaesthesia’. 
 Sectie 1 van de algemene inleiding geeft een overzicht van de verschillende 
intraveneuze (IV) farmaca die gebruikt worden als continu infuus (CRI) in combinatie 
met volatiele anesthetica tijdens algemene anesthesie bij paarden. Lidocaïne, ketamine 
en opioïden kunnen toegediend worden om analgesie te bekomen en tevens om de 
minimum alveolaire concentratie (MAC) van inhalatie-anesthetica te verlagen, alhoewel 
ze niet vrij zijn van neveneffecten. Alfa2-agonisten zijn krachtige analgetica en verlagen 
de MAC van inhalatie-anesthetica, maar hebben zelf ook een duidelijke impact op het 
cardiovasculair systeem. De farmacokinetische eigenschappen van de meest selectieve 
2-agonisten, medetomidine en dexmedetomidine, lijken gunstig voor gebruik in CRIs, 
vooral ook omdat de cardiopulmonaire effecten van zeer korte duur zijn.  
Een overzicht van de karakteristieken en de toepassingen van dexmedetomidine 
wordt gegeven in de Sectie 2 van de algemene inleiding 2. Dit product werd reeds 
gebruikt bij zowel mens als dier tijdens inhalatie-anesthesie, met veelbelovende 
resultaten. Tot heden is slechts één wetenschappelijke publicatie voorhanden die het 
gebruik van dexmedetomidine bij paarden onderzocht. De auteurs suggereerden het 
gebruik van dexmedetomidine als een CRI bij paarden. 
Dit leidde tot het formuleren van de wetenschappelijke doelstellingen van dit 
doctoraat. Allereerst werd er gezocht naar dosissen waaraan dexmedetomidine veilig 
gebruikt kan worden als sedativum voor de premedicatie en als CRI tijdens het 
onderhoud van een algemene anesthesie met volatiele anesthetica. Daarnaast werd 
bepaald of dexmedetomidine de MAC van sevofluraan beïnvloedt, zowel alleen als in 
combinatie met een morfine-infuus. Tenslotte werd het protocol met dexmedetomidine 
vergeleken met een morfine-infuus tijdens anesthesie bij paarden onder 
kliniekomstandigheden.  
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In Hoofdstuk 1 werden de cardiopulmonaire effecten van twee verschillende 
dexmedetomidine CRIs (1 en 1.75 µg/kg/hr) onderzocht in zes pony’s in een 
prospectieve, gerandomiseerde, experimentele studie. Na sedatie met dexmedetomidine 
(3.5 µg/kg, IV) en inductie met ketamine en midazolam (T0), werd de anesthesie 
onderhouden met isofluraan [expiratoire fractie (FE´ISO) 1.50 %] in een zuurstof/lucht 
mengsel (55% O2) gedurende 150 minuten. Drie pony’s kregen dexmedetomidine CRI’s 
aan 1 en 1.75 µg/kg/hr van T30 tot T60 en T90 tot T120 respectievelijk. Bij de drie 
andere pony’s werd de volgorde van beide infusiesnelheden omgewisseld. De 
hartfrequentie (HR), het hartdebiet (CI), de arteriële (CaO2) en veneuze zuurstofgehaltes 
en de zuurstofvoorziening (DO2) daalden significant, terwijl de systemisch vasculaire 
weerstand, systolische arteriële druk en rechter atriale druk significant stegen met beide 
infusiesnelheden. Geen verschillen werden echter gevonden tussen de beide 
infusiesnelheden. Er werd besloten dat hoewel significant, de effecten van beide CRIs 
klein en klinisch aanvaardbaar waren.  
Eens er vastgesteld was dat dexmedetomidine bij gezonde pony’s kan gebruikt 
worden tijdens de anesthesie, met slechts minimale cardiopulmonaire effecten, werd in 
Hoofdstuk 2 de hogere infusiesnelheid (1.75 µg/kg/hr) onder kliniekomstandigheden 
onderzocht bij paarden. De keuze voor deze snelheid was voornamelijk omwille van het 
zogenoemde ‘ceiling effect’ i.v.m. de cardiopulmonaire functie, terwijl de sedatieve en 
analgetische effecten mogelijks toch dosisgerelateerd zijn. Een prospectieve, 
gerandomiseerde, blinde, klinische studie werd uitgevoerd bij veertig volwassen en 
gezonde paarden aangeboden voor electieve chrirugie, met als doel de invloed van een 
dexmedetomidine CRI (1.75 µg/kg/hr) op de cardiopulmonaire functie en 
recoverykwaliteit na te gaan tijdens isofluraan anesthesie. Alle paarden werden 
gesedeerd met dexmedetomdine (3.5 µg/kg, IV) en de anesthesie werd geïnduceerd met 
ketamine en midazolam en onderhouden met isofluraan in 55-60% zuurstof. De paarden 
kregen at random een CRI van dexmedetomidine (1.75 µg/kg/hr) of fysiologische 
zoutoplossing als placebo. Voor de recovery werd aan alle paarden een kleine dosis 
dexmedetomidine (0.875 µg/kg, IV) toegediend. Statistisch significante dalingen in de 
HR en arteriële zuurstofspanning (PaO2) werden gevonden bij paarden die een 
dexmedetomidine CRI kregen. De daling in HR was echter minimaal en er waren bij 
geen enkel paard periodes van ernstige bradycardie. Ondanks deze daling verschilde de 
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CI ook niet tussen de twee groepen. Alhoewel de PaO2 lager was bij paarden die 
dexmedetomidine kregen, bleef deze steeds hoog genoeg om een volledige saturatie van 
haemoglobine met zuurstof te bekomen en was de CaO2 vergelijkbaar tussen de twee 
groepen. Er werd geen daling gevonden in de FE´ISO, maar dexmedetomidine 
verbeterde wel de recoverykwaliteit, met minder pogingen om recht te staan en 
significant langere tijden tot sternale decubitus en de eerste poging tot rechtstaan.  
Om aan te tonen dat dexmedetomidine de behoefte aan inhalatie-anesthetica bij 
paarden vermindert, werd een klassieke MAC studie uitgevoerd (Hoofdstuk 3). Zes 
gezonde pony’s werden opgenomen in een prospectieve, gerandomiseerde, blinde, 
experimentele crossover-studie. Elke pony werd 2 keer onder anesthesie gebracht met 
een tussentijd van drie weken en kreeg een infuus van ofwel dexmedetomidine (3.5 
µg/kg IV gevolgd door een CRI aan 1.75 µg/kg/hr) ofwel fysiologische zoutoplossing. 
Inductie en onderhoud van de anaesthesie gebeurde met sevofluraan in een zuurstofrijk 
gasmengsel, toegediend via een nasotracheale tube. Na het plaatsen op de chirurgietafel 
(T0) werd het respectievelijke infuus gestart en vanaf T60 werd de MAC-bepaling 
begonnen met een klassieke ‘bracketing’ benadering, d.m.v. elektrische stimuli van een 
constante stroomsterkte toegediend t.h.v. de laterale kootregio. Drievoudige bepalingen 
van de ‘MAC-no movement’ (MACNM) werden bekomen en het gemiddelde per pony 
berekend. De resultaten van deze studie toonden aan dat een dexmedetomidine CRI 
(1.75 µg/kg/hr) significant de MACNM van sevofluraan doet dalen van 2.42 ± 0.55 naar 
1.07 ± 0.21% (gemiddelde MACNM reductie 53 ± 15%).  
Gezien het succesvol uitvoeren van en de positieve resultaten bekomen met de 
voorafgaande studie, werd een tweede MAC studie uitgevoerd (Hoofdstuk 4), met als 
doel de MACNM van sevofluraan te bepalen tijdens toediening van een morfine-infuus, 
al dan niet gecombineerd met dexmedetomidine. Vijf pony’s werden gebruikt bij deze 
studie, die uitgevoerd werd zoals in Hoofdstuk 6. De MACNM van sevofluraan was 2.79 
± 0.73% tijdens een morfine-infuus, maar deze daalde tot 0.89 ± 0.22% wanneer ook 
dexmedetomidine als infuus werd gegeven (gemiddelde MACNM reductie 67 ± 11%).  
 Tot slot werd in Hoofdstuk 5 een prospectieve, blinde, klinische studie 
uitgevoerd op twintig paarden tijdens electieve chirurgie, met als doel twee protocols 
voor ‘balanced anaesthesia’ met elkaar te vergelijken, i.e. dexmedetomidine en morfine 
CRIs, m.b.t de cardiopulmonaire functie, isofluraan behoefte en recovery kwaliteit. De 
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paarden werden at random toegewezen aan behandeling dexmedetomidine (3.5 µg/kg 
IV + CRI aan 1.75 µg/kg/hr) of morfine (dexmedetomidine 3.5 µg/kg plus 0.15 mg/kg 
morfine IV, gevolgd door een morfine CRI 0.1 mg/kg/hr). In beide groepen werd de 
anesthesie geïnduceerd met ketamine en midazolam en onderhouden met isofluraan in 
55-60% zuurstof. Om na te gaan of de isofluraanbehoefte met deze behandelingen 
beïnvloed wordt, werd na inductie van de anesthesie een minimale FE´ISO van 0.9% 
gebruikt, die verder aangepast werd aan de hand van een objectieve flow-chart om een 
zo licht mogelijke maar toch chirurgische diepte van de anesthesie te bereiken. 
Met beide infusen werd een goede cardiopulmonaire functie bekomen. Bij de paarden 
die dexmedetomidine kregen was er echter minder ketamine nodig, was de FE´ISO na 
één uur anesthesie lager en werd een groter percentage van de tijd in een ‘ideale’ diepte 
van anesthesie doorgebracht, met finaal een betere recovery. Een aantal complicaties 
traden op bij de groep waar morfine toegediend werd (één koliek en longoedeem, twee 
andere ‘box-walking’). De conclusie van deze studie was dat een dexmedetomidine CRI 
een stabielere diepte van de anesthesie geeft, met lagere isofluraanbehoeftes en een 
betere recovery, zonder postoperatieve complicaties. 
Als een algemene conclusie kan gesteld worden dat een dexmedetomidine CRI 
(1.75 µg/kg/hr) veilig gebruikt kan worden, met minimale cardiopulmonaire effecten bij 
gezonde paarden tijdens algemene anesthesie en een lagere behoefte aan isofluraan, 
waarbij makkelijker een stabiele diepte van de anesthesie kan aangehouden worden. De 
recovery is langer maar wel beduidend beter. Dit protocol blijkt ook gunstiger ten 
opzichte van de combinatie isofluraan en een morfine-infuus. 
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It is very hard to leave the country and the people you love in order to improve your 
career. However, I will never regret my decision. In the last six years I grew 
professionally and personally and, with these lines, I would like to thank everyone that 
helped me in both ways. 
 My first thanks go to Professor Gasthuys. Frank, you gave me the opportunity to 
start a residency programme in veterinary anaesthesia. I hope you were happy with my 
work and, although I still need to pass the oral part of the exams, you know that I did all 
my best every single day. Moreover, I would like to thank you for all the support you 
gave me to perform the research I am presenting today. Since the first day you 
encouraged me with this project, providing the facilities, your ideas and of course, 
useful and quick remarks during the writing processes. Lastly, I also would like to thank 
you for all the good times in the congresses we went together, not only for your support 
in my presentations, but also when meeting people or having a drink in places such as 
Barcelona or Santorini. 
 It sounds a bit strange to me to say Doctor Schauvliege. Stijn, I do not have 
words to thank you for all your help during these years. Since the first day you helped 
me every single day: at the beginning with the clinical work and later with the research 
we performed together. I will never forget the extra effort you made when preparing the 
written exam and the proud you felt when we knew the result. I hope you will feel the 
same at the end of November again! And of course, thank you very much for your 
patience, your trust and for being always there when somebody needs you. Finally, I 
cannot forget the good times we also had after work. Department dinners, assistant 
parties and of course, anaesthetists meetings. I will be proud to say that we are the 
‘Franky boys’, always staying longer than the ‘Regula girls’! 
 Who is happy doing statistics? Professor Duchateau is the answer. Thank you 
very much for the time you spent analizing our data. Although I followed some statistic 
courses, it was always great to have your back up and knowledge to confirm the 
interpretation of our results. Furthermore, I would like to thank you for accepting being 
a member of the Guidance Committee and for your critical reading of the first version 
of the present PhD. 
 I would like to be grateful to the members of the Reading and Exam Committees 
as well. First of all I would like to thank Professor Polis and Doctor Waelbers, not only 
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by their work reviewing this manuscript, but also by supporting me when I was a 
resident rotating in their department. Ingeborgh, Tim: although you knew that I was 
more interested in equine anaesthesia, you always trusted on my work and made my life 
easier. It was a pleasure to work with you and also to spend some time together in 
several meetings. Professor Yves Moens: thanks for participating in my PhD defense. I 
know you love to be back in your country and meet old friends. I hope we will see each 
other (and I will have to be able to guess if you are talking serious or just making a joke 
). Doctors Bouchez and Foubert: it is an honour that you are members of the Reading 
Committee. The opinion and comments of 2 recognized human anaesthetists make our 
work of more value. Thanks also to Edwin Claerebout, Chairman of the Exam and 
Reading Committees for the organization of this PhD defense. Thank you all for being 
present on this important day. 
Going back in time, I would like to remember the people who helped me to be 
here today. I would not be the anaesthetist I am without Pepe Antón. Driving along 
Castilla for hours and hours I met not only a tireless equine vet, but also a good friend. 
Thanks for guiding me in my first steps Pepe! The time spent as an equine intern and 
clinician in the Hospital Veterinario Sierra de Madrid was a very intense period, full of 
good and bad moments. First of all I would like to thank Miguel Bajón and Luis de la 
Ossa for choosing me to work in their hospital. From this period I really appreciated the 
time I worked with Jorge de la Calle. He showed me that he is not only a very good 
surgeon but also a humble professional and a better person, supporting me in difficult 
moments. I also would like to thank all of the people who I worked with and from who I 
learnt a lot: Gustavo, Raquel Vicario, Víctor, Juanfran, Juan (blacksmith), Jero, Paco 
Tendillo and Martín. Also to the interns and people from small animals or 
administration: Mar, Jose Enrique, Israel, Laura, Moisés, Raquel Mena, Yolanda, María 
(and her good food), Mónica… I would like to include here David Argüelles. He was 
only a visitor for several weeks but he encouraged me to search for a residency 
programme. When you leave a place you leave friends as well. I left Amaia, a great 
housemate and a better person. I will always remember those ‘chuletitas’, our life in 
Pedrezuela and that sofa I could never use! Good luck with your baby and hope to see 
you soon. I also left Lucía in a difficult moment, but that made you stronger, still being 
a very kind and positive person. Finally, a special mention to one of my best friends that 
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I will never see again, my colleague of internship Gonzalo Lazo Martín. We started this 
together but you could not finish it. I am sure that wherever you are, you must be proud 
of me. 
 The Dierenkliniek de Bosdreef was the place where I came to complete an 
anaesthesia training and was the connection with Ghent University. I would like to 
thank Tresemiek Picavet for her time and trust when I was just a visitor (with a bad 
English, by the way). Also to the people working there: Hans, Bernard, Paul, Eduardo 
Félix,… and to Tim Samoy, who offered himself to send my CV to the ‘big boss’ in 
Merelbeke.  
 When I started to work in our department, I realized that running a busy equine 
clinic is not an easy matter, and a good ‘team work’ is mandatory. Since the first day, I 
felt very comfortable working with good and very professional colleagues. First, I 
would like to thank my colleagues from anaesthesia: Hannah and Lindsey by helping 
and teaching me a lot during the first months of my stay (and of course for their 
patience), Stefanie by her positive attitude and the good moments after work and Sofie, 
a hard worker and a good person (I am glad to see that you enjoy your new position). 
And of course, the anaesthesia residents. Caroline, I wish you all the best in life. 
Barbara and Sanne, good luck with the end of your residency and for the exams that are 
coming. Diego, you are just starting but with a lot of work and sacrifice I am sure you 
will be able to make it. I will be there if you need any help. 
 When visiting other places you can see that sometimes the relationship between 
surgeon and anaesthetist is not great. I cannot say the same in our department. I would 
like to thank Professors Ann Martens, Lieven Vlaminck and Frederik Pille for their trust 
on my work. As an anaesthetist it is really important to feel that the surgeon appreciates 
your job and relies on your decisions. Working with all of you I felt very confident. 
Moreover, I would like to mention to all the surgery residents I have worked with: 
Jeroen (all the best in your job), Tamara (imposible to forget ), Mireia (good luck with 
your PhD), Helga (my best wishes for your near future and in your next steps) and 
Thomas (all the best in your residency). Caroline, take care of all the calves with 
‘spastiche parese’ as well as Marteen does it with the sarcoids. Maarten and Michèle, 
thanks for your help at the beginning of my residency during your anaesthesia duties. 
The same for Geert and Annelies, now with other positions. Kelly, I met you when you 
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were an intern and now you are an orthopaedic expert. If someone touches your 
shoulder when you are checking your e-mails it will be probably me . Together with 
Jan, enjoy with Jade! Lore, good luck with your PhD. Eva and Daphné, continue with 
the good job in hospitalization (also Daphné with your enthusiasm in anaesthesia). By 
the way, next year we should fight for a department DINNER, not lunch, and then we 
can continue with the party in Ghent. 
 The work we performed everyday would not be possible without the help of the 
people of sterilization. Caroline, Cindy: it is very nice to work with people like you, 
making jokes and bringing chocolates to the anaesthetists when the surgeons are 
working . Valerie, I really appreciate your friendship, our talks and your support. 
Keep on taking care of all the animals at home! Also, I would like to mention the people 
from administration: Heidi (100% efficacy), Johan (a strange connection was made 
beween us, still wondering why), Veerle and Cindy. It was also nice to work with the 
blacksmiths (Jan and Didier), Remi (a good option when you need to fix something) and 
the stable people (Didier, Bart, Nadine,…). I would like to mention the effort of the the 
interns and students. It is nice to see them grow professionally in the period of one year. 
I would like to include in these lines Stephanie, Evelien, Babette, Jan, Veronica, 
Maxim, Kimry, Evelyne, Anais, Emmanuelle, Arianne and, of course Aurélie. 
Obviously, I cannot remember the names of all the students I worked with. However, I 
hope they could learn something during the time they spent with me in an easy, friendly 
way. 
  I also would like to mention the people from other departments. Thanks to 
everyone from Internal Medicine (Piet, Gunther, Dominique, Laurence, Sara, Kirsten, 
Barbara, Wendelien, Tiago, Nicky, Thomas and Hans) and from Medical Imaging 
(Ingrid, Annemie, Kaatje, Eva, Kim, Marnix and Casper). Finally, to the people from 
small animals that treat me well and who with I had good times during my residency 
(Koen, Inge, Geert, Pascale, Miguel Campos, Alejandro, Sabine, Hilde, Alessandra,…). 
A special place for my good friend Tim Bosmans: maybe you can be a better 
anaesthetist (I think you are a very good one) but you cannot be a better person. My 
regards to Christine, Noah and Finn. 
 One of the aims of the residency and PhD is to be able to perform research, to 
obtain results and present them to other colleagues in international meetings. These 
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events are good opportunities to meet people working in the same or different fields, the 
so-called ‘networking’ and even to make friends. Miguel and Fernando Martínez, thank 
you very much for your advices and help when studying for the exam. I am sure that the 
PAVA (Peña Atlética de Veterinarios Anestesistas) will survive for a very long time. To 
Simone Ringer, Regula Bettschart-Wolfensberger, Lea Hatz, Andrea Schwarz and all 
the ‘Regula girls’, not only for the good fun in the congresses but also for your 
enthusiastic cooperation in the MACNM studies together with the people from Hannover 
(Sabine Kästner, Klaus Hopster and Anna Elisabeth Krajewski). I also have to be 
thankful to the people that allowed me to go to their institutions to perform my 
externships, Jackie Brearley, Tim Bouts, Hatim Alibhai and Eric Mortier. Special 
thanks to Chris Seymour, who helped me with my credentials and took good care of me 
when I was visiting Cambridge and London. Chris, thank you very much for your 
knowledge, the stories about the WWII and for your friendship. Also, to Alan Taylor 
and Sarah Thomson by helping me correcting my English. Finally, I would like to 
mention to all the Spanish anaesthetists I met in the SEAAV (or in other congresses) 
who are ready to dance the ‘takatá’: Eliseo, Maite, Eva y Luis, Paco Laredo, Gaspar, 
Clara, Viscasillas, Sandra, Alejandra, Carolina, María del Mar, Amaya, Cristina, Miki, 
Nacho´s…See you on Thursday in Zaragoza! 
 But after work, there is always life. I am already missing those Friday evenings 
in the ‘Boerderijte’ with people from other departments, where we could share not only 
our scientific knowledge but also our life experiences. It will be always a pleasure to 
remember people like Sebastiaan, Stijn Hauspie, Peter de Schutter, Bart Pardon, Johnny 
Vlaminck, Tao, Cyrile, Myl or João discussing about several topics with a pintje in our 
hands. And, definitely, I will miss the assistant parties, dressing as romans, rappers, 
angels or devils. They were fun! 
 During my stay in Belgium I met lots of people, some of them are now my 
friends. In a special place are those I met during my first year (in their Erasmus), when 
they were only little “polluelos” that had to learn to fly. We spent great moments 
together, Gentse Feesten, the trips to Normandy, Valladolid, Bérriz, Cantabria, 
Nijmegen, and other places to make the “gañán”. We will meet again for sure (several 
times, chacho). Thanks Kike, Celia, Inés, Adri, Dani-Agorer, Kachenka and Peñu for 
making my first year in Ghent easier. 
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 But some other people stayed to work and we made a big group. I will remember 
these years as good years with you Príncipe, Juliana (thanks for giving me the excuse to 
be the godfather in your wedding and visit Pernambuco), Conchi, Amparo, Follonero, 
Celine, Lobo, Ali, Imagine, Luis, Laurinha, Pili, Joana, Nuria, Paco I (el portero), Paco 
XVI, Yiyus, Fernando, David, Wilson, Glenn, Kenny, CF7, María Castellón, Yara, ‘Il 
Dottore’ Valozzi, Maria, Viviana, Ivone (Mozambique), Ana, Michèlle, Silke, María 
Teresa, Manolo, Eva…and the kids (que nos dan la vida y a veces nos la quitan, Celine, 
Kevin, Jacqueline, Sofie and Yaiza). Organizing parties, visits to the Cabraliego (Ángel, 
Julio and Ramón) and other social events with you no tiene precio. 
 Not everything was partying in our after-work hours. I will miss the football 
matches against the students, organized (or disorganized) by Sebastiaan and Stijn 
Samoy. Moreover, I will remember the origins of Steaua Mineral, how I became the 
coach and the MAP of the season 2010-2011 and all the ‘pachangas’ we played against 
several communities in Ghent: the ‘Latinos’, the Vietnamese, the Chinese… 
 When you are in another country it is good to confirm that your friends in Spain 
are still there whenever you need them. I would like to mention my friends of the 
childhood from ‘Las Flores’, Isaac, Sandra, Terrenos, Marquitos, Oscarín, Mai, Nacho, 
Lorena, Luismi, Inma, Orni, Valles, España, Vane, Picas, Eva, Malabares, Noe, Vane, 
Amalia, Merce…Thanks for making me remember the good years every time I go back 
home. Of course, I cannot forget Sonia and Isma in this important day for me. Other 
people from Valladolid that always have time to make a phone call are Alicia and Javi 
Cano, Sebas, Marta, Mario… and the people from Madrona ‘Los del Corral’. 
 My love for horses started in Arbejal when I was only a child. I would not be 
here today if my parents would not have met ‘Casa Simón’. It is nice to remember the 
routes around the ‘Montaña Palentina’ with Niño, Tordo, Wanda and Salvaje. Thanks to 
Simón, Antonia, Felipe, Ermitas, Rubén, Yovana, Andrés, Miguel Ángel and Carmen 
(and for being here today), Manolo, Carmen, Chema, Pilar, Elena, Chemari, Blanca, 
Fernando, Ceci… Also to Alberto Colino that spent good times there with my parents 
(and Gresca).  
 The way that Simón loved his horses made me love them as well. He was 
(together with Pepe Antón) the person that influenced me more to start my studies in 
veterinary medicine in León. There, in the CMU San Isidoro I spent the best years of 
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my life. When I arrived there we were young, innocent, crazy ‘novatos’, but there I 
learnt to appreciate important values for life: respect, friendship and loyalty. I can say 
that many of my best friends are ‘Isidoros’: Penebé, Pelayo, los Ulibarri, el Abuelo, 
Penkas, Leandro, Proyect, Nachín, Cabrero, Potes, Colibrí, Lomillos, Puma, Choni, 
Bigotes and many others. I am already waiting for the next meeting in the ‘Húmedo’!  
 I never felt alone in Belgium. Here, I met a second family, the Vervaet in 
Eksaarde (Luc, Els, Nathalie, Matthias, Gilda, Boy and Maestro). Thanks for your 
hospitality and for treating me as one more inviting me to the Lokeren matches, fietsen, 
the Paris-Roubaix, your wedding anniversary, fishing in the Netherlands,… I also 
would like to mention the students I was living with for the first two years. Nicholas, 
Thomas and Inne: good luck in your career!  
 I thought that all the people from Andalucía were very funny, making good 
jokes. I met two exceptions in Belgium. In Liége I met the most successful veterinary 
surgeon perfoming ‘spinal disc herniations’, un gitanillo de Málaga. Juanmi, disfruta del 
buen tiempo del sur y suerte con el examen! Here, in Merelbeke, I met my good friend 
Alfonso. Foske, try to follow as usual, giving ‘negative’ comments to the people and 
trying to defend that Sevilla FC is the best team ever. Take care of Evelyne, Mireille 
and your ‘cachorros’. Alfonso made possible that Rubén came to work here. Trompi, 
you are my best friend and I cannot say anything you do not know. These years living 
with you (in León and in here) were good years! Regards also to your colleagues 
Annelies and Luca. A PhD student from Brazil came to their department in January 
2011. Silvana, muchas gracias por todos los momentos que vivimos juntos estos años y 
por hacerme muy feliz. También por tu apoyo mientras preparaba mis exámenes. Espero 
que disfrutaras de nuestros días y viajes por Europa. Estoy seguro de que pronto nos 
volveremos a ver y, como tú dijiste, recuerda que es SIEMPRE! 
 The family is always there. Best regards to Israel, Eva, Patro, Chuchi (and the 
nights in the ‘Peeters’), Puri, Javi y las niñas, Cristina, Beni, Rubén (and his help with 
my English), Miriam, Jano, tía Pilar, Ismael y tío Javi. Also to my grandparents and 
others that are not with me anymore. Virgilio, you are like one more of one family. 
Thanks for your friendship and the good work you do with my father at ‘Pinedo y 
Gozalo’. Last thoughts to our ‘family’ in Lires. I hope those summers with you will 
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come back in the future. Big kisses to Antonio, Marisa, Placeres, Rocío, Mario, Jose 
María, Manolo, Blanca, Delia, Pablo… 
 Finally, to my parents. Muchas gracias por estos 32 años a mi lado. Por dejarme 
crecer como un niño feliz, descubriendo las cosas bellas de la vida (la naturaleza, el 
respeto a los demás, el ser feliz y el valorar lo que tienes). También por la educación 
recibida y los valores que me transmitisteis (lo más importante en esta vida es ser una 
buena persona). Soy consciente que todo ello lo habéis conseguido con un gran esfuerzo 
diario. Muchas gracias también por darme la oportunidad de estudiar la carrera que 
elegí, aunque supusiera el irme a estudiar a otra ciudad. Cada día me levanto feliz y voy 
a trabajar en algo que me fascina. Sólo os pido que no cambiéis nunca y que disfrutéis 
de la vida como más os gusta, viajando, en el campo y en compañía de vuestros amigos. 
Espero que estéis orgullosos de mi. 
 
  Muchas gracias a todos! Bedankt allemaal! 
 
 Miguelito 
   
 
 
  
 
 
